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SUMMARY 
Monoclonal antibodies (mAbs) have shown great promise as immunotherapy of cancer in 
the past decades. They mediate the antibody-dependent immune responses to eliminate 
the malignant or suppressive cells and proteins and restore anti-cancer immunity. 
However, the application of monoclonal antibodies as therapeutics is greatly hampered 
by its high production cost as well as high dosage required to generate significant 
therapeutic effect due to limited tissue penetration and retention. Additionally, 
monoclonal antibodies targeting some important immunological targets, such as myeloid-
derived suppressor cells (MDSCs), regulatory T cells, are still waiting to be developed.  
Here, we have developed a novel type of artificial antibodies, the synthetic nanoparticle 
antibodies (SNAbs), which are Janus nanoparticles multivalently displaying both binding 
ligands for the selected cellular targets and Fc-mimicking ligands that can activate Fc 
receptors. Our primary hypothesis is that the designed SNAbs could induce antibody-
dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP) of cellular targets 
efficiently both in vitro and in vivo. A simple chemistry to fabricate Janus gold 
nanoparticles and to modify these nanoparticles with peptide ligands was designed to 
generate SNAbs. We evaluated the capability of SNAbs to target MDSCs, as a model cell 
type in both ex vivo assays and in vivo tumor model systems. We showed that SNAbs can 
selectively induce the antibody-dependent killing of MDSCs in the mixture of various 
types of cells and are also able to deplete MDSCs in a tumor model. The research 
completed in this thesis demonstrated that the SNAbs are a functional alternative to 
monoclonal antibodies and hold great promise as a potent immunotherapy for cancer.  
 1 
CHAPTER 1 OVERVIEW, HYPOTHESIS AND SPECIFIC AIMS 
1.1 Overview 
Malignant cells utilize several mechanisms to evade the immune system, including 
recruiting/promoting regulatory cells (e.g. myeloid derived suppressor cells (MDSCs)), 
up-regulating inhibitory surface ligands, releasing suppressive cytokines or enzymes to 
repress the activity of immune effector cells (e.g., cytotoxic T cells).
1,2
 Monoclonal 
antibodies (mAbs), comprised of Fab domain for targeting specific antigens and Fc 
fragment for immune activation, have shown great promise in treatment of cancer in the 
past decades
3,4
. A handful of available mAbs (e.g.,atezolizumab) take advantages of the 
antibody-dependent immune responses to eliminate the suppressive cells/proteins and 
restore anti-cancer immunity.
5–8
 On the other hand, some malignant cells express their 
own cancer-associated antigens (e.g. Her2, CD20). Antibodies (e.g.,trastuzumab, 
rituximab), which are able to bind to these antigens, can kill tumor targets by eliciting 
antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP).
9–11
 However, the 
application of monoclonal antibodies as therapeutics is greatly limited by its high 
production cost 
12
 as well as high dosage required to generate significant therapeutic 
effect due to limited tissue penetration.
12,13
 Furthermore, monoclonal antibodies targeting 
some important immunological targets, such as MDSCs, regulatory T cells, are still 
waiting to be developed.  
Small molecule ligands, such peptides and aptamers, have emerged as potent 
biotherapeutics for diagnosis, drug or gene delivery and disease treatment.
14–16
 Various 
screening techniques, such as phage display biopanning, exist to accelerate the 
 2 
identification of effective small molecule ligands for specific biomedical applications. 
14,15,17
These ligands were widely applied on particulate systems to facilitate the targeted 
delivery of drugs or induction of therapeutic responses.
18–20
 The particulate systems, on 
the other hand, are facile presentation platform and carriers for the ligands and drug, and 
also provide unique, easy tailorable physical and chemical properties to modulate the 
therapeutic effects.
21–23
 We believe that synthetic nanoparticle antibodies (SNAbs), which 
are Janus nanoparticles multivalently displaying both binding ligands for the selected 
targets and Fc-mimicking ligands, can activate Fc-receptor-mediated immune responses 
and serve as a functional alternative to conventional mAbs. By combining the advantages 
of peptides and nanoparticles, SNAbs could be a promising immunotherapy for cancer 
via depleting malignant or suppressive cells or proteins. As a flexible platform 
technology, SNAbs may also have broad application potential in other biomedical areas, 
such as disease diagnosis, drug/gene delivery, imaging and analytical biotechnology.  
1.2 Hypothesis 
Our primary hypothesis is that the designed SNAbs could induce ADCC/ADCP of 
cellular targets efficiently both in vitro and in vivo. The overall objective is to develop the 
chemistry fabrication method of SNAbs as a platform technology. As a proof of concept, 
a type of SNAbs was designed to target MDSCs, as a model cell target, and deplete these 
MDSCs by activating antibody-dependent immune responses in vitro and in murine 




1.3 Specific Aim 1: To design and develop SNAbs that display both target-binding 
ligands and Fc-mimicking ligands  
In this aim, we developed a novel fabrication approach to generate SNAbs. We first 
synthesized Janus nanoparticles by an adapted solid-phase chemistry method
24
 and then 
designed the chemistry to conjugate target-binding peptides as well as Fc-mimicking 
ligands 
25,26
 onto their surfaces to make fully functional SNAbs. The physical and surface 
chemistry properties and peptide modification of these SNAbs were characterized and 
validated using colorimetric, microscopic and spectrometric methods.  
1.4 Specific Aim 2: To demonstrate ex vivo, the specificity of cell targeting and 
activation of immune responses by the SNAbs 
In this aim, we hypothesized that the surface presentation of target-binding ligands and 
Fc-mimicking ligands on SNAbs enables them to bind specifically to target cells and 
trigger antibody-dependent responses. MDSCs were selected as the model cell target. We 
validated our hypothesis for MDSC-SNAbs through evaluating the binding capability, 
targeting specificity, and the induction of ADCC/ADCP of MDSCs by effector cells. We 
also studied the major mechanism of action of MDSC-SNAbs and also investigated the 
function of Janus structure in the activation of immune responses by MDSC-SNAbs.  
1.5 Specific Aim 3: To evaluate the therapeutic potential of the MDSC-SNAbs in 
tumor models  
The 4T1 breast cancer murine model is an aggressive cancer model that recapitulated the 




accumulated in the spleen, tumor, blood and lymph nodes in the 4T1-tumor bearing mice 
and promote the metastasis of the tumor cells. In this aim, we hypothesized that the 
MDSC-SNAbs can deplete the MDSCs in vivo and provide therapeutic benefit in the 
murine tumor model. To evaluate the efficacy of SNAbs to deplete MDSCs, we 
administered MDSC-SNAbs to 4T1-tumor bearing mice with different dosing frequency 
and treatment duration and analyzed the major organs for cell composition and immune-
cell functions. We also studied the biodistribution of SNAbs in vivo with inductively-
coupled plasma-mass spectrometry and conducted survival studies with MDSC-SNAbs 
alone or in combination with immune-checkpoint inhibitors to assess the potential of 
MDSC-SNAbs as an immunotherapy for cancer. 
1.6 Outline 
This concludes the introduction to the dissertation, which detailed the hypothesis, three 
Specific Aims and the approaches we used to test the hypotheses in each Aim. A 
summarization of the aims is provided below in Figure 1. Chapter 2 discusses the 
background information regarding the monoclonal antibodies, small molecule ligands, 
nanoparticles and the significance and innovation of SNAbs. Chapter 3 covers the first 
Aim, specifically how the SNAbs were developed and characterized. Chapter 4 illustrates 
the capability of SNAbs to kill target cells in ex vivo cellular assays with MDSCs as the 
model system. Chapter 5 demonstrates one application of SNAbs in the treatment of 
cancer by evaluating the therapeutic efficacy of MDSC-SNAbs in a murine tumor model. 
Finally, conclusions and future directions are presented in Chapter 6.  
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Figure 1. The flow of Aims 
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CHAPTER 2 BACKGROUND AND SIGNIFICANCE 
During the past decades, monoclonal antibodies have emerged as one of the most potent 
and specific drug types. So far, over 80 monoclonal antibodies have been approved by the 
US Food and Drug Administration (FDA) for treatment of diseases, such as cancer, 
infectious diseases, autoimmune disorders.
29
 However, in fact, they are not the perfect 
“magic bullets” and still face great challenges and limitations in their production and 
applications. In this Chapter, we will first discuss the functions and problems with 
monoclonal antibodies, further introduce existing artificial antibody types and the 
conceptual design of SNAbs. Finally, we will discuss the significance and innovation of 
our work.  
2.1 Background 
2.1.1 Monoclonal Antibodies 
Antibodies, also known as immunoglobulins (Ig), are a family of proteins typically 
secreted by plasma B cells upon exposure to pathogens. They are composed of two heavy 
chains and two light chains of polypeptides, forming a “Y” shape structure. On the end of 
the two branches, a tertiary structure of polypeptides establishes the complimentary 
determining regions (CDRs) in the Fab region, which recognize specific epitopes on the 
antigen through molecular interaction. The stem of Y structure, also called Fc region, 
possesses the sequence that can bind the Fc receptors on innate immune effector cells, 
such as macrophages, natural killer (NK) cells and polymorphonuclear leukocytes 
(PMN), or interact with complement proteins. As an important player in the immune 
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defense system, antibodies can neutralize toxins, pathogens (bacteria or virus) or sick 
cells by attaching to the protein antigen epitopes with Fab region to prevent infections, 
clear cancerous cells or reject xenotransplanted organs.  By engaging the Fc receptors, 
antibodies can also trigger a cascade of signaling events in the effector cells, which leads 
to the cytolytic response, phagocytosis of immune complexes, antibody-coated malignant 
cells or opsonized pathogens. Some antibodies are also capable of activating the 
complement-dependent cytotoxicity, which kills target cells or microorganisms by 
damaging cell membrane. There are five major types of immunoglobulins: IgA, IgD, IgE, 
IgG, IgM, which are distinguished by their constant regions, consisting of part of the Fab 
and the entire Fc regions. IgA usually helps to defend against germs in the body fluid and 
IgM is potent at inducing complement pathway activation. IgE is important mediator of 
allergic reaction and the function of IgD is still under investigation. Among all the five 
types of immunoglobulins, IgG is the most abundant type and the key contributor to 
antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), which are 
the major way how antibody-labeled targets are destroyed or eliminated.
30
  
2.1.2 Mechanisms of actions of monoclonal antibody therapy work in cancer 
Monoclonal antibodies, i.e., antibodies produced by clones of one parent cells or a cell 
line and composed of identical protein molecules, as treatments for cancer, have been 
developed for over two decades and has proved their efficacy in a number of 
hematological malignancies and solid tumors. 
10
 Over the past 30 years, over 80 
monoclonal antibodies have received market approval from US Food and Drug 
Administration, among which around 30 were indicated for cancer.
31
 Generally, 
monoclonal antibody therapy for cancer can be divided into two categories: (1) directly 
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eliminates the tumor cells by antibody-dependent immune responses; (2) the other type 
modulates the immune factors in tumor microenvironements. The success of the first type 
of antibody-based therapies relies on the expression of tumor-associated antigens 
(TAAs), which are a group of proteins or molecules that are either selectively expressed, 
mutated or overexpressed on the malignant cells compared to normal tissues.
32
 For 
example, rituximab, a chimeric IgG antibody for CD20 on malignant B cells, has 
achieved great clinical response rate in B non-Hodgkin’s lymphomas.
33
 Upon binding on 
the CD20 overexpressed on neoplastic B cells, rituximab engages the activating Fc 
receptors on immune cells and elicits ADCC to kill B cells. An increase in the overall 
survival of patients with non-Hodgkin’s lymphoma is observed after treatment with 
rituximab with low dose-limiting toxicity.
34
 Another successful story is trastuzumab, 
which targets the overexpressed-antigen Her2 in aggressive breast cancer and a fraction 
of ovary and stomach tumors. Trastuzumab interacts with macrophages and triggers 




 Other similar examples include 
Alemtuzumab for CD52 in chronic lymphocytic leukemia and J591 for PSMA in prostate 
carcinoma.
10
 However, the majority of tumor/cancer types do not have a TAA that is 
suitable for mAb-targeting. 
Instead of clearing the malignant cells, the second type of antibody-based therapy 
depletes immunosuppressive factors or regulatory immune cells and thus restoring the 
immune attack against cancer cells. For example, Ipilimumab blocks the cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4) on T cells, as a result of which regulatory T 
cell-mediated immune-suppression is impaired.
36,10
 Clinical trials in patients with 




 Another major roadblock to successful anti-tumor attack is the 
interaction between programmed death ligand 1 (PDL1) on tumor cells and programmed 
death 1 receptor (PD1) on T cells, which leads to dysfunction of antigen-specific T cells. 
To interrupt this interaction, Atezolizumab (anti-PDL1, Genetech) or nivolumab (anti-
PD1, Merck), as two examples, were developed and used in clinic for a number of tumor 
types. These antibodies achieved good clinical results, showing tolerable toxicity, 
regression of tumors in patients and improved survival.
38
 Despite the encouraging results 
from the above-mentioned mAb therapies, there are obstacles in cancer treatment that 
have not been overcome by mAbs.  
One of those obstacles is myeloid derived suppressor cells (MDSCs), which are a 
heterogeneous populations of cells consisting of myeloid progenitors, immature 
macrophages, immature granulocytes, and immature DCs.
39
 Upon the onset of tumor, 
MDSCs accumulate in tumor, spleen and blood and secrete various cytokines (e.g. IL-10, 
TGF-β), enzymes and reactive species to inhibit the proliferation, activation of T effector 
cells, and also regulate the cytokine production of macrophages and impairs the function 
of nature killer cells.
40,41
 Similarly to MDSC, regulatory T cells are required for the 
protection against autoimmune diseases, which suppresses the reactivity of anti-tumor T 
cells.
42
 It is widely acknowledged that inhibition of MDSC and regulatory T cells is 
essential to improve the outcome of anti-tumor therapies.
43
 Some mAbs (e.g., 
Ipilimumab) can reduce the number of MDSCs or regulatory T cells in the body; but, 
because of lack of specific surface antigen, no effective mAbs have been developed 
specifically for human MDSCs and regulatory T cells. 
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2.1.3 Limitations of monoclonal antibodies 
Despite the success of a few types of mAbs, their production and application poses 
several problems. The first is inherent in the process of their production. A typical 
process to acquire a new type of mAb involves the immunization of animals (transgenic 
or non-transgenic) with antigens, the isolation of antibody-producing B cells, hybridoma 
production, the selection of high binders by screening, cloning, mAb production in a 
single cell line, purification and validation. Obviously, this is a long, complex process, 
which usually lasts months and requires large amount of labor and high production cost. 
To avoid clearance and allergic reaction of murine antibodies and also to be able to 
activate the antibody-dependent immunity in human, chimeric, humanized and human 
antibodies must be produced by various antibody-engineering techniques, such as 
complementarity-determining region grafting and transgenic ‘humanized’ mice
12
, adding 
difficulty to the process. The advent of antibody (scFv)-phage display screening 
technique solves parts of the problem by using human DNA in the library.
30
 At the same 
time, this new method reduces the time and amount of effort required by avoiding the 
immunization and hybridoma production steps.
44
 However, the fragments selected 
through phage display still need to be constructed into a complete antibody followed by 
mAb production in cell lines. As for the production of mAbs after selection and cloning, 
sophisticated eukaryotic machinery is required to produce them in active form because 
antibodies are large protein molecules containing numerous disulfide bonds and post-
translational modifications, such as glycosylation.
12
 As a result, considerable cell culture 
work is needed. High expenditure also stems from the following intensive purification 
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steps of mAbs from cell cultures and validation steps, all of which together make mAb a 
very expensive drug.  
In terms of application, mAbs face several challenges in the following aspects. First, as 
discussed previously, for a lot of immunological targets and most cancer types, we can 
hardly develop a type of effective mAbs due to the lack of identified surface antigens. In 
addition, pharmacokinetics properties of antibodies, which are dictated by their molecular 
characteristics (e.g.,molecular size, shape, affinity and valency), give them not only an 
advantage for treating hematological malignancies thanks to the long serum half-life, but 
also a curse for solid tumors, which make up 85% of human tumors, because of the 
inefficient tissue penetration and poor retention.
12,13,45
 A third possible limitation lies in 
its mechanism of function. The mAbs have to compete with patient’s IgG for binding to 
Fc receptors and therefore must be injected at a high dose to achieve significant clinical 
responses, contributing to the high cost of mAb therapy. 
12
 
2.1.4 Alternatives to monoclonal antibodies 
To overcome the challenges facing by mAbs therapies, we’ve been striving to develop 
functional alternatives during the past few years. There are now limited types of artificial 
antibodies or antibody-mimetics developed so far (e.g.,nanobody, diabody, minibody, 
affibody and peptibody), most of which are peptide/protein surrogates of part of or the 
full structure of monoclonal antibodies. Nanobody is one of the most promising types of 
artificial antibody, which is single targeting-domain antibody retrieved from an immune 
library of Camelidae.
46
 Their advantage lies in better tissue penetration than conventional 
mAbs because of their small dimensional size (2.5nm in diameter).
46–49
 Nanobodies have 
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been successfully applied in solid tumor treatment, targeted drug delivery and 
bioimaging, but they cannot trigger antibody-dependent immune responses because of 
lack of Fc fragments. Their rapid renal clearance and high accumulation in kidney also 
impeded their advancement in clinical application.
49
 Diabody (a dimer of single-domain 
variable regions of both heavy chains and light chains) and minibody (single-domain 
antibodies) have similar advantages and drawbacks as nanobody, except that they possess 
the functional protein fragments to induce immune responses. Affibodies are a library of 
engineered protein molecules that can be used as tools for molecular recognition, but 
similar to nanobodies, they do not have Fc fragments.
50,51
 Another option is peptibody, 
which consists of two copies of synthetic peptide ligands for target binding, which are 
covalently linked to the amino terminus of a recombinant IgG Fc domain. They exhibit 
potent biological activity and good targeting specificity.
52
 Despite better pharmacokinetic 
properties, they are still subject to renal excretion and face the same production and 
application problems as mAbs. 
52
 Patrick McEnaney et al. have developed a chemically 
synthesized, bivalent molecule functioning similar as anti-PSMA antibodies, called 
synthetic antibody, by utilizing a PSMA-binding peptide and a human-Fc receptor 
gamma I binding peptide. The binding peptide cp33 is  (AQVNSCLLLPNLLGCGDDK 
with Cys-Cys cyclization, referred to as cp33 in Ref. 26) utilized in this thesis as well.
53
 
The molecule they synthesized was able to induce phagocytosis of PSMA-expressing 
cancer cells in vitro with U937 human monocytes, but its function in real tumor is still 




2.1.5 Crosstalk between mouse and human antibodies 
In general, there are four types of monoclonal antibodies most commonly in use for 
therapy, i.e., murine, chimeric, humanized, and human antibodies. The first type of 
monoclonal antibody evaluated in the clinic was murine antibody. However, 
administration of murine antibodies in human induces the development of anti-mAb 
antibodies and the rapid clearance limited their efficacy.
54
 Therefore, it is necessary to 
use chimeric, humanized and human antibodies, which all have human Fc regions, to 
treat cancer patients. Mouse models of cancer are the most prevalently used, clinical 
relevant and economical animal model to evaluate the efficacy of a new type of 
monoclonal antibodies before undertaking clinical trials in human.  Therefore, whether an 
antibody with human Fc regions can activate an immune response in mouse are 
intensively studied to discover the best way to design the most effective monoclonal 
antibody-based treatment strategy for diseases.  
Human IgG has four isotypes, IgG1, IgG2, IgG3, and IgG4 and mouse IgG has IgG1, 
IgG2a, IgG2b, IgG2c and IgG3. Different isotypes have variable specificity and affinity 
for different Fc gamma receptors (FcγRs) and mediate effector functions in slightly 
different ways. 
55,56
 In this thesis, we used a human IgG1-mimicking peptide in mouse 
systems, and focused on the reactivity of human antibodies in murine models. Human 
IgG1 is the most commonly used isotype used in antibody therapy of cancer because they 
are easier to produce and the most potent inducer of ADCC/ADCP by human activating 
Fc gamma receptor (hFcγRI, hFcγRIIa, hFcγRIIc, hFcγRIIIa, and hFcγRIIIb).
57
 Tests in 
mouse models repeatedly reported that human IgG1 are able to bind on all activating 
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FcγRs (I, II, III, IV) in mouse with modest affinity and induce ADCC/ADCP by mouse 
NK cells, macrophages and sometimes polymorphonuclear leukocytes (PMNs). 
55,56,58
 
2.1.6 Small molecule binding ligands 
Protein-protein interaction, including the interaction between antibodies and antigens, 
largely depends on the molecular forces determined by a defined surface composed of a 
group of spatially adjacent amino acids. In this sense, smaller peptides also have the 
potential to mimic the binding structures in the original macromolecules. A variety of 
peptide mimetics (also called peptidomimetics) have been generated by structure-based 
procedures and exhibits similar biochemical and biological properties to its template 
proteins.
59–61
 In addition to the peptidomimetics, peptide-phage display techniques enable 
the identification of ligands that have comparable affinity to the relevant antigens as 
conventional mAbs.
17,62
 These peptidomimetics or ligands, usually produced by solid-
phase chemical synthesis, can functionally substitute the binding domains and/or the Fc 
regions in antibodies without the involvement of animal/cell work.  
Aptamers are another prevalently used class of small molecule ligands, which are short, 
single-stranded DNA or RNA molecules. They fold into various secondary structures 
because of their propensity to form complementary base pairs, as a result of which they 
form unique three-dimensional structures and are able to bind to their specific cognate 
targest.
16
 One well-known example is pegaptanib, which targets vascular endothelial 
growth factor (VEGF) and already approved by FDA. Similar to peptides, aptamers are 
usually selected through screening methods, such as SELEX (systematic evolution of 
ligands by exponential enrichment).  
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Both peptides and aptamers have the advantages of small physical size, flexible structure, 
low immunogenicity, and easier, cheaper and quicker chemical production.
16,17
 Their 
binding capability enables them to be used directly as antagonist or agonist.
63,64
 Also, 
owing to the targeting ability, they were used to guide drug or gene delivery.
18,65,66
 The 
small physical size of them usually results in metabolic instability, so peptide/aptamer-
Fc/antibody complexes and particle-conjugates were usually developed to extend the 
serum half-life.
15,65,67
 The small physical size also leads to higher attainable surface 
density, so multimerization or multivalent-presentation of the peptides/aptamers on 
carriers (e.g., particles) are possible and brings in advantages of higher avidity, 





2.1.7 Multivalency effect 
Another aspect relevant to antibody and antigen interaction as well as antibody-
dependent immune responses is the valency of interaction. Multivalent interaction is 
required in most biological processes, including cell-cell recognition and the induction of 
signaling transduction after receptor-ligand pairing. Specifically, the initiation of 
antibody-dependent phagocytosis activity by monocytes relies on the clustering of 
multiple Fc-receptor molecules on cell membrane by IgGs coated on the pathogens in the 
immune complexes.
71
 A number of previous studies also support the conclusion that a 
multivalent display of antibodies/binding ligands on the surface of a particle-carrier or 
construct increases the binding avidity of the conjugates as well as the biological 
functions of the bound molecules.
68,72,73
 For example, multiple copies of RGD peptides 
displayed on the surface of nanoparticles have decreased EC50 and IC50 on endothelial 




 Similarly, Irina and her coworker showed that antibody-gold nanoparticle 
conjugates with different valencies have affinity of three magnitude higher than that of 
the free antibody to its target virus.
72
 Liposomes presenting tetrameric targeting-peptides 
also delivers more cytotoxic drugs to cells than that with monomeric peptides.
62
 In 
addition, multivalent binding with ligands allows the nanoparticles to distinguish the cell 





Synthetic nanoparticles usually refers to particles within the size range of 1-1000nm, 
made with polymers, metal, lipid, peptides or other biological material through chemical 
synthetic routes. In the past decades, they have been widely applied in the biomedical 
field for drug or gene delivery, imaging and treatment of diseases. Unlike monoclonal 
antibodies, nanoparticles offer some specific physicochemical properties different from 
large biomolecules, such as tunable size and surface chemistry. They also have a high 
surface-area-to-volume ratio, which indicates that they may carry a high density of 
ligands and render high binding efficiency. In addition, sub-50nm nanoparticles exhibit 
improved tissue penetration and lymphatic trafficking.
75,76
 Because of these advantages, 
nanoparticles have numerous applications in the biomedical field. Some successful 
examples include the targeted delivery of chemotherapeutic drugs to tumors by antibody-
coated nanoparticles,
77
 neovasculature imaging by RGD-modified nanoparticles,
78
 and 




Among the many types of nanoparticles, gold nanoparticles have the advantages of 
chemical stability, biological inertness and ease of surface modification and tracking due 
to their unique optical property. Therefore, it is a favored option to develop tools or 
nanoparticle-based therapies for biomedical applications.
80–83
 For example, the 
conversion of radiation to heat due to plasmon resonance of gold nanoparticles lead to the 
hyperthermic damage of cancer cells, so gold nanoparticles are widely applied as radio-
sensitizers in the cancer treatment.
84
 Oligonucleotides-conjugated gold nanoparticles 
have been widely used in the diagnosis of diseases combining the DNA hybridization and 
nanoparticle-facilitated fluorescence, chemi-luminescence or radioactive detection 
together.
85,86
 Similarly, antibody- or ligands-modified gold nanoparticles can easily 
deliver the drugs to the targeted cells owing to the endocytosis of nanoparticles. 
82,87,88
 
Janus particles are a group of particles, including polymeric, inorganic or hybrid, micro- 
or nano-particles, which has anisotropic surface property, named after the two-faced 
Roman Gold Janus. Typical fabrication methods for Janus particles are phase-separation, 
microfluidic and electrohydrohynamic jetting, immobilization.
89,90
 Janus particles could 
offer unique optical or catalytic properties owing to the combination of different 
materials on the same particles, such as a red shift in the UV-vis adsorption of gold 
nanoparticles after turning into a SiO2-Au Janus particle.
91
 Some Janus nanoparticles 
have the capability to self-assembly into disk-shaped micelles or chain-like structures, 
presenting distinguished modulating ability for drug delivery and imaging.
92–94
 The most 
promising use of Janus particles relies on their capability to simultaneously and 
incompatibly present two types of ligands or delivery two types of drugs on different part 
of the particle surface. However, it was mostly utilized on the Janus microparticles (size 
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over 1000 nm), for example, anti-CD3 and protein coated Janus microparticles as 
artificial antigen-presenting cells to activate T cells. 
95–97
 Few applications in this way 
were reported using Janus nanoparticles. Despite it is hard to characterize the Janus 
surface composition on a nano-scale, Janus nanoparticles conjugated with multi-types of 
ligands or drugs still hold great promise in biomedical applications, such as multi-
functional drug delivery and therapeutic modulation.  
2.2 Overview 
Here, we propose to develop a type of artificial antibody using metallic Janus 
nanoparticle with ligand modifications, called synthetic nanoparticle antibodies (SNAbs). 
The modification includes two peptide ligands on the opposite surface areas, one of 
which has binding affinity towards specific surface proteins on the selected target cells, 
and the other mimic the biological function of Fc region of human IgG1 such that they 
can bind to human and mouse Fc gamma receptors (FcγRs) and trigger the activation of 
innate effector cells (e.g.macrophages, NK cells, polymorphonuclear neutrophiles).  
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Figure 2. The structural design of SNAbs.  
The primary hypothesis is: the designed synthetic nanoparticle antibodies (SNAbs) with 
the mentioned characteristics in Chapter 2 could induce antibody-dependent cellular 
cytotoxicity (ADCC) and/or phagocytosis (ADCP) efficiently both in vitro and in vivo. 
We plan to test this hypothesis by: 1) generating synthetic nanoparticle antibodies that are 
structurally similar to monoclonal antibodies but displays multiple biologically active 
ligands on each part of the surface; 2) evaluating the ability of SNAbs to target cells of 
interest specifically and to activate Fc-receptor-mediated signaling pathways in vitro in 
comparison to mAbs; 3) assessing the degree of ADCC/ADCP induced by SNAbs. The 
therapeutic potential of the designed SNAbs will also be validated in in vivo tumor 
models. To fully demonstrate the function of SNAbs, we propose to analyze its capability 
for a murine cell target (myeloid-derived suppressor cell (MDSC)), a cell type that so far 
does not have a known specific antigen.  
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Figure 3. The hypothetical mechanism of action of SNAbs. A. A typical tumor immune-
microenvironment. B. A MDSC-targeting SNAb recognizes MDSCs in the 
microenvironment and engages with the Fc receptors on the effector cells, which 
subsequently activates the immune responses (e.g., ADCC and ADCP) and kills the 
MDSCs.  
2.3 Significance 
The significance of the proposed work lies in the following aspects: 1) we aim to design 
optimized synthetic procedure utilizing only peptides and nanoparticles to produce 
SNAbs that requires lower production cost and shorter production time than conventional 
mAbs; 2) we aim to develop SNAbs that can be a functional alternative for current 
antibody therapy of cancer with great translational potential, because these SNAbs can 
bind on specific antigen and trigger antibody-dependent cytotoxicity as what mAbs do; 3) 
the SNAbs may have potential advantages over conventional mAbs in terms of 
application: deeper tissue penetration, longer retention, wider target range than mAbs, 
and an easily adaptable platform to generate new types of SNAbs by varying the target-
binding ligands. In addition, our investigation will yield information as to whether 
multivalent presentation of peptide ligands (both targeting and Fc-mimicking) on SNAbs 
can lead to comparable, even stronger or different mechanism of Fc-mediated antigen 
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specific immune responses in comparison with conventional mAbs, which could benefit 
the development of new generations of artificial antibodies.  
2.4 Innovation 
There are several aspects that are innovative associated with our work: 
1) New targeted treatment strategy for MDSCs: MDSCs are selected as the primary 
cell target to develop the first type of SNAbs. Current options for abrogating MDSC-
mediated suppression of anti-tumor immune responses are primarily chemotherapeutics 
and small molecule inhibitors, which are indirect treatments with severe toxic side 
effects. The only two monoclonal antibodies available (i.e., anti-Gr1, anti-Tspan33) 
either have unsatisfactory and toxic side-effects in the animals or are not tested or 
applicable for diseases models and human.
98–101
 Here, we use a completely new targeting 
strategy for MDSCs, a peptide, identified through phage display library biopanning, on 
the SNAbs. The SNAbs offers an efficacious while specific depletion method option for 
MDSCs to restore the immune-competent environment for cancer.  
2) Novel design of an artificial antibody: All previous artificial antibodies or antibody-
mimetics utilize peptide/protein-based conjugates to mimic the structure of antibodies. 
By contrast, this is the first time that nanoparticles are employed as the scaffold structure 
of an artificial antibody. This may endow improved tissue penetration and retention 
property to the SNAbs in solid tumors and deep tissues.
22,23,86
 Moreover, metallic 
particles show better biocompatibility than many polymer particles that presents active 
terminal chemical groups and also allows imaging without dye-loading, which can 
benefit the monitoring after in vivo treatment of the designed SNAbs.
102,103
 Lastly, the use 
 22 
of nanoparticle also lends us the opportunity to conjugate multiple copies of various 
ligands on the same construct. All in all, nanoparticle brings in new possibilities for 
artificial antibody design.  
3) Simpler and more flexible design of artificial antibodies: Peptides are utilized as 
both antigen targeting and activation moieties for immune responses, which eliminates 
the necessity for genetic engineering and cell culturing, making it a simpler artificial 
antibody to manufacture. Additionally, peptides or aptamers that have specific binding 
affinity towards various targets can be easily identified through high throughput 
screening techniques, e.g. phage display biopanning, and thus increased the application 
potential and target range of SNAbs as an artificial antibody beyond conventional mAbs 
in terms of cell depletion. By varying the binding peptides, we can easily develop SNAbs 
for new targets. Again, the multivalent display of ligands on SNAb helps increase the 




CHAPTER 3 AIM 1. TO DESIGN AND DEVELOP SYNTHETIC 
NANOPARTICLE ANTIBODIES (SNABS) THAT DISPLAY BOTH 
TARGET-BINDING LIGANDS AND FC-MIMICKING LIGANDS 
A bacteriophage is a virus of bacteria, whose growth and proliferation relies on a 
prokaryotic host. With transcriptional fusion with the phage genome, a foreign peptide or 
protein can be expressed on the phage protein coat. Screening the phage libraries 
displaying polypeptides against a selected protein, cell type or tissue of interest is a 
powerful technique, called the peptide phage display biopanning. Several rounds of 
biopanning against the target (i.e., protein, cell, or tissue) usually leads to the harvest of 
enriched specific binding phage clones, and by analyzing the genome sequence, we can 
identify the candidates of targeting ligands with high affinities. Some interesting 
examples include H2009.1 (RGDLATLRQL) that binds to the restrictively expressed 
integrin αvβ6 on the non-small cell lung cancer, Peptide P60 (RDFQSFRKMWPFFAM) 
that can target and inhibit Foxp3
+
 regulatory T cells, and M2pep (YEQDPWGVKWWY) 
that can target and induce apoptosis of tumor-associated macrophages.
18,42,104
 As we can 
see, phage display library biopanning enables the identification of ligands for targets that 
are understudied and lack of known exclusive surface antigens. Sometimes, phage 
display can even be directly applied in vivo, such as in tumor models,
66
 to hunt for 
ligands that bind to a particular type of malignancies in a physiological environment. 
Cp33, is a peptide ligand, identified with a naïve cyclic peptide phage display library 
against human FcγRI.
26
 The soluble form of cp33 competes with human IgG1 for binding 
on FcγRI, whereas the dimerized cp33 could trigger phagocytosis of beads
26




 and superoxide burst by human monocyte-like cells, U937. Cp33 has not been 
tested for its function in a mouse immune environment, but the crosstalk between human 
IgG1 antibodies and mouse FcγRs has been well studied. It is reported that hIgG1 binds 
to all four mFcγRs and was the most potent among all the four types of human IgG1 in 




MDSCs are important regulators of the immune responses, consisting of myeloid 
progenitors, immature macrophages, immature granulocytes, and immature DCs.
105
 They 
are characterized as mainly two subsets, granulocytic MDSCs (G-MDSCs) and 
monocytic MDSCs (M-MDSCs).
40















 In human, MDSCs 















 While it is still under fierce debate which of the two 
subsets contributes more to the immune-suppression, the majority of the MDSCs in 
inflammation and cancer are G-MDSCs.
41
 In general, MDSCs reduce the essential amino 
acids (i.e., arginine and cysteine) for T cell proliferation and cytolytic activity. They 
secrete inhibitory cytokines, such as interleukin-10 and transforming growth factor-beta, 
to dampen the anti-tumor immune responses.
40,105,109
 In addition, MDSCs also secrete 
reactive nitrogen and oxygen species, which affects the function of T cell receptors and 
chemokines and thus influencing the T cell migration and inducing NK cell 
apoptosis.
110,111
 MDSCs have high expression of PD-L1 on the surface, which leads to 
reduced T cell mediated anti-tumor cellular response via the interaction with PD1 
receptor.
41
 On the other hand, MDSCs help tumor neovascularization and growth through 
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the secretion of angiogenic factors, growth factors, matrix metalloproteinases and 
cytokines, which also activates the Th2 response and regulatory T cells.
40
 In a word, 
MDSCs plays a key role in the immune-suppression of tumor. 
111–113
  
A handful of studies support that the depletion of MDSCs can significantly change the 
immune environment of tumors, markedly improved the infiltration of T cells in tumor, 
increased the activation of T cells and inhibited tumor growth. 
114,115
 MDSC depletion 
also helped improving the therapeutic effect of other immunotherapies, such as adoptive 
T cell transfer
116
 and immune-checkpoint inhibition.
117,118
 However, the options for 
removing the MDSC population from tumors are quite limited. There are a few 









) that can reduce the myeloid cells circulating in the body 
to some extent, but they are not specific for MDSCs and usually affect the healthy cells 
and tissue as well. In terms of monoclonal antibodies, group-1 protein (Gr1)-targeting 
antibody or more specifically Ly6G antibody are the only options for mouse. However, 
Gr1 antibodies are reported to elicit an effect only in young mice but not in aged mice, 




 Anti-Tspan33 is recently 
reported to recognize suppressive MDSCs in both mouse and human, but yet been 
validated sufficiently for their therapeutic effects.
100
 Tspan33 is also expressed on 
activated and malignant B cells, increasing the possibility to randomly remove B cells 
while targeting MDSCs using anti-Tspan33 antibodies. 
101
 S100A8/A9 proteins are 
calcium-binding proteins, predominantly expressed by myeloid cells, especially 
MDSCs.
121,122
 S100A9 protein inhibits the differentiation of precursor cells into mature 
macrophages and dendritic cells and is essential to the recruitment of MDSCs into tumor. 
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123
 Further, the elevated S100A8/A9 expression supports an autocrine feedback loop that 
promotes the accumulation of MDSCs in tumors, suggesting the potential of S100A8/A9 
as a useful marker for MDSCs.
121,122,124,125
 Hong Qin et al. identified a new targeting 
ligand, G3 peptide, for MDSCs isolated from various murine tumor models with phage 
display screening.
126
 G3 peptide potentially targets the S100A8/A9 heterodimer highly 
expressed on the MDSCs, which regulates the expansion and migration of MDSCs in 
both mice and human.
123,124,127
 Therefore, G3 is likely to be a good alternative targeting 
strategy for MDSCs.  
Gold nanoparticles are widely used as nano-medicine platforms due to their bio-inertness, 
facile synthesis method, unique optical properties and surface plasmon resonance peaks 
that simplify the detection and quantification. We selected 30nm gold nanoparticles as 
our scaffold structure to leverage the capability of sub-50nm nanoparticles for penetration 
and retention in tumor. The 30nm gold nanoparticles have streptavidins coated all over 
the surface to enable the chemistry for making Janus surface structures and conjugation 
of ligands. Specific segments of the Fc fragments are required to interact with the Fc 
gamma receptors to elicit a response. Because it is hard to control orientation of Fc 
fragments either alone or in the form of an antibody during conjugation, we chose to use 
cp33 to mimic the function of a Fc fragment and as our binding partner for Fc receptors. 
As the size of the nanoparticle scaffold is very small (30nm in diameter), we are also able 
to conjugate a higher number of cp33 than Fc protein fragments on the nanoparticles, 
leading to a higher valency.  
In this aim, we propose to develop SNAb that imitate the structure of antibody by 
conjugating target-binding peptides and Fc-mimicking peptides on Janus nanoparticles. 
 27 
Our target cell type is myeloid-derived suppressor cells, so we chose G3 as our targeting 
ligands, and cp33 was used as the Fc-mimicking ligands. To generate the SNAbs, we 
adapted a solid-phase chemistry methods to product Janus gold nanoparticles and took 
advantage of highly orthogonal chemical reactions to modify the surface of Janus gold 
nanoparticles with the above-mentioned two types of peptide ligands (G3 and cp33) that 
process the required biological functions. The physical and chemical properties of these 
SNAbs were characterized using fluorescence-based assays and imaging methods.  
3.1 Methods 
3.1.1 Materials 
Aminomethyl ChemMatrix resin (35-100 mesh size, ~1mmol/g loading capacity, 
Cat#.68571), tris(2-carboxyethyl)phosphine (TCEP, Cat.#.646547 and C4706), and biotin 
(Cat#.B4501-1G) were purchased from Sigma Aldrich. The heterofunctional crosslinker, 
sulfo-NHS-S-S-biotin, was purchased from Thermofisher Scientific (Cat#.21331, and 
Apexbio Technology.Inc, Cat#.A8005). HABA (4 -́hydroxyazobenzene-2-carboxylic 
acid) (Cat.#.28010) and avidin (Cat.#.21121) were purchased from Thermofisher 
Scientific, The 30nm streptavidin functionalized gold nanoparticles were made by 
Nanopartz. Inc and Nanohybrids. Inc. The 10 mL reaction vessel was purchased from 
Torviq.Inc (Cat#.SF-1000). Human IgG1-Fc functionalized with biotin was purchased 
from Acrobiosystems (Cat.#.IG1-H82E2). Peptide ligands were synthesized by Genemed 
Synthesis (See Table 1). N-ethylmaleimide (Cat.#.23030), Alexa Fluor 647 C2-
Maleimide (Cat#.A20347), and Slide-A-lyser dialysis cassettes (molecular-weight-cut-
off: 2KDa, 3KDa, 10KDa) were purchased from Thermofisher Scientific. The 3nm 
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biotin-gold nanoprobes were purchased from Nanocs. Inc. (Cat.#.GNB3). PBS buffer was 
purchased from Hyclone GE Healthcare, Corning Corporation and Sigma Aldrich or 
made from monobasic and dibasic sodium phosphate from Sigma Aldrich (Cat.#.S9638-
250G, S9763-1KG). Whatman Puradisc polyethersulfone syringe filter (0.22 μm) was 
purchased from GE Healthcare (Cat.#.6780-2502,6780-1302). BD 10 mL syringes with 
luer lock were purchased from VWR (Cat.#.BD309653). L-Leucine-N-Fmoc (13C6, 97-
99%; 15N, 97-99%) for heavy, stable isotype labeled peptide synthesis was purchased 
from Cambridge Isotope Laboratories, Massachusetts, USA.  
3.1.2 Preparation of MDSC-targeting synthetic nanoparticle antibodies (MDSC-
SNAbs) 
3.1.2.1 Production of Janus streptavidin-coated gold nanoparticles  
To generate Janus gold nanoparticles, aminomethyl ChemMatrix resins were 
functionalized with biotin groups by reacting with bifunctional, thiolytic cleavable 
crosslinkers, sulfo-NHS-S-S-biotin in a reaction vessel (Step 1 in Figure 4). Firstly, 110-
120 mg of resin was hydrated with 8 mL of pH6.95 1X PBS (0.0067M PO4) in a 10 mL 
reaction vessel on the shaker shaking at 300 rpm at room temperature for 3-4 hrs. The 
resins were washed with 5 mL PBS for 7 times. After the resin was hydrated, 100 mg of 
crosslinker sulfo-NHS-S-S-biotin was dissolved 14 mL of pH 6.95 1×PBS (0.0067M 
PO4) and filtered with 0.22 μm syringe filters. Three and a half milliliter of the 
crosslinker solution was added to each reaction vessel. The vessel was rotated at 37 °C 
for 24 hrs, after which the vessel was washed with 5ml of 1×PBS for 12 times. 
Subsequently, 6-10e11 of streptavidin-coated gold nanoparticles (SA-AuNP-SA) 
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(Nanopartz. Inc or Nanohybrid Inc, USA) in 3.5 mL of 1×PBS were added to the reaction 
vessels and reacted with the biotin-functionalized resins for overnight at 37 °C on rotator. 
After reaction, the resins in the vessels were washed with 5 mL PBS with 0.01% Tween-
20 twice and 5 mL PBS without tween-20 for another 4 times to remove the unbound and 
non-specifically bound SA-AuNP-SA (Step 2). Then, 2 mL of 0.05M tris(2-
carboxyethyl)phosphine(TCEP) (pH 7) was added into each reaction vessel. Air bubbles 
were removed and the reaction vessels were rotated at room temperature for 24 hrs.  
The resins were then washed again with 3 mL of 1×PBS for 7 times (Step 3). All the 
wash buffers containing the Janus gold nanoparticles (SA-AuNP-SH) were collected into 
fresh 50 mL tubes. The solutions of Janus gold nanoparticles were concentrated by 
centrifugation at 4500 g for 1 hr for three times. The pellets were collected and 
supernatants were transferred into a new tube after every centrifugation. Finally, the 
concentrated SA-AuNP-SH solution was dialyzed against PBS in gamma-irradiated, 
MWCO 10 KDa slide-A-lyzer to remove excessive TCEP for two days and the solution 
was then retrieved from the cassettes, filtered with 0.22 μm syringe filtered then stored in 
4 °C until use. The above procedure gave the best yield. To shorten the procedure to one 
day, some changes in the procedure are acceptable with a compromised yield: the 
reaction duration of each step can be reduced to 2 hrs; the rounds of concentration 
centrifugation can be reduced to one time or two times, or be done with ultracentrifuge at 
higher speed (e.g., 10,000 g) for 15-30 mins; instead of dialysis, the TCEP can be 
removed from the solutions of concentrated Janus SA-AuNP-SH with ultracentrifugal 
filters units (e.g., Amicon Ultra-4 MWCO 100 KDa) by centrifuging at 700 g for 5 mins 
for 4 times.  
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Table 1. Peptide sequences and functions. 
Name Sequence Functionality 
G3-biotin WGWSLSHGYQVK-biotin MDSC Targeting 
G3-SMCC* WGWSLSHGYQVK-SMCC MDSC Targeting 
Scrambled G3-biotin KSLWVQWSGGHYK-Biotin MDSC Targeting 
Cp33-biotin AQVNSCLLLPNLLGCGDDK-biotin, 
C6-C15 disulfide bond 
FcγR Binding 
Cp33-SMCC* AQVNSCLLLPNLLGCGDDK-SMCC, 
C6-C15 disulfide bond 
FcγR Binding 
IrrelPep-SMCC* AQTHFDTCSWMYCWDGWWK-




C8-C13 disulfide bond 
Irrelevant peptide 
control 


























*SMCC: succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(L): Heavy, stable isotype labeled-LEUCINE (13C6, 97-99%; 15N, 97-99%) 
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3.1.2.2 Synthesis checkpoints for quality control 
The hydrolysis or conjugation of sulfo-NHS releases NHS as a leaving group, which 
absorbs strongly at 260-280 nm. A sample of the crosslinker solution was measured for 
absorbance at 260-280 nm before and after adding NaOH (10% by volume) to determine 
the reactivity of the crosslinker. Another sample (~100 μL) of crosslinker solution before 
adding to vessels was saved in 0.5 mL tube and rotated at the same time as the reaction 
vessels at 37 °C. The saved sample, solutions retrieved from the vessels after reaction 
with the resin and the washing buffer of the last wash from the vessels were measured for 
absorbance at 260 nm again to validate the completion of reaction and the removal of free 
excessive crosslinkers in the vessels after reaction. In general, the crosslinker solution 
retrieved from the vessels after the reaction should had higher absorbance than the saved 
sample of unreacted crosslinker. The washing buffer of the last wash should have the 
same absorbance reading as the PBS solution does.  
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Figure 4. Synthesis procedure of Janus streptavidin-coated gold nanoparticles SA-AuNP-
SH.  Step 1: Functionalization of resin with sulfo-NHS-SS-Biotin crosslinker; Step 2: 
Binding of SA-AuNP-SA onto functionalized resins; Step 3; Cleavage of bound SA-
AuNP-SA with TCEP and purification of the cleaved Janus SA-AuNP-SH.  
3.1.2.3 Quantification of the SA-AuNP-SA, SA-AuNP-SH particles 
The 30 nm gold nanoparticles have a SPR peak around 522 nm-525 nm. A standard curve 
was generated with the absorbance of a series of concentration-known SA-AuNP-SA 
solutions for every new batch of SA-AuNP-SA received from Nanopartz.Inc or 
Nanohybrids.Inc. We also measured the solutions of the SA-AuNP-SA before adding to 
vessels, the solution of unbound particles after washing, and the solutions of Janus SA-
AuNP-SH before and after dialysis. The calculations was done with the following 
equations: 
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                                ............................................................................. (1), 
where C is the concentration of the gold nanoparticles (#/mL), k is the slope generated 
from the standard curve, AS(522-525) and AP(522-525) are the measured absorbance values of 
sample and PBS at 522-525nm respectively.  
        .................................................................................................................. (2), 
where T is the total number of nanoparticles in the sample, V is the volume of the sample 
in milliliter. 
          
  
  
  ................................................................................................... (3), 
where PB is the percentage of particles bound onto the resins, TU is the unbound number 
of particles measured out with the collected washing solution and TI is the total input 
number of particles.  
      
  
  
  .............................................................................................................. (4), 
where Y is the yield of Janus SA-AuNP-SH as percentages, TC is the total number of 
particles cleaved from the resins. 
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Figure 5. Surface modification of Janus SA-AuNP-SH with peptide ligands to generate 
MDSC-SNAbs.  Cp33-SMCC was conjugated onto the thiol surface of the Janus SA-
AuNP-SH through maleimide-thiol specific reaction, while G3-biotin was conjugated 
onto the streptavidin surface of the nanoparticles through biotin-streptavidin interaction.  
3.1.2.4 Surface modification of the gold nanoparticles with ligands  
To modify the Janus nanoparticles, 1×hIgG1-Fc (InvitroGen Inc, Carlsbad, CA, USA), or 
30000-molar excess of G3, scrambled G3, cp 33, and/or IrrelPep ligands (Genemed 
Synthesis Inc., San Antonio, TX, USA) with biotin or SMCC groups were conjugated 
onto the streptavidin hemisphere or the thiol hemisphere of the nanoparticles through 
streptavidin-biotin or thiol-maleimide reaction respectively at pH 7.4 in PBS with 
0.001% Tween-20 with gentle rotating at room temperature for 4 hrs or 24 hrs at 4°C. 
Excessive ligands were washed out by centrifugation at 4500 g for 50 mins. Modified 
particles were resuspended in PBS with 0.001% Tween-20 and stored in 4°C until use. 
3.1.3 Verification of asymmetric surface chemistry of the Janus gold nanoparticles 
To verify the existence of the free thiol groups on the Janus particles, an excessive 
amount of Alexa-fluor 647-C2 maleimide dye (Thermofisher Scientific, USA) was 
reacted with Janus gold nanoparticles SA-AuNP-SH or nonJanus SA-AuNP-SA for two 
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hours at room temperature. The unreacted dye was removed by dialysis against PBS with 
MWCO 6000-8000 tubing (Thermofisher Scientific, USA) for two days. The 
fluorescence of the dye-conjugated nanoparticle solution was read on a SynergyHT 
Biotek plate-reader at Ex/Em 635/680. A standard curve made with the known dilutions 
of Alexa-fluor 647-C2 maleimide dye was also read to enable calculations of the number 
of dye molecules conjugated on the particles. 
To evaluate the topology of each chemistry features on the Janus nanoparticles SA-
AuNP-SH or nonJanus nanoparticles, we tagged available biotin-binding pockets of the 
streptavidins with 3 nm biotin-gold nanoprobes and then obtained the transmission 
electron microscopy (TEM) images. More specifically, we incubated the Janus or 
nonJanus nanoparticles with a 2500-molar excess of biotin gold nanoprobes at room 
temperature for 2 hours. The suspensions were then centrifuged at 4500 g for 30 mins to 
remove unbound biotin-gold nanoprobes. The TEM samples were prepared by dropping 5 
μL of the nanoparticle suspension onto 200-mesh formvar carbon-coated copper grids 
and dried overnight in air. The TEM images were acquired using Hitachi HT7700 TEM 
operated at 400 kV.  
3.1.4 Quantification of peptide modification level on the nanoparticles 
G3-biotin and cp33-SMCC with heavy stable isotope-labeled amino acids were 
synthesized by Genemed Synthesis Inc. (See Table 1) using L-Leucine-N-Fmoc (13C, 97-
99%; 15N, 97-99%). G3-AuNP-cp33 SNAb were produced with the normal light peptides, 
i.e., G3-biotin and cp33-biotin. The SNAbs were concentrated in PBS at a concentration 









N-cp33-SMCC. The final concentration of heavy isotope-labeled peptides added in 
the SNAb samples were around 503 nM, Control samples were prepared with same 
concentration of SA-AuNP-SA, or mixture of light and heavy isotope-labeled peptides. 
To determine the amount of peptides modified to nanoparticles, an isotope dilution assay 
was performed.
128
 To remove disulfide-bonds in the peptides of interest, the samples 
were reduced with 5 mM dithiothreitol for 20 mins at 55 °C, and then alkylated with 15 
mM iodoacetamide for 15 mins at room temperature.  The samples were then divided in 
halves and two enzymes, Thermolysin or Asp-N (Promega, Sequencing Grade), were 
added for the proteolytic cleavage of heavy or light G3 and cp33, respectively.    
Following desalting, the samples were analyzed by LC-MS/MS as previously 
described
129
 with the following modification: Initially, the sample was run in a data-
dependent manner to select the proper settings for parallel reaction monitoring (PRM) of 
the peptides of interest. Next, PRM analysis was preformed and analyzed using 
Skyline.
130
 The ratio of the light to known amount of heavy isotope-labeled peptide was 
used to determine the amount of peptides modified onto the nanoparticles in the SNAb 
samples. This work was supported by Georgia Institute of Technology’s Parker H. Petit 
Institute for Bioengineering and Bioscience, including the Systems Mass Spectrometry 
Core Facility. 
3.1.5 Characterization of ligand-modified gold nanoparticles 
Sizes of the MDSC-SNAbs and other ligand-modified Janus or nonJanus gold 
nanoparticles were measured using Zetasizer Nano (Malvern, USA) and transmission 
electron microscopic imaging. The amount of ligands modified onto the surfaces of the 
 37 
Janus or nonJanus gold nanoparticles were determined using fluorophore-tagged ligands. 
Specifically, 10-molar excess of NHS-Alexa Fluor-680 (AF680) dyes were reacted onto 
the N-terminus of G3-biotin or cp33-SMCC ligands. Unreacted dye molecules were 
removed by dialysis in MWCO 2000 slide-A-lyzer cassettes (Thermofisher Scientific, 
USA). A standard curve made with the known dilutions of AF680 dye was read together 
with the fluorophore-conjugated G3-biotin and cp33-SMCC to quantify the concentration 
of the peptide solutions. The AF680-tagged G3-biotin and cp33-SMCC were than reacted 
with Janus nanoparticles SA-AuNP-SHs or nonJanus SA-AuNP-SAs. The unbound 
peptides were again removed by dialysis against PBS in MWCO 6000-8000 tubing for 
two days. Fluorescence of the nanoparticle suspension was read by SynergyHT Biotek 
plate-reader at Ex/Em 635/680nm. The values were used to calculate the number of 
peptides modified onto the nanoparticles.  
3.2 Results 
3.2.1 Validation of the synthesis procedure 
We utilized absorbance or fluorescence assays to verify the success of each step of the 
solid-phase chemistry. First, the presentation of amine groups on the aminomethyl 
ChemMatrix resin was visualized by reacting NHS-Alex Fluor 647 dye in aqueous 
solution, which resulted in blue color and fluorescence emission at around 665 nm in 
plate reader. After the crosslinker-functionalization step (step 1), we quantified the 
reaction efficiency by either absorbance of NHS leaving group. When the input ratio 
between amine group on resin and NHS ester on crosslinker is around 2.5:1, almost 100% 
of the crosslinker will be functionalized onto the resin. To determine the binding 
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efficiency of streptavidin-coated gold nanoparticles (SA-AuNP-SA) on the biotin-
functionalized resin after the 2
nd
 step (Figure 6), we compared the amount of SA-AuNP-
SA added into the reaction vessel and the amount remained in the liquid phase after 
reaction by measuring absorbance of solutions around the surface plasmon resonance 
(SPR) peak (522 nm-525 nm) of the SA-AuNP-SA. Usually, when the ratio between 
bound biotin on the resin and total number of streptavidin on the input SA-AuNP-SA is 
around 10
5
:1, 50-90% of the input gold nanoparticles will be bound onto the 
functionalized resins (Figure 6). Percentage increases when the number of streptavidin on 
the surface of SA-AuNP-SA increases.  
 
Figure 6. Streptavidin-coated gold nanoparticles bound to crosslinker-functionalized 
resins.  Crosslinker-functionalized resins bound drastically higher amount of gold 
nanoparticles (SA-AuNP-SA) as compared to resins not functionalized. The results 
shown in the graph were from a synthesis done with Apexbio batch 14 crosslinker and 




































Percentage of SA-AuNP-SA bound on resin
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Later, the amount of Janus nanoparticles (SA-AuNP-SH) released by TCEP cleavage of 
disulfide bonds was also measured by absorbance (Figure 7). Twenty to fifty percent of 
the bound gold nanoparticles, again depending on the number of streptavidin coated on 
the gold nanoparticles, can be collected. We did these above-mentioned procedures 
routinely and we are able to get reproducible synthesis outcomes. 
 
Figure 7. TCEP cleaved the di-sulfide bonds and released the Janus SA-AuNP-SH.  
Addition of TCEP resulted in the cleavage of di-sulfide bonds in the crosslinker and 
released Janus SA-AuNP-SH. Without TCEP, nanoparticles also fell off the solid resin to 
some extent, but they were not Janus nanoparticles. Nanoparticles bound on the resin 
through crosslinkers were less likely to disconnect from the resin without TCEP because 
they were more tightly bond on the resin through covalent bonds. The results shown in 
the graph were from a synthesis done with Apexbio batch 14 crosslinker and Nanohybrid 
Batch 10 particles (96 SA/NP). 
3.2.2 Validation of the thiol substitution and surface asymmetry 
We reacted fluorescent dye Alex Fluor 647-C2 maleimide with the Janus nanoparticles 
(SA-AuNP-SH) to verify the existence of thiol groups. The increase in the fluorescence 
signal at the emission peak of the dye comparing to the original streptavidin-coated gold 
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nanoparticles (SA-AuNP-SA) indicated the successful thiol-substitution of some of the 
biotin-binding sites on the nanoparticles (Figure 8). 
 
Figure 8. Free thiol groups present on the Janus SA-AuNP-SH.  Compared to unmodified 
SA-AuNP-SA, Janus gold nanoparticles SA-AuNP-SH have higher fluorescence after 
reaction with Alexa Fluor 647 C2-maleimide, indicating that they have a higher number 
of available reactive groups, i.e., -SH.  
 
To illustrate the surface asymmetry, we performed TEM imaging with biotin-gold probes 
(3nm) to visualize the distribution of available biotin-binding sites on the Janus 
nanoparticles. As shown in Figure 9, biotin-gold probes are only associated with one part 
of the surfaces, which implies the inaccessible of other part of the surface for biotins.  
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Figure 9. Validation of surface asymmetry by TEM imaging.  TEM imaging with 3nm 
biotin-gold probes showed the asymmetric surface chemistry of SA-AuNP-SH. Biotin-
gold nanoprobes (3nm) were only able to bind to part of the surface on the Janus gold 
nanoparticles (left) as illustrated with TEM imaging.  
3.2.3 Optimization of yield 
First, we separately measured the absorbance of crosslinker and the number of unbound 
SA-AuNP-SA and cleaved Janus particles collected in each washing step, and confirmed 
that the elution of both the crosslinker and the nanoparticles are a size-dependent 
chromatography process. The crosslinkers were small molecule, so the initial elution and 
first wash after crosslinker functionalization step took away the majority of the 
crosslinkers. Usually eight washes are good enough to remove all the unbound 
crosslinker or NHS leaving groups, but we performed twelve washes to eliminate any 
residuals in the solution to avoid unwanted modification on the SA-AuNP-SA. SA-
AuNP-SA and Janus SA-AuNP-SH are relatively large molecules. The initial elution and 
the following two to three washes all contained a lot of gold nanoparticles. We usually 
performed more than five washes to collect all the free and loose nanoparticles. By 
conducting stringent washing, we guaranteed that we collected all of the Janus 
nanoparticles and the yield measurement was based on this strict criterion. 
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Figure 10. The density of streptavidin affected the binding of SA-AuNP-SA on the 
functionalized resins.  Resin color was darker after binding with SA-AuNP-SA coated 
with higher density of streptavidin molecules, indicating higher number of SA-AuNP-SA 
bound onto the resins. 
 
Figure 11. The density of streptavidin affected the binding of SA-AuNP-SA on the 
functionalized resin.  The overall yield of Janus SA-AuNP-SH increased as the density of 
streptavidin on the SA-AuNP-SA increased, but stabilized after it reached a certain 
density (~98 SA/NP). 
 
As a way to increase the yield of the solid phase chemistry method, we tested the impact 
of varying streptavidin density on gold nanoparticles. Specifically, we used gold 
nanoparticles that had 25, 53, 98, 128 streptavidin per particle in synthesis. The increase 
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in the number of streptavidin molecules on the particles improved the binding on the 
resin by increasing the available sites of interaction and also led to a slight increase in the 
overall yield of the Janus gold nanoparticles, given the amount of resin, crosslinker, 
TCEP remained the same. The theoretical maximum density of streptavidin on 30nm 
gold nanoparticles calculated by the surface area is 144 per particle. However, as 
illustrated by Figure 10 and 11, it doesn’t change much after the density of streptavidin 
reaches 98 per particle. So, we chose around 100 SA/NP as our working density to ensure 
the highest yield as well as multivalency. To improve yield, we also tested the ratios of 
resin: crosslinker, concentrations of SA-AuNP-SA and TCEP concentration and pH. The 
purity of Thermofisher Scientific EZ-link Sulfo-NHS-S-S-Biotin is generally more stable 
than that of the crosslinker from Apexbio Biotechnology. Usually, for each 110 mg-120 
mg of resin, 16.6 mg of crosslinker from Thermofisher Scientific creates the same 
densely biotin-functionalized surface as that using 25 mg of Apexbio crosslinkers, which 
is optimized for the binding with 8-10e11 gold nanoparticles, giving the highest yield 
30%-40%. On the other hand, for around 110 mg of resins, below 3e11/μL for the 
binding step with a total of 3 mL, the higher the concentration of gold nanoparticles is, 
the higher the binding percentage is. Over 3e11/ml, the improvement in the binding 
percentage is not apparent. TCEP works in a wide pH range. Changing the buffer pH 
from 5 to 7 does not change the yield. At pH 7, we tried 0.005 M, 0.05 M, 0.5 M TCEP 
concentration in the last step of Janus nanoparticle production. As long as TCEP 
concentration was equal to or higher than 0.05 M TCEP, we got the same yield. When the 
concentration was 0.005 M, we barely collected any Janus nanoparticles. So, we decided 
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to use 0.05 M pH 7 TCEP in the synthesis. Other reaction conditions (e.g. temperature, 
volume, reaction duration) for each step were optimized in the same way.  
3.2.4 Generation of SNAbs by modification with ligands 
3.2.4.1 Conjugation of peptides 
To verify the modification of the SA-AuNP-SH with peptides by the described methods 
in (a), we labeled the binding ligands (biotinylated G3 peptides) as well as Fc-receptor 
binding peptides (cp33-SMCC) by Alex Fluor 680 (AF680) and reacted the fluorescent 
peptides with SA-AuNP-SHs as well as SA-AuNP-SAs. By comparing the fluorescence 
normalized to the amount of nanoparticles, we are convinced that the SA-AuNP-SHs 
were successfully conjugated with G3 peptides via biotin-streptavidin interaction and 
with cp33-SMCC through thiol-maleimide reaction and transformed into the designed 
MDSC-SNAbs. Basically, because the Janus nanoparticles have fewer biotin binding 
sites than SA-AuNP-SA, we observed lower fluorescence with G3-AF680. The presence 
of thiol groups to react with maleimide resulted in higher fluorescence intensity of the 
Janus SA-AuNP-SH and Janus G3-AuNP-SH after reaction with cp33-AF680, also 
showing no interference between the G3-biotin-streptavidin and cp33-SMCC-SH 
reactions (Figure 12).  
The hydrodynamic size and zeta potential of the unmodified and modified nanoparticles 
were monitored. The results showed a slight increase in size after peptide modification, 
part of it possibly resulted from insignificant aggregation of the particles in the buffers 
(see 3.2.4.3). Little change in zeta after synthesis and modification (See Apendix C and 
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Figure 13), which indicates that in terms of cellular uptake and in vivo biodistribution, 
the SNAbs and the parental SA-AuNP-SAs may not be drastically different. 
 
Figure 12. Qualitative analysis of the modification of Janus SA-AuNP-SH with 
fluorescent-tagged peptides. Janus particles SA-AuNP-SH were only able to conjugate 
half of the fluorescent G3-biotin on the particle as on the unmodified SA-AuNP-SA (A). 
At the same time, Janus SA-AuNP-SH has higher fluorescent cp33-SMCC conjugated on 






Figure 13. Hydrodynamic sizes of nanoparticles before and after peptide modification.  
The hydrodynamic size of particles increased from 70nm to 100nm after modification of 
Janus particles with peptides as measured with dynamic light scattering. 
3.2.4.2 Quantification of the modification level of peptides on the SNAbs 
G3-biotin and cp33-SMCC with heavy, stable isotope-labeled amino acids were 
synthesized by Genemed Synthesis Inc.. (See Table 1). The numbers of each type of 
peptide modified onto the surface of the nanoparticles were determined by measuring the 
relative peak intensity of light peptides (G3-biotin, cp33-SMCC) conjugated on the Janus 









SMCC) of known concentration in mass spectrometry. Using this method, on average, 
each SNAb has 10.63 G3-biotin and 8.81 cp33-SMCC conjugated.   
3.2.4.3 Stability of SNAbs 
We observed particle formulations under optical microscope after synthesis and before 
use for in vitro or in vivo study. The particle tends to aggregate after peptide modification 
because of the increase in hydrophobicity. A study reported that arginine, serine and 
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tryptophan-ended peptides causes the aggregation of gold nanoparticles of 13 nm and 20 
nm in aqueous solutions, which then influence the cellular uptake of these particles. 
88
 G3 
peptide contains an N-terminal tryptophan and an inner tryptophan, and indeed we 
noticed that non-Janus SA-AuNP-SA particles started precipitating out of the solution, 
aggregate into pellets and adhered to the wall of the tubes once we added G3-biotin 
peptides. Janus SA-AuNP-SH seemed to have less of this issue when modifying with G3-
biotin probably because they reacted with lower number of G3 and also had localized 
distribution of G3 (See Figure 9 and 12), reducing the hydrophobic interaction of 
modified nanoparticles. In Aim 2, we needed to compare the in vitro response to Janus 
G3-AuNP-cp33 particles and nonJanus G3-AuNP-cp33. We tested making nonJanus G3-
AuNP-cp33 in different buffers (DI water, 0.9% NaCl solution, PBS, RPMI 1640 
complete medium) at the same concentration of nanoparticles (SA-AuNP-SA, 
1.25e11/ml) and peptide concentration. NonJanus G3-AuNP-cp33 made in DI water and 
0.9% NaCl has a significant increase in the size of the nanoparticle as compared to the 
size of unmodified SA-AuNP-SA owing to aggregation of the particles (See Table 2). 
RPMI 1640 complete medium (containing 10% fetal bovine serum) seemed to have 
prevented or reduced the modification with peptides due to the potential interaction of the 
serum proteins with the particles, forming a corona on the surface of streptavidin-
modified particles. On the other hand, nonJanus G3-AuNP-cp33 made in PBS has 
detectable increase in size, but are still consistent in quality with the Janus G3-AuNP-
cp33 that were not or less aggregated. Our goal is to have control over the influence of 
aggregation on the cellular response in order to test our hypothesis with nonJanus and 
Janus peptide modified nanoparticles, so PBS is an appropriate solvent to make the 
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nonJanus gold nanoparticles. Later, we added 0.001% tween-20 in the PBS for the 
reactions to reduce the non-specific interaction between particles and particles as well as 
between particles and tubes. We saw significant improvement in the retention of particles 
from the tubes after adding the tween-20. 












Ave. Size (nm) 184.9 150.2 96.42 63.96 62.45 
ST.DEV (nm) 151.6 100.2 39.83 21.45 19.32 
Percentage (%) 98.7 98.4 97.9 100 100 
Peak 
2 
Ave.Size (nm) 5010 4609 4789 N/A N/A 
ST.DEV (nm) 604.9 825.4 729.1 N/A N/A 








In this chapter, we described the process to develop synthetic nanoparticle antibodies. 
The first step is to produce Janus gold nanoparticles. The method we used was adapted 
from a previous publication by Pubudu Peiris, et al., “Assembly of Linear Nano-Chains 
from Iron Oxide Nanospheres with Asymmetric Surface Chemistry”, published on Plos 
One in 2011. In the paper, they described a method using solid phase chemistry to create 
an iron oxide nanopshere with two faces, one presenting amine groups and the other 
presenting thiol groups.
24
 It is one type of the immobilization methods widely used to 
produce inorganic Janus nanoparticles, which meets our goal of generating Janus gold 
nanoparticles. The method also exhibited a high degree of control over the uniformity of 
the nanospheres. By step-by-step addition of particles, the same group assembled linear 
nano-chains and chemically linked drug-loaded liposomes to delivery chemotherapeutics 
to the tumor sites. The nanochain-liposome conjugates could access the micro-metastatic 
sites of tumor because of their unique biophysical properties and could release drug on-
demand by radio-frequency due to the utilization of iron oxide nanoparticles. 
28,93,94,131
  
Specifically, Pubudu Peiris, et al. used CLEARTM (crosslinked ethoxylate acrylate resin) 
resins with amine groups and homobifunctional cleavable crosslinker DTSSP 
(dithiobis(sulfosuccinimidylpropionate), amine functionalized iron oxide nanospheres 
and TCEP. In comparison, we use ChemMatrix aminomethyl resin, which has a simpler 
structure, i.e., PEG network with amine end groups. We used a heterofunctional 
cleavable crosslinker sulfo-NHS-S-S-biotin and streptavidin coated gold nanoparticles. In 
this case, the crosslinker prefers to bind the aminomethyl resin through sulfo-NHS and 
amine reaction, while reacts with the particles through streptavidin-biotin interaction. As 
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a result, we prevented the quenching of homobifunctional DTSSP by amine groups on the 
resin or nanoparticles and thus increased the efficiency of synthesis method. On the other 
hand, sulfo-NHS has the advantage of water solubility, so we could use PBS as solvent to 
avoid the need to change buffer for downstream biological assays.  
Gold nanoparticles are coated with streptavidin through sulfo-NHS-PEG-SH and thiol-
gold bonds as reported by the manufacturers’ product specification sheet. In contrast to 
iron oxide nanoparticles, gold nanoparticles cannot be detected by magnetic relaxivity, 
but instead, the concentration of gold nanoparticles can be measured through surface 
plasmon resonance. At certain wavelength of light, collective oscillation of electrons on 
the gold surface after interaction with the photons results in the adsorption and scattering 
of light, as reflected by the reduction in absorbance reading. This property is easier than 
magnetic relaxivity to measure, as it is detectable by a common benchtop plate reader or 
UV-VIS spectrophotometer, while the latter requires a special instrument, e.g., magnetic 
resonance imaging. The SPR peak of gold nanoparticles depends on the size and shape of 
the particles and does not change significantly upon surface modification. For gold 
nanospheres of 20-100nm, the SPR peaks are usually between 520nm to 570nm, resulting 
in the red color of the solution. As mentioned in the method and results section, for the 
30nm streptavidin-coated gold nanoparticle, we use 522-525nm as the wavelengthes for 
the measurement and calculation.  
Pubudu Peiris, et al., tested the impact of particle diameter on the generation of Janus 
nanospheres. The larger the particle, the smaller the partially modified area (PMA) of 
thiol-displaying face, with PMA being around 30% of the 30nm ion oxide nanoparticles. 
We assumed the similar results of our streptavidin coated gold nanoparticles because our 
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particles are also evenly modified with the reactive groups all over the surface and we 
utilized the same reaction mechanism. Instead of particle diameter, we tested the effect of 
variance of streptavidin density on the yield of Janus nanoparticles. There is a limit in the 
number of streptavidin (~5nm in diameter) that can be conjugated on the gold 
nanoparticles because of the sensitivity of quantification method used by the 
manufacturer (Nanopartz. Inc or Nanohybrids. Inc) and the steric hindrance of 
streptaividin dense-packing. We chose to use 25, 53, 98, 128 streptavidin per nanoparticle 
(Nanohybrids. Inc) to compare the production of the Janus gold nanoparticles and 
determined the best working density as 98 SA/NP. Below 98 SA/NP, the binding of SA-
AuNP-SA on functionalized resin and the overall yield increased as the SA/NP increased. 
Although biotin-streptavidin interaction is quite specific and has a low dissociation rate, 
it is dynamic and non-covalent. Considering the large size of gold nanoparticles, a 
minimal number of biotin-streptavidin interactions have to occur to form solid binding 
between the SA-AuNP-SA and resin and to keep the SA-AuNP-SA on the resin. Hence, it 
is reasonable to have better binding when the number of streptavidin available on the 
nanoparticle for such interactions increases. However, when the density of streptavidin 
reaches a certain level, no more streptavidin is needed for each particle to be bond onto 
the resin, which is why we saw no changes in the binding and yield over 98 SA/NP. In 
addition to the streptavidin density, the solid phase chemistry was also optimized by 
varying ratios between resin and crosslinker and SA-AuNP-SA, the concentration of SA-
AuNP-SA and TCEP, and other reaction conditions (i.e., temperature, duration, volume, 
pH).  
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Generally, each 10 mL-reaction vessel gave us about 1.0-2.0e11 Janus SA-AuNP-SH. 
After modification, we can concentrate the particles to as high as 5.0-6.0e11/ml, equal to 
around 1nM. Usually, in in vitro antibody-dependent cellular cytotoxicity assays, the 
antibody concentration is in the range of 0.001 to 10 ug/mL
132,133
, corresponding to a 
molar concentration range of 0.0067-6.7 nM, so we were able to make it to the target 
working concentration for antibody-dependent response. To do an in vitro assay (Chapter 
4), we need around 500 μL, and up to 2.0-3.0e11
 
of Janus nanoparticles. Considering the 
loss of the modified particles during purification, we usually need to do a batch of four 
reaction vessels for an in vitro assay. In terms of an animal study, previous publications 
report various different doses and frequencies of mAb administration for different models 
of tumor in mice. The most frequently used dose is 100-200 μg, which is around 4.0-
8.0×10
14 
molecules, much higher than what we could achieve. Therefore, when we 
started the first in vivo study (Chapter 5), we administered the amount of SNAbs to mice 
as much as we could manage to fabricate within two-weeks (hypothesized shelf-life of 
SNAbs considering the instability of peptides at 4 °C in PBS) and tested their response. 
The dosage we used in our study is 0.75e11
 
per mouse. For each in vivo study, we need at 
least 6e11, in which case we need to do a batch of 6 reaction vessels.  
To meet the demand of larger animal studies, we need to figure out the scaling up method 
of the SNAb fabrication in the future. As discussed, the current scaling up method is to 
use multiple syringes to achieve the desired amount. Scaling up the process includes two 
aspects: one is to increase the yield of each round of synthesis, in other words, to increase 
the efficiency of the method and reduce cost; the other is to reduce the time and effort 
needed to produce the same yield. For the first aspect, we’ve optimized most of the 
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parameters (e.g. temperature, concentration, ratios between reagents, pH) for the resins, 
crosslinker, particles and TCEP we currently use, but there is still potential for further 
optimization with the length (number of CH2-) of crosslinker, length of PEG linker 
between the particle and streptavidin, which affects the reaction efficiency in step 1 and 2. 
The purity and quality of crosslinker also affects the yield. For the second aspect, as 
mentioned in the method section (3.1.2.1), we can reduce the reaction and purification 
time of each step to shorten the entire procedure from 7 days to 1 day. In addition, using 
larger reaction vessels with higher amount of reagents could be a good option. For 
example, we have tried 20 mL reaction vessel with double amount of the reagents in the 
same concentration. We did not see a significant improvement of the yield as per unit 
amount of input material, but this could be a way to significantly decrease the set-up 
monetary cost, labor cost and time. Also, for a larger reaction vessel, the amount of 
reagents and the ratio needs to be optimized again because the volume changes lead to 
concentration change and may affect the efficiency of reactions. Lastly, other fabrication 
methods, such microfluidic device and electrohydrohynamic jetting, could be 
considered.
89
 However, a change in fabrication method may require changes in material 
of the particles and modification chemistry of the ligands as well, which will be discussed 
later in Chapter 6.  
Using fluorescently labeled peptides, we successfully validated the modification of them 
on the Janus nanoparticles. When it comes to quantification of the number of peptides on 
the particle surface, we’ve tried colorimetric assays, including the micro-bicinchoninic 
acid (microBCA) assay, the fluoraldehyde o-Phthaldialdehyde (OPA) assay, and 
fluorescence-quantification of the AF647/680-tagged peptides on the nanoparticles. 
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Unfortunately, both the microBCA and the OPA have a detection lower limit of around 
10 μg/mL of protein or peptides. The corresponding concentration of SNAbs required for 
the assay is around 3.0×10
13
 per mL, far higher than what we could achieve because of 
both the yield of our method and also the expensiveness of gold nanoparticles and 
peptides. Quantifying the level of modification using fluorescence of the dye-tagged 
peptides gave us an incredibly high number, in the range of thousands of peptides on each 
particle. As the total number of available binding sites is only around 400 at most on each 
particle, we deem this result not reliable, possibly because of the remaining residual of 
unconjugated peptides in the solution after insufficient purification or the loss and 
aggregation of nanoparticles. One other method we attempted was analytical 
ultracentrifugation, which can detect the changes of molecular weight of the particles by 
measuring the sediment co-efficient during centrifugation. By analytical 
ultraentrifugation, we confirmed the available binding sites of the streptavidin-coated 
gold nanoparticles for biotinylated ligands are three per streptavidin on the particles. 
However, to quantify the number of peptides, we need more accurate detection method 
other than interference optical measurement in the analytical centrifuge as well as a 
thorough study of the partial exclusion volume of the particles in the solution, which was 
unachievable at the moment due to inaccessibility to necessary equipments. Besides, the 
poly-dispersity of the nanoparticles and large molecular weight of the gold core itself 
made the measurement of the changes in molecular weight before and after modification 
unreliable. Finally, we decided to pursue the method of AQUA (absolute quantification) 
of peptides using mass spectrometry (MS). This method uses the shift of peaks in MS 
spectrum due to the heavy, stable isotope labels in the peptides to discern between the 
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normal peptides used in the modification and the heavy peptides of known concentration 
in the solution. The relative intensity of the two peaks tells us the relative concentration 
of the normal and heavy peptides and thus yields the accurate level of modification of 
peptides on the particles. After calculation, each SNAb has around 11 copies of G3 
peptides and 9 copies of cp33 on the nanoparticles. Considering the number of 
streptavidin on SNAbs was on average 100 per nanoparticle and each streptavidin protein 
molecule has 4 biotin-binding sites, the copy numbers of G3 and cp33 were much lower 
than the maximum capacity (400) of ligands modification on the streptavidin. We think 
the reason possibly lies in the either the reduction of reaction efficiency due to the 
presence of tween-20 detergent and Janus chemistry or the difficulty of proteolytic 
cleavage of peptides on the nanoparticles by the enzymes. Positive controls of 
nanoparticles conjugated with known number of peptides need to be tested to confirm the 
results of the AQUA method. Nevertheless, we could reach a safe conclusion that SNAbs 
are more multivalent than the bi-valent antibodies and all of the artificial antibodies or 
antibody biomimetics discussed previously. This multivalent display of ligands could 
lead to better functionality, which were tested and discussed in Chapter 4 and 5.  
When the gold nanoparticles aggregates in the solution, often because hydrophobic 
interaction between ligands on the surface or high salt concentration in solution, the 
spectrum of absorbance will have red shift, changing the color of the solution to purple or 
clear. Therefore, we also use the color and spectrum changes to tell the stability of the 
particle formulation. In general, both the unmodified SA-AuNP-SAs and Janus gold 
nanoparticles collected after solid phase chemistry are pretty stable within two to three 
months. Modified Janus gold nanoparticles, or SNAbs, are less stable because the 
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hydrophobicity of the peptides and may require addition of detergent, e.g., 0.001% 
tween-20, to maintain the suspension of particles. We also noticed adhesion of 
nanoparticles on the tubes as discussed in the 3.2.4.3 section of stability of nanoparticles.  
In summary, in this chapter, we have described how we created a solid-phase chemistry 
based method to fabricate Janus streptavidin-coated gold nanoparticles and modify them 
with selected ligands to make MDSC-targeting SNAbs. In the next chapter, we will 
further explore the biological function of the SNAbs in vitro.  
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CHAPTER 4 AIM 2. TO DEMONSTRATE EX VIVO, THE 
SPECIFICITY OF CELL TARGETING AND ACTIVATION OF 
IMMUNE RESPONSES BY THE SNABS 
Antibody therapies in cancer remove the target cells, such as tumor cells, by antibody-
dependent innate immune response, primarily antibody-dependent cellular cytotoxicity 
(ADCC) and phagocytosis (ADCP). The responses happen after the antibodies bind to the 
target cells through the interaction between antigen-epitope and Fab region, and are 
carried out by Fc-gamma receptor-mediated signaling in the effector immune cells, such 
as natural killer (NK) cells, macrophages and granulocytes, triggered by the engagement 
with the Fc region of the antibodies.
133
 After the bridge is formed, the cascade of events 
starts with the tyrosine phosphorylation on the intracellular motif of gamma chains, and 
then induces the release of cytokines, reactive oxygen species (ROS), proteases, perforin 
and granzyme B, leading to the destruction of target cells.
134–137
 In ADCP, the Fc-gamma 
receptor-mediated signaling in macrophages, which are both phagocytes and antigen-
presenting cells, also induce phagocytosis of the opsonized cells and antigen presentation 
of the killed cells to the adaptive immune effector cells.
134,135
 
The major types of effector cells are natural killer cells and macrophages. NK cells in 
both human and mouse express activating Fc gamma receptors on the surface and can 
detect the cells opsonized by IgG1, IgG2, IgG3, and IgG4, but at different affinity. NK 
cells are not phagocytic nor antigen-presenting cells, so it is believed that the way they 
kill target cells is mainly ADCC by cytotoxic granules, tumor-necrosis factor alpha 
(TNFα)-family receptor signaling and proinflammatory cytokines.
138
 A number of the 
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successful monoclonal antibody drugs for cancer has been shown to work in a NK-cell 
dependent way, such as trastuzumab (anti-Her2), Cetuximab (anti-EGFR) and Rituximab 
(anti-CD20).
138
 Macrophages are also important effector cells for antibody-dependent 
responses. They express all four types of Fc-gamma receptors (FcγRI, FcRIIB, FcγRIII, 
FcγRIV) in mouse and most of the activating and inhibitory receptors (FcγRI, FcγRIIA, 
FcγRIIB, FcγRIIIA) in human.
137
 Because macrophages are both phagocytes and antigen-
presenting cells, they are likely to perform both ADCC and ADCP to kill antibody-
labeled cell targets. Interestingly, conflicting results were reported in different studies for 
which of NK cells and macrophages are dominant effector cells in antibody therapy. Take 
rituximab as an example, despite previous data showing NK-mediated clearance of 
CD20
+
 lymphoma cells in immune-deficient mice,
139
 two papers published before 2010 
showed that in an immune-competent murine model treated with anti-mouse CD20 
monoclonal antibodies, macrophages mediated the ADCC/ADCP of CD20
+
 lymphoma 
cells, and no contributions from NK cells or complement pathways were detected.
140,141
 
The relative importance of different cell types in antibody-dependent responses needs to 
be discussed case by case. For instance, NK cells are likely to be more efficient in blood 
leukemia and macrophages works better in solid tumor because they can clear tumor cells 
and process and present the antigens, leading to the activation of adaptive immune 
responses. 
142
 More and more evidence appears to support that cells that co-express both 
activating and inhibitory Fc receptors, such as macrophages, and granulocytes, mediate 
the antibody responses, as the deficiency in the FcγRIIB increased the enhancement of 
ADCC/ADCP.
135,139
 Neutrophils, mononuclear cells and granulocytes stimulated with 
GM-CSF also showed enhanced ADCC capacity in vitro.
134
 Because macrophages and 
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monocytes express a variety of Fc-gamma receptors and contribute to both ADCC and 
ADCP pathways mediated by antibodies, we chose macrophage cell lines as the effector 
cells of interest in our assays.  
The most commonly used method to test the functionality of a newly developed 
monoclonal antibody is to do ADCC/ADCP assays in target-effector-cell co-culture. 
Such assays usually quantify the response through one or few of the following methods: 
51
Cr (chromium), LDH (lactate dehydrogenase) release from the pre-labeled target cells 
after killed; staining of the apoptotic/necrotic target cells with propidium iodide (PI), 
7AAD (7- amino-actinomycin D) or Annexin V; detect viability by Calcein-AM or 
MTT/MTS (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide/ 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). 
51
Cr and other release assays are gradually being replaced by other assays due to the 
difficulty of radioactive material handling and disposal and the poor reproducibility of 
release assays. In recent years, new methods were developed for ADCC/ADCP assays, 
such as using xCELLigence platform and flow cytometry. XCELLigence platform 
enables measurement of real-time proliferation or cell death in a cell-culture plate by 
electrical impedance of the adherent target cells. In a typical flow-cytometry-based assay, 
the effector and target cells are usually labeled with different fluorophores. The 
advantage of such assays is to be able to tell ADCC and ADCP apart. The ADCC activity 
is evaluated by the number of dead cells stained with PI, 7AAD or other dead-cell labels 
and ADCP activity is assessed by the fraction of double-positive cells. In most cases, the 
effector cells used in such assays are, in human, NK cell line NK-92MI, monocyte cell 
lines (e.g. U937, THP-1) or peripheral blood mononuclear cells (PBMC), and in mouse, 
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mouse PBMCs, bone marrow derived macrophages or RAW 264.7 cell line. 
35,132,133
 In 
this chapter, we tested our hypothesis using RAW 264.7 cell line as our effector cells in 
flow-cytometry-based assays. We’ve also developed a new type of cytotoxicity assay 
using splenocytes to better recapitulate the responses happening in the physiological 
environment.  
 The hypothesis for this aim is that the designed SNAbs can target the cell of interest 
specifically, activate Fc gamma receptor (FcγR)-mediated intracellular signaling cascade, 
and trigger ADCC/ADCP of target cells by immune effector cells. Respectively, G3 
enabled the specific recognition of MDSCs while multivalent cp33 on SNAbs empowers 
them to engage with FcγRs on RAW macrophages, which results in down-stream 
signaling and immune responses. We tested our hypothesis with optimized imaging-, 
flow-cytometry-based assays and also compared the performance of our SNAbs with 
mAbs to assess their promise for in vivo applications. 
4.1 Methods 
4.1.1 Materials 
Ebioscience RBC lysis buffer (Cat.#. 00-4333-57),  Normocin (Cat.#.NC9390718), 
RPMI 1640 medium (Cat.#.22400105), DMEM medium (Cat. #.11995-073)  and  Bovine 
serum albumin (BSA, Cat.#.23209) were purchased from Thermofisher Scientific. 
Collagenase D was purchased from Sigma-Aldrich (Cat.#.11088882001). Characterized 
fetal bovine serum (FBS, Cat.#.SH3007103), USDA FBS (Cat.#.SH30910.03)  and 1% 
Penicillin-Streptavidin (PS, Cat.#.SV30010) were purchased from GE Healthcare. 
Fixation buffer and Alexa Fluor 647-anti-S100A9 antibodies (Cat.#.565833) were 
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purchased from BD Bioscience (Cat.#.554655). Cell strainer was purchased from 
CellTreat.Inc (Cat.#.229481). QuanTI-Blue (Cat. # rep-qb1) for Alkaline phosphatase 
detection and Zeocin (Cat.#.ant-zn-1) were purchased from InvivoGen.  MACS LS 
columns (Cat. #.130-042-401), anti-biotin beads (Cat.#.130-105-637) and myeloid-
derived suppressor cell isolation kit (MDSC-Kit, Cat.#.130-094-538) were purchased 
from Miltenyi Biotechnology. Purified anti-mouse CD16/32 (Clone 93, Cat.#.101302) for 
Fc receptor blocking and biotin anti-mouse Ly-6g/Ly-6C (Gr1, clone RB6-8C5, Cat. 
#.108403) for MDSC sorting was purchased from Biolegend. Antibodies used for cell 
marker staining includes anti-F4/80-FITC, anti-CD11c-PE, anti-B220-FITC, anti-CD8-
FITC, anti-CD4-PE, anti-CD3-PE-Cy7, anti-CD11b-PE-Cy7, anti-Ly6G-PerCP-Cy5.5, 
anti-Ly6C-APC-Cy7, anti-CD49b-APC, anti-FoxP3-APC and anti-CD25-APC-Cy7, all 
purchased from Biolegend (Please see Appendix D). Fluorophore (FITC, PE, PE/Cy7, or 
APC)-conjugated streptavidin for detecting biotin-labeled cells were purchased from 
Biolegend (Cat.#.405207, 405206, 405204) or Thermofisher Scientific (Cat.#.PI21224). 
FACS buffer was prepared by adding 10 mL of FBS to 500 mL of PBS. MACS buffer 
was prepared as PBS buffer (pH7.2) containing 0.5% BSA (bovine serum albumin 
(BSA)) and 2 mM EDTA.  
4.1.2 Cells and animals 
4T1 breast cancer cell line from American Type Culture Collection (ATCC, Manassas, 
VA, USA).  was cultured in RPMI 1640 medium with 10% characterized FBS and 1% 
PS. RAW 264.7 macrophages cell line from ATCC (TIB 71) was cultured in DMEM 
medium with 10% USDA FBS and 1% Penicillin-Streptavidin. RAW-Blue macrophages 
from InvivoGen.Inc (Cat. #. raw-sp) was cultured in DMEM medium with 10% 
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characterized FBS and 1% PS. Heat-inactivated fetal bovine serum was made by heating 
the normal FBS at 56°C for 30mins. All the cells were cultured in 37 °C, under 5% CO2.  
Mice were purchased from Jackson Laboratory. The use of animals was approved by The 
Institutional Animal Care and Use Committee (IACUC) at Georgia Institute of 
Technology (Atlanta, GA) 
4.1.3 Splenocyte suspension preparation from the spleen of 4T1 tumor-bearing mice 
Five-to-twelve-weeks old female Balb/c mice were inoculated subcutaneously with 4T1 
breast cancer cell line, 0.5×10
6
 in 50 μL of PBS, at the fourth mammary fat pad. On day 
16 post tumor inoculation, mice were euthanized with CO2 gas and cervical dislocation. 
Spleens were collected and digested using collagenase D, 2 mg/mL for 15-30 mins. The 
mixture was passed through a 40 μm cell strainer with gentle grinding. The solution was 
then centrifuged at 500 g for 5mins, followed by red blood cell (RBC) lysis with RBC 
lysis buffer for 5-10 mins at room temperature. The cell suspension was neutralized with 
complete medium and washed with PBS by centrifugation at 500 g for 5mins. The cell 
pellet was resuspended in the desired buffer (e.g. PBS, FACS buffer, MACS buffer) for 
the following assays. 
4.1.4 MDSC isolation from splenocyte suspension 
MDSCs were isolated using Miltenyi MDSC-Kit from splenocytes of the 4T1-tumor 
bearing mice. Briefly, 100 million splenocytes was resuspended in 350 μL of MACS 
(magnetic-activated cell sorting) buffer (PBS, pH7.2, 0.5% BSA, 2mM EDTA), and then 
incubated with 50 μL of the Fc-receptor blocking reagent (from the kit or anti-CD16/32 
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antibodies) at 4 °C for 10 mins. The cell mixture was subsequently mixed and incubated 
with 100 μL anti-Ly6G-Biotin in the MDSC-kit or biotin-anti-Gr1 antibodies for 10mins 
at 4 °C. Following a wash with 5-10 mL of MACS buffer and 10 mins centrifugation at 
300 g, the cells were resuspended in 800 μL buffer and incubated with 200 μL of anti-
biotin microbeads for 15 mins at 4 °C. The cell mixture was washed again with 10-20 mL 
of buffer and centrifuged at 300 g for 10mins at 4 °C and then the pellet was resuspended 
in 500 μL of MACS buffer. A MACS LS column was placed on a magnet separator and 
washed with 3 mL of buffer and the 500 μL of cell suspension was passed through the LS 
column followed by 3×3 mL of buffer to wash the column. The solution can be collected 
or discarded depending on the desired application. After the column was removed from 
the separator, 5 mL of buffer was added and using the plunger to flush the column. The 





 MDSCs. If using anti-Ly6G antibody for the above steps, another round of 
isolation may be performed on the collected Ly6G
-





 cells.  
4.1.5 Free peptide binding on cells 
4.1.5.1 Free peptide binding on isolated MDSCs 
Mouse MDSCs were isolated (see 4.1.4) and added into FACS tubes, 1 million cells per 
tube. The cells were washed with PBS 1mL/tube by centrifugation at 500 g for 5 mins 
and then resuspended into 1mL of 0.001% streptavidin-PBS solution and incubated at 
room temperature for 30 mins to quench the endogenous biotin in the cells. The cells 
were then washed again with PBS 1mL/tube by centrifugation and incubated with 1mL of 
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0.001% biotin-PBS solution to quench the streptavidin for 30 mins at room temperature. 
After another wash, the cells were incubated with different biotinylated peptide solutions 
(100 μM) in 100 μL PBS for 30 mins at room temperature, at least 3 technical replicates 
for each type of peptides. The excessive peptide ligands were removed by washing. 
Subsequently, the ligands-labeled cells were stained with streptavidin-PE or streptavidin-
APC at room temperature for 30 mins. After removing excessive staining reagents, the 
cells were washed and resuspended in 200 μL of FACS buffer (PBS, 2% FBS) and 
analyzed on BD LSRFortessa flow cytometer.  
4.1.5.2 Free peptide binding on RAW 264.7 macrophage cell line 
Similarly to the procedures of testing peptide binding on MDSCs, RAW 264.7 
macrophages 1 million/mL were added to FACS tubes. Cp33-biotin peptide solutions 
were prepared at different concentration (2 μM, 20 μM, 100 μM) in PBS. The cells were 
incubated with the cp33-biotin solutions first and then stained with streptavidin-FITC 
conjugates and then analyzed on BD Accuri C6 flow cytometer.  
4.1.5.3 Free peptide binding on splenocytes 
The experiments were done in a similar way to what’s described in 4.1.4.2. Two million 
cells of the single-splenocytes suspension prepared from the 4T1-tumor bearing mice 
were added to each FACS tubes. Following the incubation with different peptide 
solutions, the cells were then stained with antibodies for cell surface markers as well as 
the fluorescent streptavidins for 30 mins at room temperature. Following washing with 
FACS buffer, the samples were analyzed on a BD LSRFortessa flow cytometer. 
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4.1.5.4 Colocalization of S100A9 and G3 peptides on MDSCs 
Mouse MDSCs were isolated and added into FACS tubes, 1 million cells per tube. The 
cells were washed with PBS 1mL/tube by centrifugation at 500 g for 5 mins and then 
resuspended into 1 mL of 0.001% streptavidin-PBS solution and incubated at room 
temperature for 30 mins to quench the endogenous biotin in the cells. The cells were then 
washed again with PBS 1mL/tube by centrifugation and incubated with 1 mL of 0.001% 
biotin-PBS solution to quench the streptavidin for 30 mins at room temperature. Half of 
the samples were fixed with BD Cytofix buffer for 30 mins at room temperature. After 
wash with PBS, both the fixed and unfixed cells were incubated with G3-biotin solution 
(200 μM) in 100 μL PBS for 30 mins at room temperature. Half of the samples were 
fixed with BD Cytofix buffer for 30 mins at room temperature. The excessive peptide 
ligands were removed by washing. Subsequently, the ligands-labeled cells were stained 
with streptavidin-PE and Alexa Fluor 647-anti-S100A9 antibodies at room temperature 
for 30 mins. After removing excessive staining reagents, the cells were washed and 
resuspended in 200 μL of FACS buffer (PBS, 2% FBS) and analyzed on BD 
LSRFortessa flow cytometer.  
4.1.6 Photoacoustic imaging of peptide-modified particles binding on cells 
SNAbs were prepared as described in Chapter 1. Peptide-modified nonJanus 
nanoparticles were prepared by reacting biotinylated peptides with unmodified AuNP-SA 
for overnight at 4 °C in 0.002% Tween-20-PBS solution. All the particles were washed 
twice with PBS and resuspended with PBS. The isolated MDSCs were fixed with BD 
cytofix buffer or without fixation but conditioned to 4 °C to minimize endocytosis of 
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particles. Cells were then incubated with particles at a ratio at 5×10
10
/million cells (for 
Janus NPs) or 2×10
11
/million cells (nonJanus NPs) in 1mL of PBS for 1 hr (for live cells) 
or 4 hrs (fixed cells) at 4 °C. After incubation, cells were washed three times with PBS by 
centrifugation at 500 g for 5 mins and then fixed with BD cytofix buffer. The cell-NP 
samples were resuspended into 20 μL per 0.5 million cells in PBS and kept in the fridge 
until use. 
For photoacoustic microscopy, we acknowledge Kelsey Kubelick in Dr. Emelianov’s 
group for the acquisition and processing of photoacoustic images. The gelatin phantom 
used was composed of a base layer containing 8% gelatin and 0.2% silica. The solution 
was heated to around 50 °C under stirring and after dissolution of the gelatin, the solution 
was degassed to remove bubbles, poured into a container and solidified at 4 °C. Each 
cell-NP sample was mixed with an equal volume of hot 16% gelatin solution (heated and 
degassed) and solidified on the gelatin phantom in the fridge into dome-like inclusions. 
The container with the gelatin phantom and the inclusions was filled with degassed 
ultrapure water and allowed to come to room temperature. The inclusions were imaged 
with a photoacoustic imaging microscope, the Vevo LAZR (Fujifilm VisualSonics Inc, 
Toronto, Canada), a combined US/PA imaging system. Three cross-sections of each 
sample were randomly selected to ensure statistical power of the results. US/PA 
(ultrasound/photoacoustic) images were acquired at a frame rate of 0.5 Hz with an OPO, 
Q-switched Nd:YAG pumped laser (λ = 532 nm or 680-970 nm) with a 40MHz US/PA 
linear array transducer (LA550). The data was exported and post-processed in MATLAB 





4.1.7 Activation of NFκB signaling pathway by SNAbs 
Twenty microliters of SNAbs and control formulations were seeded in 96-well plates. 
RAW-Blue cells were resuspended in test medium according to manufacturer’s protocol 
and seeded at 100,000 cells/180 μL in each well. The plates were cultured in 37 °C for 20 
hours in incubator and then 50 μL of the medium from each well was transferred to a new 
plate for further quantification of the secreted embryonic alkaline phosphatase (SEAP) 
inducible by NFκB and AP-1 transcription factors from the activated RAW-Blue cells 
with QUANTI-Blue detection reagents. After 0.5-6 hours of incubation in 37 °C, the 
assay plates were read with a SynergyHT BioTek Plate-reader at 625 nm for absorbance.  
4.1.8 Quantification of ADCC/ADCP of MDSCs triggered by SNAbs 
RAW 264.7 macrophages primed with 25 ng/mL of IFNγ overnight at 37 °C were used 
as effector cells and plated in a flat bottom 96 well plate at certain densities between 1 to 
5×10
5
 per well to achieve the desired effector and target ratio. In certain assays, to 
quantify phagocytosis, the RAW 264.7 macrophages were stained with CellTrace 
reagents (Thermo Fisher Scientific) before seeding. MDSCs isolated from the spleen of 
4T1 tumor-bearing mice were labeled with a different color of CellTrace Reagents 
(Thermo Fisher Scientific) and incubated with MDSC-SNAbs (i.e., G3-AuNP-cp33), 
control particles (e.g., AuNP-cp33, SA-AuNP-SA), antibodies (e.g. anti-Gr1 antibody), 
or buffers respectively for 20 mins at 37 °C. Following that, the mixture of MDSCs and 
treatment formulations were dispensed at the required density per well (0.5-2×10
4
/well). 
The co-culture system was incubated at 37 °C for 4 or 24 hrs. Cells were harvested and 
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stained with viability dyes (e.g. propidium iodide, Zombie UV fixable dye or Annexin V) 
and then analyzed by flow cytometry.  
4.1.9 Splenocyte killing of MDSCs triggered by MDSC-SNAbs 
RBC-lysed splenocyte suspension was seeded into 96 well plates at 1×10
6
 cells/well in 
200 μL of RPMI 1640 complete medium. MDSC-SNAbs (i.e.,G3-AuNP-cp33), control 
particles (e.g., AuNP-cp33, SA-AuNP-SA), antibodies (e.g. anti-Gr1 antibody, isotype rat 
IgG2b,κ), or buffers in 50 μL sterile PBS was added into the corresponding wells 
respectively. After 20 hrs of incubation at 37 °C, cells were harvested for flow cytometry 
analysis using BD LSRFortessa. Viability of cells was evaluated with Zombie UV fixable 
kit, 7AAD or PI. Antibodies used for cell marker staining includes anti-F4/80-FITC, anti-
CD11c-PE, anti-B220-FITC, anti-CD8-FITC, anti-CD4-PE, anti-CD3-PE-Cy7, anti-
CD11b-PE-Cy7, anti-Ly6G-PerCP-Cy5.5, anti-Ly6C-APC-Cy7, anti-CD49b-APC, anti-
FoxP3-APC and anti-CD25-APC-Cy7.  
4.1.10 Molecular dynamic (MD) simulation of G3 and G3* peptide interaction with 
human S100A8/A9 heterodimer 
Zijian Zhang and Katie Kuo performed the computational simulation in Dr. Gumbart’s 
group in the school of physics of Georgia Institute of Technology. One S100A8/A9 
protein (PDB ID code 1XK4
144





 Sixteen copies of the biotinylated G3 peptide were distributed in the unit cell 




 ions were added to 
neutralize the system at a concentration of 150 mM, giving a final system size of 
~200,000 atoms. Five independent systems were constructed, each with a different 
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arrangement and orientation of the G3 peptides. Five copies of these systems were also 
constructed with the G3* peptides replacing G3 peptides. All systems were constructed 
using Visual Molecular Dynamics (VMD).
146
 
The CHARMM36m force field was used for proteins in all simulations;
147
 biotin 
parameters were obtained from CGenFF
148
 and used previously.
149
 Temperature 
(310 K = 37 °C) and pressure (1 atm) were kept constant by using Langevin dynamics 
(damping constant ɣ = 1.0 ps-1) and an isotropic Langevin piston barostat, 
respectively.
150
 The time step was set to 2 fs. Bonded interactions and short-range (12 Å 
cutoff) nonbonded interactions were calculated at every time step. Long-range 
interactions were treated with the particle-mesh Ewald (PME) method
151
 and were 
updated every other time step. A total of 10 equilibrium simulations, five for G3 and five 
for G3*, were run with NAMD
152
 for 25 ns each. 
We selected 200 frames at equal intervals from the last 20 ns of each equilibrium 
simulation. Thus, a total of 1000 (200×5) frames were used to calculate the contact 
probability for each type of peptide (G3 or G3*). A contact was defined as a distance of 
3.5 Å or less between heavy atoms. Finally, the number of contacts was divided by 16000 
(16 peptides ×200 frames ×5 simulations) to obtain the contact probability. 
4.1.11 Statistical Analysis 
Student’s t-test was used to perform statistical analysis between two groups. When 
comparing more than two groups, normalization tests were performed first to test the 
distribution of data in each group. One-way analysis of variance (ANOVA) with Tukey 
post hoc test was used for data with normal distribution and non-parametric methods with 
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Dunn’s post hoc test was used for data that was not in normal distribution. When P value 
is < 0.05, the difference between groups was considered significant (**** p<0.0001, *** 
p<0.0002, ** p<0.0021, * p<0.0332). In vitro experiments were conducted a minimum of 
two iterations (n=3 or 6 for each sample) to ensure reproducibility.  
 
4.2 Results 
4.2.1 Free peptide binding on isolated MDSCs 
In an experiment with live MDSCs (Figure 15), G3 peptides were shown to have much 
higher binding on both granulocytic and monocytic MDSCs than G3* peptide, a 
scrambled peptide of G3. Comparably, monocytic MDSCs have higher mean 
fluorescence intensity (MFI) than granulocytic MDSCs do, indicating a higher expression 
level of S100A8/A9 proteins on the monocytic MDSCs. In another experiment where we 
used fixed and permeabilized MDSCs, G3* had much higher binding on a mixture of 
granulocytic and monocytic MDSCs than G3, indicating there could be some other 
proteins in the cytoplasma of MDSCs that binds G3* (Figure 14). The above results 
implied that G3* could be a potential targeting ligand for MDSCs, too. On the other 
hand, irrelevant-cp33 also binds to MDSCs as well due to the hydrophobic interaction of 
the tryptophan (W) in the peptides and cell membrane, while all other peptides, cp33, 
AHNP (a peptide targeting Her2 protein on human breast cancer cells), scrambled AHNP 
(scAHNP), don’t bind to fixed MDSCs at all.  
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Figure 14. The binding of free peptides on fixed and permeabilized MDSCs.  
Biotinylated peptides were incubated with fixed and permeabilized MDSCs isolated from 
the spleen of 4T1-tumor bearing mice after endogenous biotin quenching. Cells were than 
stained with SA-PE and analyzed on a flow cytometer (n=3). 
 
4.2.2 Cp33 binding on RAW 264.7 macrophages 
RAW 264.7 is a mouse macrophage cell line that expresses Fc gamma receptors. Cp33 
mimics the Fc region of a human IgG1 that binds to mouse Fc gamma receptors on 
monocytes. In a free peptide-binding experiments (Figure 15), we saw dose-dependent 
binding of cp33 on Fc gamma receptors, i.e., RAW 264.7 cells that were incubated with 
higher concentration of cp33 had higher fluorescent intensity than those with lower 




Figure 15. Free cp33-biotin binds on RAW 264.7 mouse macrophages. Cells were 
incubated with different concentrations of free cp33-biotin. Following the removal of 
unbound peptides, the peptide-bound cells were labeled with SA-FITC conjugates and 
analyzed with flow cytometry. 
 
4.2.3 Free peptide binding on splenocytes 
As with single-cell peptide binding experiments, we tested the binding capability of 
different peptides on splenocytes. This allows us to assess the specificity of binding of 
the peptides of interest. As shown in Figure 16 and 17, G3 and G3* have equivalent 
binding capability on granulocytic while G3 peptide binds better to monocytic MDSCs 
than G3*.  
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Figure 16. The binding of free peptides on granulocytic MDSCs (G-MDSCs) in a mixed 
splenocyte suspension. A mixture of splenocytes from 4T1-tumor bearing mice was 
incubated with different peptide solutions after endogenous biotin quenching. Following 
the removal of unbound peptides, the cells were stained with fluorescent antibodies 
against a panel of surface markers and fluorescent streptavidin. Samples were analyzed 
on a flow cytometer. Top: the percentage of SA-APC
+
 G-MDSCs, i.e., peptide-bound G-
MDSCs. Bottom: The representative histogram of the fluorescence of G-MDSCs 
incubated with the peptides or control solution. The top and the bottom graphs use the 
same color code for each type of treatment.  
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Figure 17. The binding of free peptides on monocytic MDSCs in a mixed splenocyte 
suspension.  A mixture of splenocytes from 4T1-tumor bearing mice was incubated with 
different peptide solutions after endogenous biotin quenching. Following the removal of 
unbound peptides, the cells were stained with fluorescent antibodies against a panel of 
surface markers and fluorescent streptavidin. Samples were analyzed on a flow 
cytometer. Top: the percentage of SA-APC
+
 M-MDSCs, i.e., peptide-bound M-MDSCs. 
Bottom: The representative histogram of the fluorescence of M-MDSCs incubated with 
the peptides or control solution. The top and the bottom graphs use the same color code 
for each type of treatment.  
 
As shown in the graphs (Figure 16-17), cp33 also binds to granulocytic and monocytic 
MDSCs to some extent, illustrating the existence of Fc receptors on the MDSCs. On the 
other hand, cp33 binds F4/80
+
 macrophages better than other peptides except Irrelcp33 
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and AHNP-biotin, showing its selectivity towards Fc receptor-expressing immune 
effector cells (Figure 18). Surprisingly, AHNP-biotin also binds to macrophages, 
indicating that there are some potential interaction between the AHNP-peptide and the 
surface proteins (e.g.,epidermal growth factor receptors) on macrophages. We also tested 
the MDSC-binding capability of IrrelG3, a peptide used as a negative control for G3 
peptide in Hong Qin’s paper. However, in our assays, the IrrelG3 also binds to 
granulocytic MDSCs similarly as G3 peptides, despite less binding to monocytic MDSCs 
(Figure 19). 
 
Figure 18. The binding of free peptides on F4/80
+
 macrophages in a mixed splenocyte 
suspension.  A mixture of splenocytes from 4T1-tumor bearing mice was incubated with 
different peptide solutions after endogenous biotin quenching. Following the removal of 
unbound peptides, the cells were stained with fluorescent antibodies against a panel of 
surface markers and fluorescent streptavidins. Samples were analyzed on a flow 
cytometer. Left: the percentage of peptide-bound macrophages. Right: The median 





Figure 19. IrrelG3 peptide bound to MDSCs in a mixed splenocyte suspension. A mixture 
of splenocytes from 4T1-tumor bearing mice was incubated with different peptide 
solutions after endogenous biotin quenching. Following the removal of unbound peptides, 
the cells were stained with fluorescent antibodies against a panel of surface markers and 
fluorescent streptavidin. Samples were analyzed on a flow cytometer. Left: the 
percentage of peptide-bound G-MDSCs. Right: the percentage of peptide-bound M-
MDSCs.  
 
For other cell types, G3 and G3* seem to bind to CD11c
+
 dendritic cells to some extent 
(Figure 20). This is expected given that dendritic cells express a good amount of S100 
proteins on the surface.
121
 NK cells were reported to express the receptor of advanced 
glycation end product (RAGE) for S100A8/A9 proteins.
153
 The binding data shows that 




 NK cells, which reflected the 
presence of S100A8/A9 protein on the cells. None of the peptides except Irrelcp33 bound 
to B220
+
 B cells (Figure 20). G3 and AHNP peptides bind significantly more than other 
peptides to CD3
+




T cells, indicating some potential 
interaction between the peptides and the cellular proteins (Figure 21). Unfortunately, 
Irrelcp33 binds to every cell types strongly, implying that it is not a good negative control 
peptide for the experiments. Based on the results, scAHNP peptide does not have binding 
affinity towards any of the major cell types in splenocytes and was selected as the 
universal negative control peptide for later experiments. 
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Figure 20. The binding of free peptides on dendritic cells, natural killer cells and B cells 
in a mixed splenocyte suspension.  A mixture of splenocytes from 4T1-tumor bearing 
mice was incubated with different peptide solutions after endogenous biotin quenching. 
Following the removal of unbound peptides, the cells were stained with fluorescent 
antibodies against a panel of surface markers and fluorescent streptavidins. Samples were 
analyzed on a flow cytometer. Median fluorescence intensities of DCs (A), NK cells (B), 
B cells (C) after incubation with peptide or control solution are shown on the graphs.  
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Figure 21. The binding of free peptides on T cells in a mixed splenocyte suspension.  A 
mixture of splenocytes from 4T1-tumor bearing mice was incubated with different 
peptide solutions after endogenous biotin quenching. Following the removal of unbound 
peptides, the cells were stained with fluorescent antibodies against a panel of surface 
markers and fluorescent streptavidins. Samples were analyzed on a flow cytometer. 
Percentages of peptide-bound cells of CD3
+




















4.2.4 Colocalization of G3 peptide with S100A9 protein on MDSCs 
 
Figure 22. The colocalization of S100A9 protein and G3 on MDSCs and non-MDSC 
splenocytes. Representative flow cytometry graphs show the colocalization of G3 and 
S100A9 on MDSCs but not on non-MDSC cells (A, B). Cells were stained with G3 and 
anti-S100A9 either after fixation and permeabilization (A, C) or before fixation (B,D).  
 
To test whether the target protein of G3 peptide is still S100A8/A9 protein on the 
MDSCs isolated from 4T1-breast cancer tumor model, which is not verified in the 
original study of G3,
25
 we performed staining with both G3 peptides and anti-S100A9 
antibody. Because of the lack of commercially available specific, fluorescent anti-mouse 
S100A8/A9 antibodies at the moment, we used anti-S100A9 antibodies to study the 
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colocalization of G3 peptides with its hypothetical target S100A8/A9 proteins in this 













) express S100A9 protein.  
As illustrated by this experiment, G3 peptide bound to 89.8% of G-MDSCs and 100% of 
M-MDSCs. Out of these G3
+
 MDSCs, 99.77% of G3
+
 G-MDSCs and 97.83% of G3
+
 M-
MDSCs were stained with anti-S100A9 antibody, showing both surface and intracellular 
expression of S100A9 (Table 3). On the other hand, 89.83% of S100A9
+
 G-MDSCs and 
100% of S100A9
+ 
M-MDSCs were bound with G3. These results suggested strong 
correlation between G3 binding and S100A9 expression on MDSCs. There were some 
non-MDSC CD11b
+
 cells bound with G3, but only 22.83% of G3
+
 cells among them 
showed S100A9 positive staining, and 68.7% of S100A9
+
 cells were bound with G3 
(Table 4). CD11b
-
 cells did not have G3 binding and had only 2.99% of S100A9
+
 cells in 
G3
+
 subsets while 84.87% of the S100A9
+
 subpopulation was G3
+
, which tells us that on 
non-MDSC cells, G3 and S100A9 binding were not co-localized.  
Table 3. Colocalization of S100A9 and G3 on MDSCs 
 
Granulotycis MDSCs Monocytic MDSCs 
G3+ percentage 89.83 100 
S100A9+ percentage out 
of G3+ subset 
99.77 97.83 
S100A9+ percentage 99.77 97.83 




Table 4. Colocalization of S100A9 protein and G3 on non-MDSC cells 
 
S100A9+ percentage of 
G3+ subset 
G3+ percentage out of 
S100A9+ subset 
CD11b+ 72.10 88.70 
Non-MDSC CD11b+ 22.83 68.70 
CD11b- 2.99 84.87 
All cells 59.30 88.93 
 
4.2.5 Peptide-modified particles binding on target cells.  
To test whether the peptide-modified particles also have the strong binding capacity on 
the target cells, we performed photo-acoustic imaging with isolated MDSCs and RAW 
264.7 macrophages. The acoustic signals quantified the density of cells in the inclusions 
and photoacoustic signals showed the amount of particles on the cells. As shown in 
Figure 23, SNAbs bound strongly to MDSCs isolated from 4T1 breast cancer-bearing 
mice, much more than unmodified SA-AuNP-SA. Not surprisingly, cp33-modified 
nonJanus particles (AuNP-cp33) also bound very well to MDSCs, indicating the presence 
of Fc receptors on MDSCs (See Appendix A.2). In terms of RAW macrophages, G3 
peptide-modified nonJanus particles bound better than G3* peptide-modified nonJanus 
nanoparticles. This observation matched the result of free peptide binding on M-MDSCs. 
The two types of Janus nanoparticles, G3-AuNP-cp33 and G3-AuNP-Irrelcp33, bound 
equally well to RAW macrophages, indicating the presence of G3 affected the binding 
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and eliminated the influence of cp33 or Irrelcp33 (Figure 24). All in all, peptide-modified 
nanoparticles bind to both target cell, MDSCs, and effector cells, macrophages. The 
limitation of this experiment was that the target cell population, MDSCs, had similar 
characteristics as effector cells, macrophages, which are both myeloid lineage cells and 
express S100A8/A9 proteins, leading to targeting effect of G3 to both types of cells. In 
addition, at the moment, we didn’t find a universal negative binding ligands to prove the 
specificity of the binding of G3- or cp33-modified nanoparticles. As illustrated by the 
free peptide-binding assay, scAHNP might be a good candidate for negative controls. 
Future photoacoustic imaging experiment with scAHNP-modified particles is in need for 
investigating the specificity of the binding of G3-modified and cp33-modified particles 





Figure 23. Peptide modified nanoparticles bound on MDSCs isolated from 4T1-tumor 
model.  A. Representative image of photoacoustic imaging. The top images show the 
photoacoustic signals in the cell inclusions with SNAb-, nonJanus AuNP-cp33, SA-
AuNP-SA and no NP-treated samples (from left to right). The bottom images show the 
acoustic signals of the cell inclusions in the same order. B. The quantified amount of 
SNAbs bound on each MDSC after normalizing the photoacoustic signals by the cell 
density calculated with acoustic signals and laser energy.  
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Figure 24. NonJanus and Janus peptide modified nanoparticles bound on RAW 264.7 
macrophages.  The nonJanus NP to cell ratio was 51,000:1 and the Janus NP to cell ratio 
was 22,600:1. The quantified amount of nonJanus nanoparticles (A) and Janus 
nanoparticles (B) including MDSC-SNAbs (G3-AuNP-cp33) bound on each 
macrophages were calculated by averaging the signals from the randomly-selected three 
cross-sections from at least two technical replicates after normalizing the photoacoustic 
signals by the cell density calculated with acoustic signals and laser energy.  
 
4.2.6 SNAbs activated NFκB inflammatory pathway in macrophages 
High avidity ligation of receptors associated with immunoreceptor tyrosine-based 
activation motif (ITAM), such as Fc gamma receptors, leads to activation of NFκB 
pathway in inflammatory cells (e.g. macrophages). 
154,155
 We used RAW-Blue cells, a 
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reporter cell line derived from RAW 264.7 macrophages, which were stably transfected 
with genes for a secreted embryonic alkaline phosphatase (SEAP) inducible by NFκB and 
AP-1 transcription factors. When these cells were treated with SNAbs for 16-24 hrs, we 
observed significantly higher secretion of SEAP compared to those in control-particle 
treated groups, indicating the capability of SNAbs for triggering the activation of NFκB 
pathway (Figure 25). This effect potentially will lead to the up-regulation of 
proinflammatory cytokine (e.g. interleukin-1β, IL-6) secretion and the activation of 
innate immune responses.  
                                    
Figure 25. NFκB pathway activation in RAW-Blue macrophages by SNAbs.  RAW-Blue 
macrophages were treated with equal amount of modified and unmodified gold 
nanoparticles, PBS or endotoxin-free water for 24 hrs. The supernatant was collected and 
the NFκB activation was measured with QuanTi Blue assay.  
4.2.7 Toxicity of SNAbs on MDSCs in absence of effector cells 
Before we test the function of SNAbs to induce killing of MDSCs with immune effector 
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themselves are toxic to MDSCs. MDSCs were cultured with SNAbs and control 
nanoparticles or buffer (PBS) for 4 hrs and 24 hrs and their viability was stained with 
Zombie UV fixable viability kit and Annexin V.  
 
Figure 26. SNAbs by themselves have no toxicity on MDSCs.  Isolated MDSCs were 
treated with various types of Janus nanoparticles. The viability of MDSCs was evaluated 
with Zombie UV fixable kit and Annexin V-APC at 4 hrs and 24 hrs. The left and right 













, right) cells at 4 hr 
(top) and 24 hrs (bottom), respectively.  
 
None of the nanoparticles induced any more apoptosis or necrosis of MDSCs compared 
to the untreated control groups (MDSC alone) (Figure 26). Therefore, SNAbs and other 
peptide-modified nanoparticles do not have toxicity themselves for MDSCs. At 24 hr 
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time point, nanoparticle- or PBS-treated groups had lower apoptosis rate than untreated 
group did, possibly because the treatments were all in PBS and diluted the medium, 
which may for some reason supported the survival of MDSCs.  
4.2.8 SNAbs induced ADCC/ADCP of MDSCs by macrophage in vitro 
 
Figure 27. SNAbs induced antibody-dependent phagocytosis of MDSCs by macrophages. 
Macrophage and MDSCs were labeled with CellTracker Green and Celltrace Yellow 
respectively and co-cultured for 4 hrs at a ratio of 20:1. The percentages of double-
positive (left) and single-positive (right) MDSC cells were analyzed by flow cytometry. 
Double-positive cells are macrophages that phagocytosed MDSCs.  
 
To test the capability of SNAbs in triggering specific killing of MDSCs, we conducted 
cytotoxicity assays with MDSCs and RAW 264.7 macrophages co-culture in 96 well 
plates. In such assays, MDSCs and RAW 264.7 macrophages were labeled with different 
colors and co-cultured for a certain period of time, after which their percentage and 
viability were assessed. When the ratio of macrophages and MDSCs were 20:1, at both 4 
hr and 24 hr time point, we observed significant increase in the percentage of double-
fluorescence cells out of macrophages in the SNAb treated group, indicating the 
induction of phagocytosis of MDSCs by macrophages (Figure. 27). We also observed 
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significant reduction in the percentage of MDSCs in the SNAb treated group, resulted 
from the phagocytosis. However, the single-positive MDSCs were not positive for 
Zombie UV staining, which stains for the dead cells with permeable cell membrane, and 
also didn’t show higher Annexin V staining, which stains the apoptotic cells. These 
illustrates that the MDSCs were primarily killed by phagocytosis but not specific lysis via 
ADCCs. Surprisingly, scAHNP-AuNP-cp33 Janus particles also elicited the same extent 
of increase in double-positive cell percentage and reduction in the MDSCs population, 
indicating the G3 is not playing a key role in this response. However, non-peptide-
modified Janus particles biotin-AuNP-NEM didn’t elicit such response compared to 
nonJanus SA-AuNP-SA or PBS, showing the importance of peptide modification in the 
killing of MDSCs by macrophages. In another experiment, we treated the co-culture of 
MDSCs and macrophages with SNAbs and also nonJanus AuNP-cp33 particles for 24 hrs 
and stained the cells with PI for viability of cells (Figure. 28). We observed less 
significant but apparently specific lysis effect induced by the nonJanus AuNP-cp33 
nanoparticles, again showing the critical role of cp33 in the killing of MDSCs. The 
capability of inducing specific lysis by non-Janus AuNP-cp33 is probably owing to the 
binding of AuNP-cp33 on both MDSCs and macrophages due to presence of Fc receptors 
(see Appendix A.2).  
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Figure 28. SNAbs triggered specific lysis of MDSCs in a macrophage-MDSC co-culture 
assay. The MDSCs were labeled with Celltrace CFSE and co-cultured with macrophages 
at 1:25 ratio for 16 hours. The specific lysis was quantified by staining cells with 
propidium iodide after culture and analysis with flow cytometry.  
 
4.2.9 SNAbs reduced MDSCs in splenocyte suspension 
Despite showing effective killing response induced by SNAbs in an effector-target co-
culture system, we have yet not enough proved that SNAbs could kill target cells in a 
physiological relevant condition, where multiple types of immune effector cells are 
interacting with each other and various secretory factors are changing the immunological 
environment. Therefore, we devised a splenocyte mixture assay to test the capability of 
SNAbs to reduce MDSC populations in a complex cancer-relevant environment. We 
harvested spleens from 4T1-tumor bearing mice on day 16 post tumor inoculation, when 
massive accumulation of MDSCs already occurred in spleen due to the onset of tumor. 
The spleens were processed into single cell suspension, which is composed of the 
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following major cell types: CD11b
+







 cells, including granulogycitc and monocytic MDSCs), CD3
+







 B cells, and CD49b
+
 NK cells. In such mixture, macrophage and 
NK cells were present at a disease-dictated ratio to our target cells, MDSCs. The mixture 
of splenocytes was treated with equal amount of various types of nanoparticles or control 
solution (e.g. PBS) for 20-24 hrs and then the percentage of various types of cells were 
analyzed by flow cytometry. In such assays, we also included positive nanoparticle 
controls, which is Janus nanoparticles modified with G3 for targeting MDSCs and human 
IgG1 Fc fragments for Fc-receptor crosslinking. We used dialysed, unmodified SA-
AuNP-SA as our negative particle control to exclude the effect generated by nanoparticle 
treatment, and PBS as our buffer control as all the nanoparticles were formulated with 
PBS.  
First of all, we noticed that both Janus G3-AuNP-cp33 particles (G3-SNAbs) and Janus 
G3*-AuNP-cp33 particles (G3*-SNAbs) triggered strong killing of G-MDSCs in the 
splenocyte mixture compared to control particles (SA-AuNP-SA) after 24hrs, even 
stronger than the positive Janus particle control, Janus G3-AuNP-Fc (Figure 29). This 
was illustrated by the impressive reduction of the percentage of granulocytic MDSCs and 
the increase in the percentage of dead granulocytic MDSCs in these two groups. On the 
contrary, the percentage of M-MDSCs increased after treatment with G3-SNAbs and 
G3*-SNAbs because of the drastic reduction of G-MDSCs, but meanwhile the percentage 
of dead M-MDSCs also increased, indicating a killing effect induced by the two types of 
SNAbs on M-MDSCs as well. The results were consistent across three experiments of the 
same kind conducted six-months apart. The effect of SNAbs was impressive, considering 
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that the ratio of macrophages to MDSCs was around 1:3 and the ratio of NK cells to 
MDSCs was around 1:10 , much lower than that in the effector-target co-culture assay 
(20:1). 
 
Figure 29. G3-SNAbs and G3*SNAbs triggered killing of MDSCs in a splenocyte 
suspension.The splenocyte suspension was treated with equal amount of SNAbs and 
control formulations for 24 hrs. The cells were stained with fluorescent-antibodies for 
cell markers and Zombie UV dye for viability. The top graphs show the percentages of 
total G-MDSCs (A) and the percentage of dead cells out of G-MDSCs (B). The bottom 
graphs show the percentages of total M-MDSCs (C) and the percentage of dead cells out 
of M-MDSCs (D). One-way ANOVA with Tukey test was performed to analyze the 
statistical difference among groups (**** p<0.0001, *** p<0.0002, ** p<0.0021, * 
p<0.0332). 
 
In addition, we compared the performance of Janus nanoparticles and nonJanus 
nanoparticles. The Janus nanoparticles were G3-SNAbs or Janus G3-AuNP-Fc, while 
nonJanus nanoparticles were SA-AuNP-SA particles modified with G3-biotin and cp33-
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biotin or Fc-biotin. On the nonJanus G3-AuNP-cp33, the two peptides randomly 
distribute all over the surface of the particles in 1:1 ratio. Interestingly, the nonJanus G3-
AuNP-cp33 and G3-AuNP-Fc didn’t elicit any killing effect of MDSCs, as illustrated by 
the same percentages of G-MDSCs and dead G-MDSCs as those of particle (SA-AuNP-
SA) and buffer-control (PBS) treated groups (Figure. 30). The results were consistent 
across three experiments of the same kind, indicating that Janus structures are crucial to 
the specific killing induced by SNAbs. 
 
Figure 30. Janus structure is essential for eliciting killing of MDSCs by SNAbs.  
NonJanus double peptide (G3 and cp33)-modified AuNPs failed to elicit any response in 
splenocyte suspension assays. Here, we show the percentage of G-MDSCs (left) and the 
percentage of dead cells out of G-MDSCs (right) as representative results. One-way 
ANOVA with Tukey test was performed to analyze the statistical difference among 
groups (**** p<0.0001, *** p<0.0002, ** p<0.0021, * p<0.0332). 
 









 dendritic cells (DCs), CD3
+
 T cells and B220
+
 B cells 
significantly increased because of the decrease in the percentages of MDSCs (Figure 31). 
Surprisingly, SNAbs also reduced the number of NK cells in the mixture of splenocytes, 
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possibly due to the decrease in the S100A8/A9 factors secreted by MDSCs
153
 and the 
lack of interleukin-2, which is essential growth factors for NK cells in culture.  
 
Figure 31. The specificity of SNAb-induced killing of target cells in single splenocyte 
suspension. SNAbs increased the percentages of F4/80
+





 T cells (C), and B220
+
 B cells (D), but decreased that of CD49b
+
 NK cells (E). 
The plots are representative of three repeated assays of the same kind. One-way ANOVA 
with Tukey test was performed to analyze the statistical difference among groups (**** 
p<0.0001, *** p<0.0002, ** p<0.0021, * p<0.0332). 
 
We also compared the efficacy of SNAbs with the most commonly used MDSC-targeting 
monoclonal antibody, anti-Gr1 antibodies, clone RB6-8C5, which were frequently used 
in the depletion of MDSCs in murine tumor models.
115,102 
 We tested two concentrations 
of the anti-Gr1 antibodies: the low-dose group had a concentration matched that of the 
gold nanoparticles; the high-dose group used one matched the theoretical concentration 
of each ligand modified on the SNAbs. We observed influence of the anti-Gr1 antibody 
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on the staining of anti-Ly6G-PerCP/Cy5.5 antibodies on G-MDSCs and M-MDSCs post 
treatment in the splenocytes (Figure. 32 left), so we could not directly calculate the 
percentage of those two types of cells in the anti-Gr1 treated groups. Instead, we 
examined the percentages of the parent population, the CD11b
+
 cells. Due to the 
reduction in G-MDSCs, the percentage of CD11b
+
 cells also decreased after SNAb 
treatment. However, neither of the anti-Gr1 treatment groups elicited any reduction in the 
CD11b
+
 cells. Anti-Gr1 high-dose group did increase the percentage of dead G-MDSCs 
and decrease that of dead M-MDSCs, implying different mechanism of action between 
SNAbs and anti-Gr1 antibodies (Figure. 33) and that concentration of the antibodies 
matters. At the 24 hr in the splenocyte suspension assay, SNAbs were likely to have 
induced strong ADCP of MDSCs, while anti-Gr1 antibodies functioned primarily through 
ADCC, which caused more specific lysis of MDSCs. Further, by presenting ligands 
multivalently, SNAbs were more effective than anti-Gr1 antibodies at the same dosage 
(low dose). Lastly, SNAbs targeted both granulocytic and monocytic MDSCs, while anti-
Gr1 antibodies worked on only granulocytic MDSCs and seemed to protect monocytic 
MDSCs from dying.  
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Figure 32. Anti-Gr1 monoclonal antibodies treatment didn't decrease the percentage of 
CD11b+ cells in the splenocyte suspension.  The splenocyte suspension was treated with 
SNAbs and antibodies (anti-Gr1, IgG isotype) for 24 hrs. The cells were stained with 
anti-CD11b-PE/Cy7, anti-Ly6G-PerCP/Cy5.5, anti-Ly6C-APC/Cy7 for cell markers and 
Zombie UV dye for viability. The left graph is a representative flow scattering plot of 
anti-Gr1 high dose group (red) and other samples (blue). The right is the calculated 
percentage of CD11b
+
 cells out of total cells in each group (n=6). One-way ANOVA with 
Tukey test was performed to analyze the statistical difference among groups (**** 







Figure 33. High concentration of anti-Gr1 antibody increased the death of G-MDSCs 
(left) but decreased that of M-MDSCs (right).  The splenocyte suspension was treated 
with SNAbs and antibodies (anti-Gr1, IgG isotype) for 24 hrs. The cells were stained 
with anti-CD11b-PE/Cy7, anti-Ly6G-PerCP/Cy5.5, anti-Ly6C-APC/Cy7 for cell markers 
and Zombie UV dye for viability. The left graph is the percentage of dead G-MDSCs and 
the right is the percentage of dead M-MDSCs cells (n=6). 
 
Surprisingly, in one assay, we observed inconsistency in the result of the killing of 
MDSCs in splenocytes (Figure 34). One observation in this assay was that IrrelG3-biotin- 
or scAHNP-biotin-modified Janus AuNP with cp33-SMCC, basically IrrelG3-SNAb and 
scAHNP-SNAbs, which should have less strong or no targeting effect for MDSCs, also 
decreased the percentage of G-MDSCs and increased that of M-MDSCs comparable to 
G3-SNAbs (Figure 35). The other observation was that G3 and Irrelcp33 modified Janus 
AuNPs also induced similar killing effect as that of G3-SNAbs, contradicting with the 
results in other assays. Such accidental failures prompted us to examine the effect of the 
non-peptide-modified Janus nanoparticles in killing MDSCs in both in vitro (see 4.2.8) 
and in vivo (see 5.2.4 and 5.2.5) and the reproducibility of the splenocyte assays.  
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Figure 34. Some inconsistent results of the MDSC killing experiments.  The splenocyte 
suspension from 4T1-tumor bearing mice was treated with equal amount of SNAbs and 
control formulations for 24 hrs. The cells were stained with fluorescent-antibodies for 
cell markers and Zombie UV dye for viability. The top graphs compare the percentage of 
G-MDSCs (A) and the percentage of dead cells out of G-MDSCs (B) after treatment with 
Janus nanoparticles modified with different targeting ligands. The bottom graphs 
compare the percentage of G-MDSCs (C) and the percentage of dead cells out of G-








4.2.10 MD simulation of the interaction between G3 and G3* peptides and human 
S100A8/A9 heterodimer protein 
Figure 35. MD simulation of the interaction of G3 and G3* with S100A8/A9 protein. A 
and B are the superposition of the final frames of the five G3 simulations (A) and G3* 
simulations (B). C and D are the contact probability (defined as coming within 3.5 Å) 
determined from all five G3 simulations (C) and G3* simulations (D). The sequence 
along the x axis is that of each peptide. 
 
As we noticed that both G3 and G3* peptide have strong binding affinity with 
S100A8/A9-expressing MDSCs in experiments, we collaborated with Dr. Gumbart’s 
group in the school of physics in Georgia Institute of Technology to computationally 
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predict the binding mechanism. S100A8/A9 mouse heterodimer protein-crystal structure 
was not determined yet, but human heterotetramer has the similar amino acid sequence 
(over 50%) as the mouse counterparts and its structure was available from protein data 
bank. Therefore, the computational modeling was done with human S100A8/A9 
heterotetramer protein (PDB ID code 1XK4
144
) and G3-biotin, G3*-biotin peptides in a 
modeling system to shed some light into the possible binding sites between them.  
No unique binding site was observed in any of the simulations; whether this is due to the 
lack of such a site or the time scale of the simulation being too short is uncertain. 
However, G3 peptides were observed to interact with two predominant areas on the 
S100A8/A9 protein, as seen in Fig. 35 A. Since both the distribution of G3 peptides (top 
and bottom) and the structure of S100A8/A9 heterotetramer are symmetrical, it further 
supports the preference of G3 for these areas. Contrary to G3, the G3* peptides interact 
with many different regions of S100A8/A9 in multiple conformations.  
At the end of the G3 simulations (Figure 35 A), there are 21 peptides (out of 80 total) 
within 3.5 Å of S100A8/A9 across all five simulations. In the G3* simulation, there are 
30 peptides total within 3.5 Å of S100A8/A9 heterotetramer across all five simulations 
(Figure 35 B). This suggests that the G3* peptide has a stronger ability to bind with the 
S100A8/A9 protein. 
In order to dissect and further quantify the interactions between the peptides and 
S100A8/A9, the contact probability between the peptides and S100A8/A9 was measured 
with a cutoff distance 3.5 Å across all the simulations. Compared to G3 and S100A8/A9, 
the aggregate binding probability between G3* and S100A8/A9 is notably higher. We 
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broke down contacts by amino acid in the peptide, revealing which are important for 
binding to S100A8/A9 (Fig. 35 C-D). Compared to G3 in which the two lysines are next 
to each other, both with relatively low contact probability, the two lysines of G3* appear 
separately at the N- and C-termini (not counting biotin), both with relatively high contact 
probability. This suggests that the location of the lysines in G3* enhances binding to 
S100A8/A9. In addition, the tryptophan at the N-terminal end of G3 promotes 
aggregation between the peptides, making it less likely for the G3 peptide to interact with 
the S100A8/A9 protein. 
 
4.3 Discussion 
Two of the essential prerequisites for an antibody to function well are the capability to 
recognize target cell types and the ability to crosslink Fc gamma receptors on the effector 
cells. We tested the binding capability of both the free peptides and the peptide-modified 
nanoparticles. The free G3 bound to their target cells, MDSCs, strongly. They also bound 
to CD11c
+
 DCs slightly because DCs express S100A8/A9 proteins
121
 and Fc receptors as 




 T cells and NK 





 T cells also express some S100A8/A9 proteins or have 
receptors that can engage with such proteins. However, G3 modified-SNAbs didn’t affect 




 T cells. For NK cells, Kenta, et. al., reported that NK cells 
express the RAGE receptors on the surface and bind with S100A8/A9 proteins secreted 
by pancreatic cancer cells.
153
 The S100A8/A9 proteins in the tumor stimulated the 
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proliferation of NK cells, induced interferon gamma (IFN-γ) production and enhanced the 
NK group 2D ligand-mediated intracellular activation pathway in NK cells. Therefore, 
G3 could be binding to NK cells via S100A8/A9 engaged with the RAGE receptors. We 
also observed reduction in the percentage of NK cells in the splenocyte suspension assay. 
There could be two potential reasons: one is that G3-SNAbs might bind to NK cells and 
induced phagocytosis of NK cells by macrophages; the other is that the reduction of 
MDSCs removed the source of S100A8/A9 proteins and the lack of IL-2 factors, resulted 
in the reduction in viability of NK cells in the culture. Cp33 was shown to bind to RAW 
264.7 murine macrophage-like cell line in a concentration-dependent manner, and also 
preferably bound to F4/80
+
 macrophages in a mixed splenocyte suspension. IFN-γ 
priming could induce their expression of FcγRIII and FcγRIIb on macrophages (See 
Appendix A.1), but didn’t increase the binding of cp33 on macrophages (Figure A.1.2). 
Anti-CD16/CD32 antibody treatment also didn’t reduce the binding of cp33 on 
macrophages significantly (Figure A 3), indicating that cp33 possibly favors the FcγRI, 
which are highly expressed on macrophages, but not so much on PMNs, and are not 
expressed on NK cells. This observation matches what we saw in the macrophage-
MDSCs co-culture assays. In such assays, MDSCs were killed mainly by phagocytosis 
rather than cytolysis mediated perforin or granzyme B. Cp33 functionally mimics the 
property of human IgG1, which is evolutionally conservative and similar to mouse IgG1. 
Both human and mouse IgG1 binds to mouse FcγRI, and human IgG1 actually binds to 
FcγRI more strongly than to other mouse FcγRs. 
55,56
 FcγRIs are more efficient at 
mediating phagocytosis
101,115 
and thus cp33-modified nanoparticles can trigger 
phagocytic process of target cells by macrophages. This conclusion is not only supported 
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by our own data but also the published results on the ADCP of prostate cancer cells 
induced by a chemically synthesized small molecule involving cp33.
53
 
The nanoparticles we used are 30nm in size, which is challenging to visualize in 
microscopy. Unfortunately, the available amine groups on the streptavidin molecules 
were used to functionalize streptavidins on the nanoparticle surface, so they are 
unavailable for convenient labeling of the particles with amine-reactive dyes. Therefore, 
we’ve tried labeling the cp33 peptides with Alexa Fluor 647 dye on the N-terminus and 
use the fluorophore-conjugated peptides to modify the nanoparticles. When we 
performed confocal imaging with these particles, we saw clustering of cp33-modified 
Janus AuNP particles on macrophages (See Figure A 4). Besides confocal imaging, dark-
field microscopy can visualize the gold nanoparticles utilizing the optical scattering 
property of them, but the limited resolution of dark-field microscope (inferior to confocal 
microscope) and difficulty of thoroughly cleaning and maintenance of cleanness of glass 
slides impeded the collection of convincing evidence of SNAbs binding on cells. After 
trials and error, we determined that photoacoustic (PA) imaging is the best way to 
illustrate the co-localization of nanoparticles and cells. Photoacoustic effect is the 
conversion of light to sound with a nanosecond pulsed laser. Gold nanoparticles are 
optical absorbers that absorbs the electromagnetic radiation, leading to localize thermal 
deposition and the production of a pressure wave, and thus can be detected by PA 
imaging microscope.
143
 Therefore, we can use PA imaging to quantitatively assess the 
binding of peptide-modified gold nanoparticles on target cells. The significant increase of 
the PA signals in G3-SNAbs-treated MDSCs and macrophages demonstrated the 
capability of G3-SNAbs on the target and effector cells. The binding of cp33-modified 
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nanoparticles on MDSCs can be explained by the expression of Fc receptors on myeloid 
lineage cells and the binding of G3 or G3*-modified particles on macrophages can be 
explained by the interaction of S100A8/9 protein with macrophages. Although the cross-
binding occurs for G3-AuNP-cp33 particles as shown in PA imaging results, we didn’t 
notice any significant toxicity of the SNAbs on macrophages in the killing assays, 
indicating that the engagement of two phagocytes could not induce killing of one another.  
G3* peptide, which is a scrambled G3 peptide, was originally designed as the negative 
control peptide for G3. However, G3* sequence was not included in the Ph.D. -12 phage 
display library, so it was not tested for its binding to MDSCs in the original publication.
25
 
Both of the flow-cytometry peptide binding assay and the PA imaging experiments 
proved that capability of G3* to bind to MDSCs, especially G-MDSCs. The experimental 
results were also supported by the computational modeling of interaction between G3* 
and human S100A8/A9 heterotetramers. Functionally, G3*-SNAbs was also shown to be 
able to elicit strong killing of MDSC in the splenocyte suspension. Therefore, we can 
draw a conclusion safely now that G3* is also a targeting ligand for MDSCs isolated 
from 4T1 breast cancer-bearing mice.  
The clustering of FcγRs by IgG immune complexes will lead to the tyrosine 
phosphorylation of ITAMs by the Src family tyrosine kinases, which in turn activates 
multiple signaling pathways, including the activation of spleen tyrosine kinase (Syk), 
phosphatidylinositol 3-kinase (PI3-K), mitogen-activated protein (MAP) kinases and 
phospholipase Cγ (PLCγ). These signaling events result in actin polymerization and 
phagocytic cup formation, the release of various inflammatory mediators, such cytokines 
and reactive oxygen species (ROS), and eventually the phagocytosis of IgG-coated 
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particles or the cytolysis of target cells. The entire process is ATP-dependent and 
involves the refluxes of calcium. Unfortunately, we failed to detect the phosphorylation 
of Syk by western blotting of cell lysate or the increase in ROS production from RAW 
macrophages treated with SNAbs (Appendix B). We also could not capture the calcium 
reflux as it is very transient and time-dependent response.
155,158,159
 We could only 
detected the activation of the downstream signaling events, i.e., NFκB pathway 
activation, in the highly sensitive reporter cell line, RAW-Blue macrophages, which is 
highly involved in the transcriptional modulation of inflammatory cytokines. These 
results prompted us to think about one of our hypotheses, which is that the multivalent 
presentation of cp33 ligands on the nanoparticles can crosslink the Fc receptors on the 
effector cells and activate immune responses. Apparently, our SNAbs were not capable 
enough to elicit antibody-dependent activation of the macrophages without the presence 
of target cells, which ensures the safety of SNAbs and avoid the unspecific cytotoxicity. 
In fact, previous studies on the artificial antigen-presenting-cells (aAPCs) for T cell 
activation have demonstrated that increasing the densities of ligands on the beads alone 
could not increase the ability to stimulate T cells if the beads were too small (50 nm) and 
the activation of T-cell receptor (TCR) nanoclusters by multi-receptor ligation is size-
dependent for aAPCs (larger than 300nm is required).
160
 Given Fc receptor mediated 
activation of innate immune cells is a similar process as TCR-mediated T cell activation, 
we think that the 30 nm SNAbs were not large enough to induce the immune response by 
themselves and thus a target cell is needed to form a large immune complex and trigger 
the Fc receptor-dependent signaling cascade. Further investigation on the effect of 
SNAbs of different sizes could provide us with better understanding of how SNAbs work.  
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In the effector-target cell co-culture assays, we demonstrated that SNAbs could induce 
phagocytosis of MDSCs by macrophages. Additionally, we developed a new cytotoxicity 
assay, the splenocyte suspension assay, to test the functions of SNAbs. The splenocyte 
suspension assay better reflects the physiological events in the following three aspects: 
one is that it enables us to test the functions of the MDSC-SNAbs at a disease-determined 
effector-target ratio (macrophage to MDSCs ratio was around 1:3 instead of 20:1 in the 
co-culture assays), and thus produces more clinically relevant results; a second is that it 
includes multiple immune effector cells types (e.g. macrophages, NK cells, DCs, T cells 
and B cells), which is very important for predicting in vivo immune responses because 
innate immunity interacts with adaptive immunity in vivo (for example, macrophages are 
also antigen-presenting cells and can activate cellular immune responses); another aspect 
is that it allows us to study whether the SNAbs affect other cell types that are either in 
close proximity spatially with MDSCs or in the similar lineage. Using this assay, we 
successfully proved that MDSC-targeting SNAbs could still efficiently reduce the 
MDSCs at a low effector-target ratio after the onset of tumors and this effect was specific 
for MDSCs, not affecting other cell types ex vivo. The G3-SNAbs and G3*-SNAbs did 
better than the positive Janus control nanoparticles, G3-AuNP-Fc, possibly because the 
number of Fc fragments conjugated on the nanoparticles were lower than that of cp33 on 
the SNAbs, leading to the weakened capability of effector activation. Besides, the 
nonJanus control G3-AuNP-Fc failed to trigger any response, possibly because the 
competitive binding between G3-biotin and Fc-biotin on the SA-AuNP-SA resulted in a 
nonJanus nanoparticle mostly covered with G3 ligands. However, our data still 
undoubtedly demonstrated that Janus structure is essential for induction of such responses 
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as nonJanus G3-AuNP-cp33, coated with both G3 and cp33, also didn’t induce any 
killing of MDSCs. Moreover, Janus nanoparticles without peptide modification (Biotin-
AuNP-NEM) didn’t elicit a response, indicating peptide ligands are important as well. 
Surprisingly, we noticed similar effect in the control SNAb (scAHNP-SNAb) groups and 
Irrelcp33-modified Janus NP groups inconsistently. Irrelcp33 was excluded from the 
following experiments or analysis because of its hydrophobicity and strong binding 
capability on all types of cells. For the control SNAbs, we will see in the next chapter that 
the in vivo experimental results disagreed with the ex vivo results and showed that control 





CHAPTER 5 AIM 3. TO EVALUATE THE THERAPEUTIC 
POTENTIAL OF THE SNABS IN TUMOR MODELS 
MDSCs are key players in the immunosuppressive microenvironment of tumor, which 
dampens the anti-cancer immune attack and facilitates the growth and metastasis of 
tumor. Removing MDSCs from the tumor microenvironment was proven to be an 
important strategy for restoration of immune-surveillance and the eradication of 
tumors.
117,161,162
 However, as discussed in Chapter 3, there are limited options for 
depleting MDSCs in vivo and therapeutics that work in vitro may not necessarily function 
as well in vivo. Therefore, after we validated the capability of SNAbs to induce killing of 
MDSCs ex vivo, we moved forward to test its efficacy in murine tumor models.  
Murine tumor models are designed to capture the complexities of human cancer and offer 
the platform to study the mechanism of therapeutics and evaluate their efficacy and 
potency before going into human clinical trials. Expansion of MDSCs populations was 
observed in a variety of murine tumor models, such as EL4 lymphoma, B16 melanoma, 
EG.7 thymoma and 4T1 breast cancer.
25,105
 To test the SNAbs for MDSC depletion, we 
chose the orthotopic 4T1 breast cancer model, which represent the human triple-negative 
breast cancer (TNBC) in mouse and is capable of metastasizing efficiently to the sites 
affected in human.
27,117
 The TNBC is defined by a lack of expression of the three human 
receptors, epidermal growth factor receptors (Her2), estrogen receptor (ER) and 
progesterone receptor (PR). It accounts for 10%-15% of the breast cancers and has no 
effective clinical therapy yet. 
163,164
 Therefore, using 4T1 breast-cancer model to test 
SNAbs could provide new rationale for TNBC treatment.  
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In this aim, we tested our hypothesis that SNAbs could deplete MDSCs populations in 





 MDSCs in bone marrow and then enter the peripheral 
blood and accumulate in the spleen and tumors, and to a lesser extent in the lymph nodes. 
We evaluated the efficiency of SNAbs in the depletion of MDSCs in blood, tumor, bone 
marrow and spleen. It is one of the advantages of nanoparticle-based artificial antibody 
platform that by tailoring size, shape, and surface chemistry, we can enhance the 
penetration and retention of them in the disease sites. MDSC-SNAbs were designed to be 
in the size range that they can preferentially accumulate in solid tumors, so we also 
analyzed the biodistribution of SNAbs after intravenous injection to validate this 
hypothesis. In the end, we studied whether MDSC-SNAbs could improve the survival of 




Aqua regia for dissolving tissue samples in the biodistribution study was prepared by 
mixing concentrated nitric acid:hydrochloride acid in 1:3 volume ratio; nitric acid was 
purchased from Sigma Aldrich (Cat.#.695025); hydrochloride acid was purchased from 
VWR International, (Cat.#.BDH3030). Collagenase D, RBC lysis buffer, and cytofix 
buffer were the same as described in Chapter 4. Anti-PD1 (Clone RMP1-14) and anti-
CTLA-4 (Clone 9H10) were purchased from BioXCell, New Hampshire, USA. The 
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antibodies used in flow cytometry were the same as those described in Chapter 4, except 
for some new antibodies for functional markers (See Appendix Table for antibodies) 
5.1.2 Cell lines and Animals  
Murine triple-negative breast cancer cell line 4T1 were purchased from American Type 
Culture Collection (Manassas, VA, USA). The 4T1 cell lines were cultured in RPMI 
1640 (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (GE 
Healthcare, Chicago, IL, USA) and 1% PS (Thermo Fisher Scientific) under standard cell 
culture condition (37°C, 5% CO2).  
Five to Six-week-old Balb/c female mice were purchased from the Jackson Lab. All mice 
were maintained in a pathogen-free mouse facility according to institutional guidelines. 
All of the animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Georgia Institute of Technology (Atlanta, Georgia). The 
experimental sample sizes ensured adequate statistical power.  
5.1.3 Biodistribution of MDSC-SNAbs by inductively-coupled mass spectrometry 
(ICP-MS) 
Single-cell-suspension of 4T1 cells before passage 25 was prepared in PBS (Hyclone) at 
a concentration of 1×10
7 
cells/mL. Five-to-six-weeks-old Balb/c mice were inoculated 
with 0.5×10
6
 4T1 breast cancer cells orthotopically on the fourth mammary fat pad on 
day 0. We injected 200 μL of SNAbs (0.80×10
11
) via tail veins into Balb/c mice with 
around 3 mm 4T1 breast tumors on day 9 post tumor inoculation. At t=6, 24, 48 hrs, we 
harvested and weighed the lung, liver, spleen, kidney, tumor, and blood and dissolved 
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them in aqua regia for overnight at room temperature. Samples for ICP-MS analysis were 
prepared by boiling aqua regia-tissue solution at 200 °C and then diluting the sample with 
DI water. The debris of tissue samples was removed by going through 0.2 μm syringe 
filters and the concentration of Au in each sample was analyzed by ICP-MS (NexlON 
300Q, Perkin-Elmer). We acknowledge Da Huo in Dr. Younan Xia’s group for the 
acquisition of data with ICP-MS.  
5.1.4 In Vivo Depletion of MDSCs by MDSC-SNAbs 
Single-cell-suspension of 4T1 cells before passage 25 was prepared in PBS (Hyclone) at 
a concentration of 1×10
7 
cells/mL. Five-to-six-weeks-old Balb/c mice were inoculated 
with 0.5×10
6
 4T1 breast cancer cells in 50 μL sterile PBS orthotopically into the fourth 
mammary fat pad of each mouse on day 0. MDSC-SNAb (i.e., G3-AuNP-cp33 or G3*-
AuNP-cp33) formulation or control SNAbs (e.g., scAHNP-AuNP-cp33, Biotin-AuNP-
NEM) or unmodified streptavidin functionalized gold nanoparticles (SA-AuNP-SA) 
formulation containing 0.75×10
11
 nanoparticles were administrated intravenously through 
tail vein injection to mice (n=6) according to the designed injection schedule. For single 
treatment study, at 24 hrs after the injection, mice were euthanized and the spleens, 
tumors were collected. Spleens and tumors were treated with collagenase D and RBC 
lysis to make single cell suspensions, as described previously in Chapter 4. We also 
collected blood by cardiac puncture. A minimum of 100 μL of blood from each mouse 
was transferred to fresh FACS tubes and treated with 2 mL RBC lysis buffer at room 
temperature for 10 mins and then centrifuged at 700 g for 10 mins. Cell pellets were 
resuspended in FACS buffer and kept in 4 °C until use. In some experiments, we also 
collected the bone marrow from tibia and femur. Briefly, the skin and muscle tissue were 
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removed from the bones and then bone marrow was flushed with medium using a 25 
gauge needle and syringe. Red blood cells in the bone marrow were lysed and cells were 
washed with PBS and resuspended in FACS buffer. All the cell samples from spleen, 
tumor and blood were stained with antibodies for MDSC (CD11b, Ly6G, Ly6C), 
macrophages (F4/80), dendritic cells (CD11c), T cells (CD3, CD4, CD8, Foxp3, CD25), 
B cells and NK cells (CD49b, CD3, B220). Tumor samples were also stained with 
functional or proliferation markers (Granzyme B, Perforin, CD107, CD69, PD1, LAG3, 
Ki67, IFNγ). Samples were fixed with BD Cytofix buffer and analyzed on BD 
LSRFortessa flow cytometer.  
5.1.5 4T1 breast cancer survival study with MDSC-SNAbs 
Single-cell-suspension of 4T1 cells before passage 25 was prepared in PBS (Hyclone) at 
a concentration of 0.2×10
7 
cells/mL. Five-to-six-weeks-old Balb/c mice were inoculated 
with 0.1×10
6
 4T1 breast cancer cells orthotopically on the fourth mammary fat pad on 
day 0. MDSC-SNAbs or control particles SA-AuNP-SA (0.75×10
11
 NP/200 μL in PBS) 
were then given intravenously through tail vein injection on day 7, 9, 11. The size of the 
tumor and the weight of the mice were measured every other day. The mice were 
sacrificed according to the IACUC protocol when the tumor size reached 1.5 cm in any 
direction or any of the following was observed: significant weight loss (over > 10%), 
perforation of skin, or severe cachexia. Tumor volume was calculated by the following 
equation:          
  
 
 , where l is the length and w is width of the tumor. Median 
survival and Kaplan-Meier survival curves were generated, and Log rank (Mantel-Cox) 
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tests were performed to compare survival between various groups using GraphPad prism 
7 software. *P<0.05, ** P<0.01, and *** P <0.001 were considered significant.  
5.1.6 4T1 breast cancer survival study of the combination therapy of MDSC-SNAbs 
and immune-checkpoint blockade 
Single-cell-suspension of 4T1 cells before passage 25 was prepared in PBS (Hyclone) at 
a concentration of 0.2×10
7 
cells/mL. Five-to-six-weeks-old Balb/c mice were inoculated 
with 0.1×10
6
 4T1 breast cancer cells orthotopically on the fourth mammary fat pad on 
day 0. MDSC-SNAbs or control particles SA-AuNP-SA (0.75×10
11
 NP/200 μL in PBS) 
were then given intravenously through tail vein injection on day 7, 9, 11, 13. Anti-PD1 
and anti-CTLA-4 antibodies were given 200μg/mouse, intraperitoneally on day 6, 10, 14. 
The size of the tumor and the weight of the mice were measured every other day. The 
mice were sacrificed according to the IACUC protocol when the tumor size reached 1.5 
cm in any direction or any of the following was observed: significant weight loss (over > 
10%), perforation of skin, or severe cachexia. Tumor volume was calculated by the 
following equation:          
  
 
 , where l is the length and w is width of the tumor. 
Median survival and Kaplan-Meier survival curves were generated, and Log rank 
(Mantel-Cox) tests were performed to compare survival between various groups using 





5.1.7 Statistical Analysis 
Student’s t-test was used to perform statistical analysis between two groups. When 
comparing more than two groups, normalization tests were performed first to test the 
distribution of data in each group. One-way analysis of variance (ANOVA) with Tukey 
post hoc test was used for data with normal distribution and non-parametric methods with 
Dunn’s post hoc test was used for data that was not in normal distribution. When P value 
is < 0.05, the difference between groups was considered significant (**** p<0.0001, *** 
p<0.0002, ** p<0.0021, * p<0.0332). In vitro experiments were conducted a minimum of 
two iterations (n=3 or 6 for each sample) to ensure reproducibility. Two-way ANOVA 
was performed to study the difference among groups in the tumor growth curve. Log-
rank (Mantel-Cox) test was used to analyze the statistical difference among groups in the 
survival curve. 
5.2 Results 
5.2.1 MDSCs accumulated in spleen and blood during tumor progression 
Our lab has previously established this 4T1 breast cancer model for vaccine studies. 
Before doing MDSC depletion studies with SNAbs in this model, we examined the 
accumulation of MDSC in the spleen and blood. Balb/c mice were orthotopically 
inoculated with 0.5×10
6
 4T1 tumor cells in the fourth mammary fat pad and after around 
7 days, subcutaneous primary tumors could be seen at the site of injection. MDSCs 
started to accumulate in spleen, blood, tumor and bone marrow, The percentages of 
MDSCs could reach 5%-10% and 10%-20% in spleen and blood respectively by day 10 
(Figure 36). Healthy mice of age 5-12 weeks will continue to gain weight over time, but 
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tumor-bearing mice have slower weight growth and scar tissue forms over the site of 
tumor inoculation typically between day 14-21. Without treatment, tumor dimension will 
reach the 1.5 cm end-point in about 20-30 days.  
 
Figure 36. Gating strategy for MDSCs. The graphs are selected from the blood samples 
of breast cancer tumor-bearing mice. The CD11b
+
 cells were first gated out from the 








 were then 
gated in the CD11b
+
 population.  
 
5.2.2 The biodistribution of MDSC-SNAbs in 4T1 breast cancer tumor-bearing mice 
As the element Au does not naturally exist in the body of animal, we were able to 
accurately quantify the amount of gold nanoparticles in the tissues collected from mice to 
analyze the distribution of MDSC-SNAbs (Janus G3-AuNP-cp33) after tail vein 
injection. Because they were introduced intravenously, blood was found to have a high 
concentration of the SNAbs at 6 hr time point after injection (Figure 39). The SNAbs 
circulated in the blood and travel to other organs over time, resulting in a gradual 
decrease in the blood concentration of Au over time. At t=48 hr, the concentration of 
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SNAbs almost returned to zero. The calculated half-life of SNAbs in blood is 26 hrs. 
After SNAbs left blood vessels, their first destination was liver. At t=6 hr, over 30% of 
the SNAbs were found to be in the liver, and they remained in the liver for the rest of the 
time (Figure 37). Spleen was apparently the second favorable organ for SNAbs to 
accumulate in. In fact, from 6 hr to 48 hr, spleen remained to be the organ with the 
highest SNAb concentration (ng/g of tissue). Lung and kidney hardly had any retention of 
SNAbs, but the SNAbs kept accumulating in the tumors. The percentage of SNAbs 
traveled to tumor increased from around 0.90% at 6hr time point to 3.39% at 48hr time 
point (Figure 38). The concentration of SNAbs in tumor was the third among all the 




Figure 37. Biodistribution of SNAbs in 4T1-tumor bearing mice by mass of Au.  SNAbs 
were administered by intravenous injection through tail vein. Tissue and blood samples 
were collected at t=6, 24, 48 hrs post injections. ICP-MS was conducted to analyze the 
amount of SNAbs in each sample. The graphs show the total amount of Au elements in 




Figure 38. Biodistribution of SNAbs in tumor-bearing mice by percentage.  SNAbs were 
administered by intravenous injection through tail vein. Tissue and blood samples were 
collected at t=6, 24, 48 hrs post injections. ICP-MS was conducted to analyze the amount 
of SNAbs in each sample. The graphs show the percentage of SNAbs distributed in each 
type of organs at different time points (A-C) out of total amount of SNAbs administered 






Figure 39. Biodistribution of SNAbs in tumor-bearing mice by concentration (ng of Au 
per g of tissue).  SNAbs were administered by intravenous injection through tail vein. 
Tissue and blood samples were collected at t=6, 24, 48 hrs post injections. ICP-MS was 
conducted to analyze the amount of SNAbs in each sample. The graphs show the 
concentration of SNAbs distributed in each type of organs at different time points (A-C) 
as nanograms of Au per gram of tissue collected (n=3) and the changes over time (D). 
 
5.2.3 MDSC depletion with single treatment of MDSC-SNAbs  
In a preliminary study, we administered 0.75×10
11 
of SNAbs or control particles (SA-
AuNP-SA) on day 10 post tumor inoculation into the 4T1-breast tumor-bearing mice and 
after 24 hrs, we analyzed the percentage of major immune cells types in the spleen, blood 
and tumors.  
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Figure 40. The numbers of cells in the spleens after treatment. Nanoparticles were 
injected into the 4T1-tumor bearing mice through tail veins on day 10 post tumor 
inoculation. The spleens were collected 24 hrs after injection and the total number of 
cells in each spleen was counted with trypan blue. Statistical difference was analyzed 
with ANOVA with Tukey test (n=6, *p<0.05)  
 
First, we observed significant lower number of cells in the spleen in the G3-SNAb-treated 
groups compared to the control-particle-treated group or untreated tumor-bearing group 
(Figure 40), showing an amelioration of splenomegaly, the enlarged spleen symptom 
resulted from tumor progression. More prominently, we observed apparent reduction in 
the percentage of granulocytic MDSCs in the spleen and blood, by 55.7% and 46.4% 
respectively compared to those of the untreated group (Figure 41) and also significant 
reduction of the number of monocytic MDSCs in spleen by 69.6%. However, SNAbs 
didn’t change the accumulation of MDSCs much in the tumors compared to untreated 
group. Because of the reduction of MDSCs, the percentage of CD3
+









 cytotoxic T cells in the spleen (Figure 42) 
after treatment with G3-SNAbs, indicating higher probability of effective anti-cancer 
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 T regulatory cells decreased in the G3-SNAb-
treated group by 40.1% compared to the untreated group (Figure 43). Interestingly, the 
percentage of NK cells increased by 12.4% in the spleen after G3-SNAb treatment, 
contradicting with the result of the splenocyte suspension assay (Figure 44). Besides, 
control particle treatment (SA-AuNP-SA) also reduced the percentage of MDSCs to 
some extent compared to untreated groups, but they do not affect any other cell 




Figure 41. Percentages of G-MDSCs and M-MDSCs in spleen, blood and tumor after 
treatment.  Nanoparticles were injected into the 4T1-tumor bearing mice through tail vein 
on day 10 post tumor inoculation. The spleens, tumors and blood were collected 24 hrs 
after injection. The cells in the samples were stained with fluorescent-antibodies against 
cell surface and intracellular markers and analyzed on a flow cytometer. The graphs show 
the percentages of G-MDSCs (left column) and M-MDSCs (right column) of spleens 
(A,B), blood (C,D), and tumors (E,F). Statistical difference was analyzed with one-way 
ANOVA with Tukey post hoc test or Kruskal-Wallis test with Dunn’s multiple 
comparison, * p < 0.05, **p<0.01, ****p<0.001, n=6.  
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Figure 42. The percentages of T cells in spleens after treatment.  Nanoparticles were 
injected into the 4T1-tumor bearing mice through tail veins on day 10 post tumor 
inoculation. The spleens were collected 24 hrs after injection. The cells in the samples 
were stained with fluorescent-antibodies against cell surface and intracellular markers 
and analyzed on a flow cytometer. The graphs show the percentages of the CD3
+









 cytolytic T cells (C) in the spleens. 
Statistical difference was analyzed one-way ANOVA with Tukey post hoc test or 
Kruskal-Wallis test with Dunn’s multiple comparison, *p<0.0332, **p<0.0021, 




Figure 43. The percentages of CD4
+
 T cells and T regulatory cells in blood after 
treatment.  Nanoparticles were injected into the 4T1-tumor bearing mice through tail 
veins on day 10 post tumor inoculation. The spleens were collected 24 hrs after injection. 
The cells in the samples were stained with fluorescent-antibodies against cell surface and 













 regulatory T cells (B) 
in the blood. Statistical difference was analyzed with one-way ANOVA with Tukey post 
hoc test, * p < 0.0332, n=6. 
 
Figure 44. The percentages of CD49b
+
 NK cells in the spleens after treatment.  
Nanoparticles were injected into the 4T1-tumor bearing mice through tail veins on day 10 
post tumor inoculation. The spleens were collected 24 hrs after injection. The cells in the 
samples were stained with fluorescent-antibodies against cell surface and intracellular 




 NK cells in the spleens. Statistical difference was analyzed with one-way 





5.2.4 MDSC depletion with three treatments of MDSC-SNAbs  
Single-treatment depletion study didn’t affect the accumulation of MDSCs in the tumor, 
so we tested the therapeutic effects of three treatments in tumor. G3*-SNAbs or other 
control particles (Janus IrrelG3-AuNP-cp33, G3*-AuNP-Irrelcp33, SA-AuNP-SA) or 
PBS were administered in the 4T1-tumor-bearing Balb/c mice on day 7, 9, 11 post tumor 
inoculation. After three treatments with SNAbs, we saw significant enhancement in the 
depletion of MDSCs in tumor, with 52% and 90% decrease in G-MDSCs and M-MDSCs 
respectively compared to untreated group, and 69% and 88% decrease compared to SA-
AuNP-SA treated group (Figure 45). However, surprisingly, the control SNAbs, IrrelG3-
AuNP-cp33, and G3*-AuNP-Irrelcp33 also had strong depletion effect. After we tested 
the binding of free IrrelG3 peptide and Irrelcp33 on MDSCs (See 4.2), we noticed that 
both peptides have strong binding capability to MDSCs. Therefore, the Janus particles 
modified with these two peptides were also capable to affect the MDSC populations in 
vivo. In the following analysis, we will not consider these two types of nanoparticles as 
control SNAbs any more and in the later depletion study, a non-peptide-modified Janus 
nanoparticles, biotin-AuNP-NEM, was used as a universal negative Janus nanoparticle 
control for the SNAbs.  
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Figure 45. Percentages of MDSCs in spleen, blood and tumor after three injections.  
Nanoparticles or PBS were injected into the 4T1-tumor bearing mice through tail veins 
on day 7, 9 and 11 post tumor inoculation. The spleen, tumor, bone marrow and blood 
were collected 24 hrs after the last injection. The cells in the samples were stained with 
fluorescent-antibodies against cell surface and intracellular markers and analyzed on a 
flow cytometer. The graphs show the percentages of G-MDSCs (left column) and M-
MDSCs (right column) of spleens (A,B), blood (C,D), and tumors (E,F). Statistical 
difference was analyzed with one-way ANOVA test with Tukey or Kruskal-Wallis test 




We observed similar reduction in the percentages of G-MDSCs and M-MDSCs in spleen 
and blood after SNAb treatment as well as compared to PBS-treated and untreated groups 
(Figure 45). Unlike the first depletion study, SA-AuNP-SA treatment didn’t affect 
MDSCs in tumor and spleen this time, but slightly reduced MDSCs in blood.  
Tumor growth significantly increased the percentage of both G-MDSCs and M-MDSCs 
in the bone marrow, but MDSC-SNAbs failed to deplete any MDSCs in the bone marrow 




Figure 46. Percentages of MDSCs in bone marrow after three injections.  Nanoparticles 
or PBS were injected into the 4T1-tumor bearing mice through tail veins on day 7, 9 and 
11 post tumor inoculation. The bone marrow was isolated 24 hrs after the last injection. 
The cells in the samples were stained with fluorescent-antibodies against cell surface and 
intracellular markers and analyzed on a flow cytometer. The graphs show the percentages 
of G-MDSCs (A) and M-MDSCs (B) in bone marrow. Statistical difference was analyzed 
with one-way ANOVA with Tukey post hoc test, n=6. Naïve group was significantly 
different from other groups statistically.  
 





 T cells slightly increased in tumors after SNAb treatments. Also, the 
percentage of IFNγ
+




 T cells increased due to SNAb treatment 
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compared to SA-AuNP-SA-treated and PBS-treated groups, indicating stronger anti-
tumor activity in the T cells (Figure 47).  
 
Figure 47. Percentages of cytotoxic T cells in tumors after three injections.  Nanoparticles 
or PBS were injected into the 4T1-tumor bearing mice through tail veins on day 7, 9 and 
11 post tumor inoculation. The tumors were collected 24 hours after the last injection. 
The cells in the samples were stained with fluorescent-antibodies against cell surface and 









 T cells (B) in tumors. 
Statistical difference was analyzed with one-way ANOVA with Tukey post hoc test, n=6. 
 
Although there were more CD49b
+
 NK cells infiltrated into the tumors after SNAb 
injections, all the treatments seemed to have negatively affected the functionality of the 







48). It could be that triggered by the treatments, these NK cells have unloaded factors 
into the tumor microenvironment to kill the malignant cells or the target cells, MDSCs, 
leading to a reduced percentage of positive cells detected by flow. Otherwise, it could be 
possible that due to the binding of the Janus nanoparticles to NK cells, the viability and 
activity of NK cells were dampened.  
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Figure 48. Percentages and functional characterization of NK cells in tumors.  
Nanoparticles or PBS were injected into the 4T1-tumor bearing mice through tail veins 
on day 7, 9 and 11 post tumor inoculation. The tumors were collected 24 hrs after the last 
injection. The cells in the samples were stained with fluorescent-antibodies against cell 





 NK cells (A) and IFNγ
+





(D) NK cells in tumors. Statistical difference was analyzed with one-way ANOVA with 
Tukey post hoc test, n=6. 
 
5.2.5 A comprehensive MDSC depletion study with MDSC-SNAbs 
After summarizing the information we got from the previous two MDSC depletion 
studies, we planned to further investigate whether more dosages of treatment and earlier 
treatment might have better chances to reduce the MDSC accumulation in tumor. Also, 
we still haven not reached a conclusion about whether peptide ligands modified on the 
particles are essential for the selective depletion of MDSCs or not as we got controversial 
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results from previous ex vivo and in vivo studies. Therefore, we designed a more 
comprehensive MDSC depletion study, in which we included a three-injection and a 
single-injection group of G3-SNAbs, and also single-injection groups of Janus scAHNP-
AuNP-cp33 and Biotin-AuNP-NEM. Specifically, the single injections were given on day 
10 post tumor inoculation and the three injections of G3-SNAbs were given on day 6, 8, 
10 through tail vein. The tissue samples were collected on day 11 post tumor inoculation 
to study the changes in cell composition in the spleen, blood and tumors. As we didn’t 
see any changes in the bone marrow samples in the last study, bone marrow was excluded 
from the analysis.  
Interestingly, unlike previous results, both single-injection and three-injection groups did 
not affect granulocytic MDSCs much, but reduced the percentage of monocytic MDSCs 
in the tumors (Figure 49). The results of single-injection of G3-SNAb group didn’t show 
any difference from those of three-injection group.  
Similar to previous results, in the spleens, the treatment with G3-SNAbs resulted in huge 
reduction (around 69.8%) in the percentage of G-MDSCs in the spleen (Figure 49 C). 
The single-injection group still had no difference from the three-injection group. While 
the scAHNP-AuNP-cp33 induced a smaller decrease in the G-MDSC percentage, biotin-
AuNP-NEM treated groups didn’t change it much. However, due to the decrease in the 
G-MDSCs, the percentage of M-MDSCs slightly increased in the spleen in the treatment 
groups. The G3-SNAb three-injection group seemed to have smaller increase in the M-
MDSCs groups, indicating a better control in the therapeutic effect.  
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Figure 49. Percentages of MDSCs in spleen, blood and tumors after injections.  SNAbs 
(Janus G3-AuNP-cp33) was injected either one time on day 10 or three times on day 6, 8, 
10 through tail vein into the 4T1-tumor bearing mice. Other treatments were given only 
one time on day 10 to mice. The spleens, blood and tumors were collected on day 11. The 
cells in the samples were stained with fluorescent antibodies against cell surface and 
intracellular markers and analyzed on a flow cytometer. The graphs show the percentages 
of G-MDSCs cells (left) and M-MDSCs (right) out of total cells in tumors (A, B), spleens 
(C,D) and out of CD11b
+
 cells in blood (E,F) (n=6). Statistical difference was analyzed 
with one-way ANOVA with Tukey post hoc test or Kruskal-Wallis test with Dunn’s 
multiple comparison. 
 
However, in blood, the single-injection of G3-SNAbs did better than the three-injection 
groups in reducing G-MDSCs. ScAHNP-AuNP-cp33 didn’t induce any changes in the 
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percentages of G-MDSCs, suggesting that the targeting-ligands are playing an important 
role in the depletion of G-MDSCs in vivo. Interestingly, the administration of Janus 
Biotin-AuNP-NEM also affected the G-MDSCs and M-MDSCs as much as the single-
injection of G3-SNAbs.  
 




 T cells in tumors after injections.  The graphs show 









 T cells (right) in tumors (n=6). Statistical difference was analyzed with one-
way ANOVA with Tukey post hoc test or Kruskal-Wallis test with Dunn’s multiple 
comparison., * p<0.05, **p<0.0021, ***p<0.0002.  
 





T cells in the tumor, as shown in Figure 50. Other Janus nanoparticles 
didn’t elicit the same response, indicating the importance of the targeting-ligand 
modification on the particles. However, the scAHNP-AuNP-cp33 seemed to be able to 




T cells to produce IFNγ more than other groups 
(Figure 50 B), which we haven’t found any explanation yet. 
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Figure 51. The percentages of activated or regulatory T cells in the tumors after 
treatment. The graphs show the percentages of CD107
+
 cells (A) and Ki67
+





 cytotoxic T cells and the percentages of T regulatory cells (C) in tumors 
(n=6). Statistical difference was analyzed with one-way ANOVA with Tukey post hoc 
test or Kruskal-Wallis test with Dunn’s multiple comparison. 
 




T cells being 
activated in the tumors after G3-SNAb treated compared to control treatments, as those T 
cells express the CD107 marker representing degranulation during the cytotoxic 
responses (Figure 51 A). G3-SNAb treatment also seemed to relieve the proliferation 
inhibition on T cells by MDSCs to some extent compared to control Janus nanoparticle 
treatments (Figure 51 B). In addition, fewer regulatory T cells were detected in the G3-
SNAb groups, indicating the abrogation of immune-suppression due to MDSCs depletion 
systemically (Figure 51 C).  
In terms of T cells in the spleen, we didn’t notice any changes except the percentage of 
the CD3
+




and other phenotypes) increased slightly after 
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treatment with G3-SNAbs (Figure 52 A). Interestingly, in blood, there was a trend of 
growing percentages of CD4
+ 
T cells out of CD3
+ 
T cells and a trend of decreasing 
percentages of CD8
+ 
T cells out of CD3
+ 
T cells from the untreated tumor-bearing groups 
to SNAb-treated groups.  
 
Figure 52. T cell percentages in the spleen and blood after treatment. The graphs show 
the percentages of CD3
+
 T cells in the spleen (A), CD8
+
 T cells (B), CD4
+
 T cells (C), 
and regulatory T cells (D) out of CD3
+ 
T cells in the blood after treatment (n=6). 
Statistical difference was analyzed with one-way ANOVA with Tukey post hoc test or 
Kruskal-Wallis test with Dunn’s multiple comparison, **p<0.0021.  
 
Although the G3-SNAb treatment reduced the percentages of B cells and IFNγ
+
 cells out 
of NK cells in the spleens (Figure 53) and blood (Figure 54), but G3-SNAb single 
treatment remarkably increased the percentage of NK cells infiltrated in the tumors 
(Figure 55). No enhancement or reduction of NK cell function or activation in tumors 
was observed. Interestingly, biotin-AuNP-NEM increased the percentages of B cells out 
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of CD3- cells and SA-AuNP-SA increased in percentages of IFNγ
+
 cells out of NK cells 
in blood (Figure 54).  
 
Figure 53. Percentages and characterization of B and NK cells in the spleens. The graphs 
show the percentages of CD3
-
 cells (A), B220
+
 B cells out of CD3
-





B cells out of all cells (C), and CD49b
+
 NK cells out of CD3
-





cells out of all
 
cells (E), and IFNγ
+
 cells out of NK cells (F) in the spleens after treatment 
(n=6). Statistical difference was analyzed with one-way ANOVA with Tukey post hoc 





Figure 54. Percentages and activation of B cells and NK cells in blood after treatment. 
The graphs show the percentages of B220
+
 B cells out of CD3
-
 cells (A), CD49b
+ 
NK 
cells out of CD3
-
 cells (B), and IFNγ
+
 cells out of NK cells (C) in the blood after 
treatment (n=6). Statistical difference was analyzed with one-way ANOVA with Tukey 




Figure 55. Infiltrated NK cells increased in the tumors after G3-SNAb single injection. 
The graphs show the percentages of CD49b
+ 
NK cells out of CD3
-
 cells (A), CD49b
+ 
NK 
cells out of total cells (B), Granzyme B
+
 cells out of CD49b
+ 
NK cells (C), IFNγ
+
 cells 
out of NK cells (D), and Perforin
+
 out of CD49b
+ 
NK cells (E) in the tumors after 
treatment (n=6). Statistical difference was analyzed with one-way ANOVA with Tukey 
post hoc test or Kruskal-Wallis test with Dunn’s multiple comparison, **p<0.01. 
 
5.2.6 MDSC-SNAb treatment prolonged the survival of 4T1-tumor bearing mice 
As shown in the depletion studies, MDSC-SNAbs not only deplete MDSCs in the tumor, 
spleen, and blood, but also affect other cell types. Therefore, we wanted to investigate 
how these changes after MDSC-SNAb treatment translate into therapeutic effects in 
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tumor models. We administered MDSC-SNAbs through tail vein injections to 4T1-tumor 
bearing mice on day 7, 9 and 11 post tumor inoculation.  
 
Figure 56. MDSC-SNAb treatments prolonged the survival of 4T1-tumor bearing mice. 
MDSC-SNAbs (Janus G3-AuNP-cp33) or control nanoparticles were administered into 
4T1-tumor bearing mice on day 7, 9, and 11 post tumor inoculation (A). The graphs and 
table show the growth curve of tumors in each group (B), the survival plot (C) and 
median survival of each group (D) (n=10). Two-way ANOVA was performed to study 
the difference among groups in the tumor growth curve. Log-rank (Mantel-Cox) test was 
used to analyze the statistical difference among groups in the survival curve.  
 
We observed that MDSC-SNAbs prolonged the survival of mice by delaying tumor 
growth significantly compared to the control-particle treatment after day 27 (Figure 56). 
We were requested to end the study on day 30 because of the onset of skin perforation on 
the primary tumors causing pain in the mice. At day 30, 60% of the mice were still alive 
(didn’t meet any criteria for euthanization) in the MDSC-SNAb-treated group, but only 
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20% of mice remained alive in the control groups. The median survival of MDSC-SNAb 
group is 30 days, while that of SA-AuNP-SA-treated group and untreated group is 23 and 
26, respectively. These confirmed that depleting MDSCs by SNAbs conferred survival 
benefits to 4T1-tumor-bearing mice. 
5.2.7 MDSC-SNAb treatment had little enhancement over the immune-checkpoint 
blockade therapy in 4T1-breast tumor model. 
Anti-PD1 and anti-CTLA-4 antibodies are the most well-known immune-checkpoint 
inhibitors (ICIs), which were shown to induce remarkable therapeutic responses in 
various cancers, but had limited effects in poor immunogenic tumors, such as 4T1 breast 
cancer. Previous studies have shown that MDSC depletion could enhance the therapeutic 
effects of immune-checkpoint inhibitors, so we tested the combination of MDSC-SNAb 
and anti-PD1, anti-CTLA-4 treatments in our 4T1-tumor models.
117,118
 We administered 
the nanoparticles and antibodies according to the treatment schedule described in Figure 
57 and tracked the growth of tumors in the mice every other day. Although we didn’t 
observe noticeable difference in the tumor growth rate between the group treated with 
antibodies plus G3-SNAbs and the group treated with antibodies plus control particles or 
only antibodies, the MDSC-SNAb treated group had longer median survival time (37 
days) compared to the control groups (See Figure 57 C). MDSC-SNAbs had a therapeutic 
effect in the early period of disease progression after adminstration, but the effect was 
lost after 39 days and mice in MDSC-SNAb-treated groups were euthanized when they 
met the end-point criteria.  
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Figure 57. Survival study of the combination therapy with immuno-checkpoint inhibitors 
and MDSC-SNAbs.  A. MDSC-SNAbs (Janus G3-AuNP-cp33) or control nanoparticles 
were administered into 4T1-tumor bearing mice on day 7, 9,11 and 13 post tumor 
inoculation via tail vein injections (A). Anti-PD1 and anti-CTLA-4 antibodies were 
administered on day 6,10, 14 via i.p. injections. The graphs and table show the survival 
plot and median survival (B) and the growth curve of tumors in each group (C, D) 
(n=10). Two-way ANOVA was performed to study the difference among groups in the 
tumor growth curve. Log-rank (Mantel-Cox) test was used to analyze the statistical 
difference among groups in the survival curve. 
 
5.3 Discussion 
Among all the tumor models, 4T1 is one of the few that is highly metastatic and closely 
recapitulates the properties triple-negative breast cancer in human, which affect millions 
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of women in the world and lack effective treatment strategy.
27
 The syngeneic 4T1 mouse 
model also have the advantage of normal immune functions, which provides more 
translational information for human breast cancers.
28,117
 Meanwhile, according to our 
observation, once inoculated on the mammary fat pad orthotopically in mice, the 4T1 
cells establish primary tumors fast and rapidly metastasize to other organs, such as bone 
marrow, lymph nodes and lung, within 20 days. As a result, the window of treatment and 
analysis in 4T1-tumor model is short, allowing fast study completion. Also taken into 
consideration that 4T1-breast cancer strongly promotes the expansion of MDSCs, 4T1-
orthotopic murine tumor model is a good choice to evaluate the therapeutic efficacy of 
MDSC-SNAbs.  
Intravenous (i.v.) injection is the most common route of administration for monoclonal 
antibodies, followed by subcutaneous (s.c.) and intramuscular (i.m.) injection.
13
 
Adsorption of monoclonal antibodies after s.c. and i.m. injections are slower process 
compared to that after i.v. injections, because it is dependent on the convective transport 
of antibodies through interstitial space into the lymphatic system and the flow rate of 
lymphatic fluid is slow.
165
 By i.v. injection, monoclonal antibodies can distribute into the 
tissue from the blood through convective transport, which relies on the flux of fluid by 
the blood-tissue hydrostatic gradient and sieving effect of the para-cellular pores.
13
 We 
selected intravenous injection as the route of administration for MDSC-SNAbs to match 
the common practice used for monoclonal antibodies and also to take advantage of the 
fast distribution of SNAbs into the tissues, such as spleens and tumor, which are two 
major sites where MDSCs resides. In addition, after getting out of the bone marrow, 
MDSCs circulate in the blood to the spleen and tumor following the inflammation cues, 
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so capturing the blood MDSCs in circulation early by i.v. injection would help enhance 
the therapeutic effect of MDSC-SNAbs by reducing the systemic immune-suppression of 
cancer.  
To investigate the biodistribution of SNAbs after i.v. injection in the mice, we have tried 
the following method: 1. Quantifying the fluorescence of organs isolated from mice 
injected with SNAbs labeled with fluorescent probes at desired time points using IVIS in 
vivo imaging system; 2. Imaging the whole mice with photoacoustic imaging microscope 
at 680-970 nm after injection with unlabeled SNAbs at desired time points; 3. Using 
inductively-coupled plasma-mass spectrometry, quantifying the amount of Au element in 
the tissues collected from the mice injected with unlabeled SNAbs at desired time points. 
For the first method, we labeled the SNAbs with Vivotag 647-NHS ester dye. Although 
the fluorescence of the labeled-SNAbs were detectable in the Biotek microplate reader, 
we failed to acquire any signal distinctly higher from the organs collected from the 
SNAb-injected mice compared to the untreated mice. Vivotag 647 dye covalently binds 
to the amine groups. However, the amine groups on the streptavidin were occupied for 
the conjugation of them onto the gold nanoparticles and the number of available amines 
on the peptides were also limited, so the nanoparticles were able to produce enough 
signals to penetrate through the tissue and be detected in the IVIS system. Despite other 
chemically active groups exist in the structure of SNAbs, they do not present in high 
enough numbers to enhance the fluorescent signals of the nanoparticles. For the second 
method, the photoacoustic imaging microscope failed to discern the signals of SNAbs 
from those of the oxygenated hemoglobin at around the SPR peak (532nm) of 30nm gold 
nanospheres. As a result, we cannot tell whether the increased signal from the organs of 
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the nanoparticle-treated animals was caused by more blood flow in the same area or not. 
Photoacoustic imaging actually works better with gold nanorods, which have optical 
absorption spectra in the near infrared range and thus distinguishable from the optical 
adsorption of hemoglobin.
103,166,167
 Therefore, we moved on with the third method, 
quantification of the gold element in the tissues by ICP-MS.  
The plasma half-life is a key factor in the pharmacokinetics to be considered when 
designing the dosage and frequency for drug administration.
168
 Monoclonal antibodies 
usually have elimination half-life in days (for example, 18-21 days for IgG1, IgG2, 
IgG4
13,168
), because of the recycling by binding onto the neonatal receptor, FcRn, that 
express on the surface of blood cells and mediate the internalization of IgG by cells and 
returning of the antibodies to the cell surface under certain physiological conditions. As 
shown in the ICP-MS results, the SNAbs extravasated the circulation within 48 hrs. 
Seemingly, the SNAbs have a much more rapid clearance rate from the circulation than 
monoclonal antibodies, with the half-life being 26 hrs. In this case, SNAbs should be 
dosed more frequently than monoclonal antibodies. However, they preferentially 
accumulated in the spleen after they left the blood, which are the of the main target 
organs for MDSC-SNAbs to deplete MDSCs. This observation matches the remarkable 
decrease of MDSCs in the spleen of 4T1-tumor bearing mice after treatment of SNAbs. 
MDSC population expands rapidly in the spleen after tumor onset, constituting as high as 
80% of the myeloid-derived cells and up to 40% of the total cells in the spleen (data not 
shown). Therefore, the capability of SNAbs to accumulate in the spleen and deplete 
splenic MDSCs could lead to significant reduction of MDSC migration to the tumors, and 




More promisingly, SNAb concentration in tumors was observed to keep increasing from 
6 hr to 48 hr post injection. The size of the SNAb (actual size 30-50nm, hydrohynamic 
size 70-100nm) definitely is playing a critical role in the process as previous literatures 
suggested nanospheres in the size range of sub-50nm are better at escaping from the 
tumor vasculature, penetrating and retaining in the tumors by the EPR (enhanced 
permeability and retention) effect. The favorable accumulation and long retention of 
SNAbs in the tumor definitely projects greater response and better long-term therapeutic 
efficacy, and potentially reducing the dosage and treatment duration requirements. 
Indeed, the dosage we administered of SNAbs in the MDSC depletion studies was 10,000 
times lower than those used in previous reports for anti-Gr1 monoclonal 
antibodies
98,115,156,169
 , but we achieved comparable level of MDSC depletion in the 
blood, spleens and tumors as anti-Gr1 monoclonal antibodies. One other observation is 
that MDSC-SNAbs also accumulates in the liver to a great extent. It is important that a 
novel antibody-like therapeutic is safe to patients. So, a future step is to evaluate the liver 
and hematological toxicity of SNAbs.  
The results from the three depletion studies clearly verified our hypothesis that the 
SNAbs can specifically deplete MDSCs in vivo. The first depletion study used the SNAbs 
generated with the SA-AuNP-SA from Nanopartz.Inc, on which only 21 streptavidins 
were coated, while in the later two studies, we used the SA-AuNP-SA from 
Nanohybrid.Inc, on which 100 streptavidins were coated. In other words, the first 
depletion study used a batch of SNAbs with theoretically lower valency of ligands than 
the later two studies did. However, we achieved similar level of depletion of G-MDSCs 
in these studies in the spleens and blood. This result indicates that either the change in the 
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number of streptavidins on the nanoparticles didn’t alter the valency of SNAbs or the 
change in valency of SNAbs does not impact the capability of them to induce targeted 
responses for granulocytic cells, which necessitates further investigation on the valency 
effect of SNAbs with accurate quantification of ligand modification. On the other hand, 
compared to the first study, the later studies with the theoretical higher-valency SNAbs 
showed greater reduction in the percentages of M-MDSCs in the collected samples and 
better depletion effect of both MDSC subsets in the tumors. The valency of the ligands on 
the SNAbs could possibly be an important reason for it, since the increase in avidity may 
lead to higher affinity and specificity of SNAbs on the target cells and regulate the 
penetration and retention of the nanoparticles in the tumors.  
We did see some unexpected results elicited by the control Janus nanoparticles 
unmodified or modified with peptides other than G3 or G3*. One possible explanation for 
these observations is that the surface property (e.g., hydrophobicity, electrostatic charges) 
of the Janus nanoparticles after modification changed their interaction with the blood 
cells. Different Janus nanoparticles would be taken up and cleared by cells in the blood 
differently, leading to completely different pharmacokinetics of them. Apparently, G3-
SNAbs are more prone to get around with blood clearance and get into the tumor and 
spleens to take an effect. More in vitro and in vivo investigations need to be carried out to 
study how the surface property changes after ligand modification impact the 
nanoparticle-cell interaction, protein corona composition of the nanoparticles and how it 
translates into the in vivo responses elicited by the nanoparticles. This information is 
crucial for the design of SNAbs as a versatile artificial antibody platform. 
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MDSCs were known to suppress the adaptive immune responses by reducing the 
proliferation and activation of cytotoxic T cells and promoting the differentiation of T 
cell into T regulatory cells. Repeatedly in our MDSC-depletion studies, we observed 




 T cells, higher percentage of activated, IFNγ-
secreting T cells and lower numbers of regulatory T cells in the tumors in the MDSC-
SNAb treated groups. These all suggested that MDSC-SNAbs are capable of restoring 
anti-tumor cellular immune responses by depletion of MDSCs. In our preliminary single-
therapy in vivo study, the MDSC-SNAb-treated group had a much higher percentage of 
mice remained alive at the end of the study compared to the control groups, which 
validated that MDSC-SNAbs has therapeutic potential to prolong the survival of 4T1-
breast tumor-bearing mice. In the ICI-MDSC-SNAbs combination studies, we didn’t see 
a statistically significant difference in the tumor growth rate among the groups, but from 
the survival curve, MDSC-SNAbs helped to improve the therapeutic effects of the ICIs in 
the early times points (before day 39). Previous studies by KiBem Kim et al. and by 
Olivier De Henau et al. both showed significant improvement in survival in the 
combination therapy groups with both ICIs and MDSC depletion compared to ICI alone 
group.
117,118
 The reason why we didn’t achieve similar results could be that MDSC-
SNAbs affected the functions of NK cells to some extent, as shown in the depletion 
studies. NK cells are the major effector cells for ADCC elicited by IgG2a and IgG2b 
(anti-PD1: IgG2a, anti-CTLA4: IgG2b), and previous studies report ADCC of regulatory 
T cells as one of the mechanism of anti-CTLA4 antibodies and potentially for anti-PD1 
antibodies.
6,170
 Therefore, a dampened NK cell response may affect the therapeutic 
efficacy of ICIs and thus leading to no improvement in the combination therapy group.  
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Lastly, based on the collected results from the above-discussed in vivo studies, some 
other studies would be interesting and important for the evaluation of therapeutic 
potential of SNAbs. Instead of intravenous injection, intratumoral injection of MDSC-
SNAbs could possibly enhance the depletion effect of MDSCs in the tumor and thus 
more effective inhibit the growth and metastasis of tumors. An imagable 4T1-luc cell line 
could be used to track the metastasis of the tumor and study whether depletion of MDSCs 
could delay or inhibit the metastasis of the 4T1 cancer cells to lung, lymph nodes and 
bone marrow.
27,28,94
 Breast cancers were usually surgically removed before treatment 
with medicines, but the residuals of malignant cells in the original sites will lead to the 
re-occurrence of tumor and more rapid progression and metastasis of cancer. So, it would 
be interestingly to see if MDSC-SNAbs treatment after the surgery could decrease the 
chances of re-occurrence of tumor or improve the prognosis by removing the 
immunosuppression microenvironment. In addition, the aggressiveness of 4T1-breast 
tumor model limited the design of the in vivo studies in terms of injection schedule. We 
were only able to inject the SNAbs before day 12 post tumor inoculation due to the 
collapse of tail vein caused by dehydration of the mice. Therefore, a less aggressive 
model of 4T1 with a decreased dose of tumor inoculation could be useful to allow wider 
treatment window and study the effect of late SNAb treatment. We would also like to 
validate the therapeutic effect of MDSC-SNAbs in other cancer models, such as B16 
melanoma, A20 lymphoma, C26 colon carcinoma, pancreatic or prostate cancers, and 
human breast cancer models in humanized mice.   
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CHAPTER 6 CONCLUSION AND FUTURE DIRECTION 
6.1 Concluding Summary 
Over the past decade, we saw an increasing number of monoclonal antibodies being 
tested in clinical trials and approved by the US Food and Drug Administration (FDA) for 
use in metabolic disorders, autoimmune diseases, infectious diseases, and various 
malignancies. Out of the fifty-nine drugs approved in 2018, eleven of them are 
monoclonal antibodies and they are forecasted to be the potential blockbusters in sales 
29
. 
While we are celebrating the success of monoclonal antibody therapy, we have to keep 
their limitations in mind. Humanized and human monoclonal antibodies (mAbs), which 
are the two popular types of mAbs because of their safety in human, are difficult to 
develop and produce, causing an extremely high price of these mAbs.
12,171
 Moreover, 
their molecular properties resulted in the unsatisfactory therapeutic effects in treating 
deep, solid tumors due to a lack of penetration and retention.
12,23,172,13,45,168
 It is also 
challenging to develop mAbs towards cellular targets that do not have known unique 
surface protein markers because of the challenges in the immunization and screening 
process.
10,12
 Therefore, there is still a need for antibody engineering or the development 
of alternative artificial antibodies to meet the clinical demand.  
During the past decades, particulate systems have gained huge attention as promising 
platform for delivering a variety of synthetic and biological therapeutics and the ease to 
modulate their functions by tailoring physical parameters makes them a good choice in a 
wide range of immunotherapeutic applications.
1,21,22,173
 On the other hand, synthetic small 
molecules, such as peptides and aptamers, have emerged as advantageous targeting and 
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binding ligands for guided and targeted therapies.
16,17,174
 Because of the advent of various 
screening platforms, for example, phage display biopanning, we are allowed to identify 
such small molecular ligands directly with the isolated target protein or cells and tissues 
in animals.
17,67,175
 A combination of the particulate system and small molecule ligands 
enables the design of synthetic therapeutics to mimic the functions of macromolecular 
biologics, such as antibodies, but with much lower developmental cost, higher flexibility 
and versatility. 
18,19,173,176
 Therefore, we designed a novel type of artificial antibody with 
Janus nanoparticles and synthetic ligands, named synthetic nanoparticle antibodies 
(SNAbs). 
To development SNAbs, we first examined whether there are appropriate ligands for the 
engagement with Fc receptors on the immune effector cells and the specific binding of 
target cells. Cp33 is a ligand identified through phage display system that can block the 
binding of human IgG1 and FcγRI by docking onto the binding pockets on the 
receptors.
26
 It was also shown to be able to trigger super-oxide burst and phagocytosis by 
phagocytes when constructed into dimers.
53
 Therefore, cp33 is a good option as Fc-
mimicking ligand. For the proof of concept, we selected myeloid-derived suppressor cells 
as our first target cell type. MDSCs are important therapeutic targets in cancer, which 
suppresses the innate and adaptive immune responses by various mechanisms.
41,162
 The 
depletion of MDSCs was shown to be able to augment the anti-tumor attack and inhibit 
tumor growth.
115,117
 G3 peptide was selected as the targeting ligand for MDSCs, as it is 
capable of recognizing both granulocytic MDSCs and monocytic MDSCs isolated from 
various murine tumor models, potentially through binding to S100A8/A9 heterodimer 
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proteins on the surface of MDSCs.
126
 G3* peptide, a scrambled form of G3 peptide, was 
also found to have specific binding capability on MDSCs. 
To generate SNAbs, we started with streptavidin gold nanoparticles and designed a solid-
phase chemistry method to fabricate Janus nanoparticles with the capability to react with 
biotinylated ligands and maleimide-conjugated ligands on spatially segregated parts of 
the nanoparticle surface. Subsequently, we modified the Janus gold nanoparticles with 
biotinylated targeting ligands (e.g.,G3, G3*) and maleimide-terminated Fc-ligands (cp33) 
to make various functional nanoparticle-ligand conjugates, i.e., MDSC-targeting SNAbs 
(MDSC-SNAbs). In Aim 1 (Chapter 3), we completed the design, fabrication and 
characterization of MDSC- SNAbs, and validated that the chemistry method we 
developed can produce the desired Janus gold nanoparticles, or say SNAbs, that present 
both targeting and Fc-mimicking ligands on the two segregated areas on surface and form 
the antibody-like structure.  
In Aim 2 (Chapter 4), the functions of SNAbs were evaluated in ex vivo systems. Firstly, 
the results of both free peptide-splenocyte binding assay and photoacoustic imaging 
supported the strong binding of G3 peptide on MDSCs and that of cp33 on macrophages, 
for both free peptides and peptide-conjugated nanoparticles. G3*, which is a scrambled 
G3 peptide, also stood out as an effective binding ligand for MDSCs, especially G-
MDSCs. The calcium-binding, proinflammatory protein S100A8/A9 is highly expressed 
on myeloid cells, and is a potential marker for tumor-associated MDSCs. Further 
computational simulation of the interaction between G3, G3* and human S100A8/A9 
heterodimmer not only verified the binding capability of G3 and G3* on the S100A8/A9 
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protein, but also suggested their applicability in human therapies as well. Therefore, both 
G3-SNAbs and G3*SNAbs are considered efficient MDSC-targeting SNAbs.  
In general, antibody mediates the elimination of target cells mainly in two ways, ADCC 
and ADCP. SNAb-treatment alone does not kill MDSCs, meaning that SNAbs do not 
have cytotoxicity on these cells, but in the effector-target cell co-culture assay, we 
observed strong specific lysis of MDSCs by macrophages induced by MDSC-SNAbs 
compared to that by control nanoparticles. The results also illustrated that macrophages 
primarily relies on phagocytosis to kill target cells in the presence of MDSC-SNAbs. 
Another strategy we developed to study the function and specificity of MDSC-SNAbs is 
the splenocyte suspension assay. In this assay, even at an extremely low effector:target 
ratio (1:3), the MDSC-SNAbs were still able to successfully reduce the MDSC 
population in the culture to a great extent and increase the percentage of dead MDSCs 
compared to control treatments. Moreover, MDSC-SNAbs didn’t affect other cell types, 
including macrophages, dendritic cells, T cells and B cells. A negative impact on the 
numbers of NK cells was observed. However, this possibly was due to the decrease of 
S100A8/A9 proteins caused by MDSC depletion. These results validated our hypothesis 
that MDSC-SNAbs can mediate antibody-dependent responses to specifically kill 
MDSCs in the presence of immune effector cells. Interestingly, G3 and cp33 modified 
non-Janus gold nanoparticles failed to induce any responses towards MDSCs, indicating 
that the spatial arrangement of the ligands is crucial to the induction of ADCC or ADCP.  
The fact that MDSC-SNAbs can induce antibody-dependent specific killing of MDSCs in 
an ex vivo environment does not legitimate them as effective therapeutic antibodies for 
treatment of diseases. In Aim 3 (Chapter 5), we further tested the efficacy of MDSC-
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SNAbs in a 4T1 murine tumor model, which recapitulates the properties of human triple-
negative breast cancer. MDSC-SNAbs had a short half-life in circulation, but 
accumulated favorably to the spleen and tumors after intravenous injection. Spleen and 
tumors are the two major sites of interest for MDSC-targeting therapy as MDSCs 
proliferate in the spleen and then migrate to the tumor to suppress the anti-tumor immune 
responses. The retention time of MDSC-SNAbs in these two sites are over 48 hrs, 
suggesting a promising, long-term therapeutic effect on the MDSCs in these organs. The 
preferentially distribution in tumor also matches the previous observations by other 
studies on nanoparticles of sub-50nm in size, showing good tumor-targeting effect. The 
depletion studies proved our hypothesis about the therapeutic effect in spleens and 
tumors. MDSC-SNAbs eliminated the majority of MDSC populations in the spleen and 
also affected the MDSCs in the tumors after one or three injections. Following the 
depletion of MDSCs, we observed an increase in the infiltrated and activated cytotoxic 
CD8
+
 T cells. In other words, MDSC-SNAbs mitigated the immune-suppression in the 
tumor microenvironment and thus strengthened the cellular responses towards tumor. 
Additionally, despite the short half-life in blood, MDSC-SNAbs were able to remarkably 
reduce the circulating MDSCs within 24 hrs of treatment, leading to systemic 
amelioration of immune-suppression and reduction of MDSC accumulation in tumors. 
The therapeutic efficacy of SNAbs in terms of MDSC depletion was comparable to that 
reported in literature achieved with anti-Gr1 antibodies at a dose that is 10,000 times 
higher than that of SNAbs in our study.  Furthermore, when the 4T1-tumor bearing mice 
were treated with MDSC-SNAbs, we observed significant inhibition on the tumor growth 
rate and a longer median survival time than that of the group treated with control particles 
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or left untreated. In summary, with MDSCs as a model target cell type, we have 
successfully proved our hypothesis that SNAbs, Janus nanoparticles with targeting 
ligands and Fc-mimicking ligands presented multivalently on the opposite surface areas, 
are an effective type of artificial antibody that can elicit specific depletion of target cells 
by antibody-mediated immune responses both in vitro and in vivo. The encouraging 
results obtained in this thesis research also prompt us to believe that SNAbs as a platform 
technology could be a functional alternative to monoclonal antibodies and widely applied 
in targeted immunotherapies for cancer.  
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6.2 Future Directions 
Although we have successfully developed a new type of artificial antibody, the synthetic 
nanoparticles antibodies (SNAbs), there are still a number of limitations in the design of 
SNAbs that need to be addressed and further investigations on parameters that affect the 
function of SNAbs are also needed to make SNAbs a more powerful immunotherapeutic 
for cancer and various other diseases.  
First of all, the generation of SNAbs relies on the production of Janus particles, whose 
yield from the solid-phase chemistry we designed so far is unable to meet the demand of 
studies in large animal models (e.g., dogs, primates) or human with a reasonable cost of 
time, money and labor. Scaling-up method using larger reaction vessels or bioreactors are 
possible solutions to increase the efficiency of the production process, as discussed in 
Chapter 3. Other technologies for Janus nanoparticle fabrication, such as, other 
immobilization method, electrohydrodynamic jetting and microfluidic systems, should be 
approached as an alternative method. The immobilization methods are widely used for 
producing inorganic Janus nanoparticles and require solid substrates to enable specific 
modification on certain area of the particles.
89
 A side-by-side configuration was usually 
used in the electrohydrodynamic jetting and the microfluidic method and merging of two 
flows of polymers with delicate control of fluidic parameters yields Janus particles.
90,177
 
These methods all have the potential to produce large amount of Janus nanoparticles 
continuously, but different methods have weaknesses in different ways, such as the 
limitation in size of the particles produced and in the cost. 
89,90,97,177,178
 Besides, a change 
in Janus nanoparticle fabrication method may require switching to different nanoparticle 
materials (e.g., polymer, lipid).
89,90,178,179
 The interaction between the material and 
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biological systems should be taken into consideration when making the choice, as some 
particulate systems themselves are immunogenic or toxic to cells. 
180–182
 
Another limitation of the designed SNAbs lies in the material selected to make the 
construct. Streptavidin-biotin specific reaction enables the easy conjugation of ligands on 
the SA-AuNP-SA nanoparticles. Streptavidin also endows negative charges to the 
nanoparticles, reducing the electrostatic interaction between the SNAbs and cell 
membranes. However, surface-coating of protein complexes the structure of SNAbs, and 
increased the instability of particles, resulting in a short shelf-life. Therefore, substituting 
streptavidin-biotin interaction with other chemistry, such as click-chemistry, could be a 
feasible option to improve the stability and structural simplicity of the SNAbs.
183–186
 On 
the other hand, despite of their advantages due to the unique optical properties, gold 
nanoparticles are expensive starting materials, which increased the cost of SNAbs. 
Polymer particles (e.g.,poly(lactic-co-glycolic acid), PLGA) could be a potential good 
alternative option as they are cheaper in price and validated for safety in biomedical 
applications. 
1,19




Further investigation on the effect of nanoparticle size on the function of SNAbs is 
necessary as it is playing a key role in the biodistribution of SNAbs and interaction with 
cells, including immune cells.
23,189,190,191
 Despite nanoparticles around 50 nm in size 
provide benefit in animal models, such as ease at reaching lymph nodes if injected 
subcutaneously or tumors if injected intravenously,
23,192
 a larger size in similar size 
dimensions to the receptor patches on the cell surface could possibly be better at 
triggering Fc-receptor mediated signaling.
160
 The size of the particles also determined the 
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distance of the effector cells and ‘opsonized’ target cells, which is likely to affect the 
induction of the immune responses.
193
 So, it would be interesting to learn how the particle 
scaffold of different sizes (from nano- to micro-particles) affect the strength of responses 
triggered in vitro or in vivo by SNAbs. The constraints of size should be considered in 
terms of organs to target and toxicity for in vivo applications. For example, the larger 
SNAbs (>100 nm) could be applied in targeting cell types that primarily reside outside 
tumor or lymph nodes (e.g., liver, lung) or in diseases other than cancer (e.g., cystic 
fibrosis, autoimmune arthritis).  
A consensus has already been reached that nanoparticles by themselves can interact with 
the immune systems, stimulating or suppressing both the innate and adaptive immune 
responses.  Material, surface chemistry, charge, size and shape are factors that can be 
used to interpret and predict such interactions.  For example, SiO2, TiO2, ZrO2, and Co 
nanoparticles were all shown to increase the expression of toll-like receptors and 
production of inflammatory cytokines of macrophages, while PLGA nanoparticles were 
shown to have immunosuppressive properties.
194,195
 Due to the negatively charged sialic 
acid on the surface of macrophages, positively charged nanoparticles generally has higher 
potential to induce inflammation by interaction with macrophages and cationic particles 
in general has stronger capability to induce cellular response than anionic particles.
191,195
 
Nanoparticles could be rapidly internalized by phagocytes by interacting with scavenger 
receptors,
196
 and could be taken up by non-phagocytes via via caveola- or clathrin-
mediated processes, influenced by the size and shape of the particles.
195
 Spherical 
particles are more readily to be taken up than rod-like particles and smaller particles 




A corona composed of a large number of serum proteins on the surface of particles will 
be formed during circulation in the blood. Because of their specific surface chemistry, 
some particles, such as imidazole-modified chitosan and dextran-coated ionic oxide 
nanoparticles, absorb more C3, a complement protein, in the corona than unmodified 
chitosan or ionic oxide nanoparticles, as a result of which complement pathway 
activation was observed following the in vivo administration of those particles in mice.
196
 
Also, as mentioned in Chapter 3, surface chemistry influences the aggregation of 
nanoparticles, leading to different extent of particle agglomeration and different ways of 
interaction with the immune systems.  Relevant to SNAbs, gold nanoparticles were 
shown to induce production of TNFα, IL-1β and IL-6 by phagocytes in a size-dependent 
manner, possibly through toll-like receptors.
84,197
 Colloidal gold nanoparticles also 
increases the production of antibodies when introduced together with antigens in the 
animals, the mechanism of which is still unclear. 
198
 In addition, a significant fraction of 
PEGylated, 50 nm gold nanoparticles was reported to distribute in MDSCs after 
intravenous injection in mice.
80
 However, the known immunogenicity properties of gold 
nanoparticles could not explain our findings that SNAbs, a Janus gold nanoparticles of 
80-100 nm in hydrodynamic size coated with MDSC-targeting and Fc-mimicking ligands, 
could induce specific killing of MDSCs both in vitro and in vivo, while non-Janus of 
similar size and coated with same ligands did not. However, we could not exclude the 
possibility that material, surface chemistry, charge, size and shape of the SNAbs are 
contributing to the induction of MDSC-specific response. Therefore, it is definitely 
necessary to conduct further investigation using various approaches (e.g., computational 
simulation, signaling study) on the interaction between SNAbs and immune systems with 
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various types of control nano-constructs and optimize the physical and chemical 
properties of SNAbs for MDSC depletion. The knowledge acquired from such 
investigation will also guide the rational design of SNAbs targeting other cells of interest 
in the future. 
Previous studies also suggested that Fc-receptor mediated responses are sensitive to the 
density of IgG molecular presented
159,199,200
 Within a certain range, the higher the density 
of IgG on beads was, the stronger phagocytosis by macrophages was elicited through 
sequential ligation of Fc receptors.
200
 However, a specific valency of Fc in the form of 
immune-complexes may actually block the activation of the FcγR systems.
159
 Therefore, 
studying the stimulatory capability of SNAbs with various densities of Fc-mimicking 
ligands on the surface is necessary to elucidate the optimal valency for targeted depletion 
of cells in diseases.  
In another aspect, the treatment strategy with MDSC-SNAbs in 4T1 breast cancer model 
still needs to be optimized in terms of route of administration, dosing, frequency and 
treatment duration. As discussed in Chapter 6, besides intravenous injection, 
subcutaneous, intratumoral and intramuscular injection could also be attempted for 
SNAbs for enhanced local therapeutic effect. Although we have achieved satisfactory 
level of target-cell depletion in spleen at the current dose of MDSC-SNAbs, we would 
like to test whether higher dosage could increase the efficacy of SNAbs in tumors and 
blood and further ameliorate the immunosuppression in tumor microenvironment to 
inhibit tumor growth and prolong survival. Lastly, frequency, treatment duration and 
time-points are key factors that influence the long-term treatment effect of SNAbs on 
cancer, so it is absolutely necessary to optimize these parameters in murine models. 
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Although ICI-MDSC-SNAbs combination therapy does not confer therapeutic benefit to 
the tumor-bearing mice over single ICI therapy, but SNAbs, as an artificial antibody, 
could potentially boost the therapeutic efficacy of other immunotherapies (e.g. adoptive T 
cell transfer), chemotherapy and radiotherapy in cancer. For example, doxorubicin-
mediated MDSC depletion enhanced the effect of adoptive T cell transfer in a breast 
cancer murine model. 
116
 Trastuzumab (anti-Her) antibody was used in combination with 
first-line chemotherapy in metastatic breast cancer that overexpresses Her2 and achieved 
improved clinical response in patients.
201
 Radiotherapy was proved to stimulate the 
immune system by broadening the T cell repertoire, activate DCs and making the radiated 
cells more vulnerable to T cell attack.
202
 It is believed that the combination of 
radiotherapy and antibody-based immunotherapy could trigger stronger immunogenic 
cell death and achieve both local and abscopal effect.
203,204
 Therefore, it is a good idea to 
combine MDSC-SNAb treatment with adoptive T cell transfer, chemotherapy or 
radiotherapy and evaluate whether these combinations has synergistic therapeutic effect 
in murine breast cancer models.  
Moreover, encouraged by the exciting results in 4T1 breast cancer model, we would like 
test the potency of MDSC-SNAbs in other tumor models as well to expand the 
applications of MDSC-SNAbs. Actually, previous studies in mouse models have 





 and lung cancer
115
, so more specific targeting strategies to 
deplete MDSCs, like SNAbs, are likely to have therapeutic benefit in these tumors as 
well.  
 159 
Lastly, we would like to develop a multitude of SNAbs targeting various other types of 
cells and proteins. SNAbs are designed as a flexible platform to mimic the function of 
monoclonal antibodies to remove the factors (i.e., proteins, cells) that cause the 
physiological disorders or playing a promoting role in the progression of the diseases, 
such as cancer and autoimmune disease. Some examples of such targets are Her2-
expressing human breast cancer cells and IL-4 protein in the autoimmune disorders. By 
activating the innate immune responses to remove such targets, SNAbs can either be a 
single therapy or a part of a combination therapy to improve the current treatment 
strategies for diseases. In the long run, SNAbs could also be used as antibodies in 
diagnosis of diseases and detection technologies, such as enzyme-linked immunosorbent 
assay (ELISA). All in all, we believe that SNAbs are a novel, promising type of artificial 




APPENDIX A. MORE INVESTIGATION ON THE BINDING OF 
PEPTIDES OR NANOPARTICLES ON CELLS 
A.1 Cp33 binding on Fc receptor-expressing macrophages 
Macrophages have high Fc receptor expression and are important mediators of antibody-
mediated responses. We have repeatedly validated the binding of cp33 peptides on 
macrophages. It is also necessary to know whether the binding of cp33 on macrophages 
is dependent by the relative expression level of specific Fc receptor types and the 
activation of macrophages to determine the condition for in vitro effector-target cell co-
culture assays used to test the biological function of SNAbs.  
A.1.1 Materials and methods 
A.1.1.1 Materials  
DMEM complete medium for the cell culture and FACS buffer were prepared in the 
same way as described previously in chapter 4. The recombinant murine interferon 
gamma (rmIFNγ) protein was purchased from PeproTech. Inc. The anti-CD16-PE 
antibodies were purchased from R&D Systems and anti-CD32-PE antibodies were 
purchased from eBioscience, Thermofisher Scientific. Streptavidin-FITC conjugates, 
CellMask Orange plasma membrane stain kit, and ProLong Gold antifade mountant were 
purchased from Thermofisher Scientific. The Corning Poly-L-lysine coated-12mm 
diameter, round coverlips were purchased from Fisher Scientific.Inc.  
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A.1.1.2 Fc receptor expression on macrophages primed with rmIFNγ 
RAW 264.7 macrophages were passaged and resuspended into DMEM complete medium 
with rmIFNγ 25 ng/mL. Cells were cultured for overnight at 37 °C. The rmIFNγ-primed 
and unprimed macrophages were then transferred into separate FACS tubes, 1 
million/tube. Following washing with PBS by centrifugation at 500 g for 5 mins, the cells 
were stained with anti-CD16-PE antibodies or anti-CD32b-PE antibodies in FACS buffer 
at 4 °C for 30 mins in dark and then washed again with FACS buffer. After resuspension 
in 200 μL of FACS buffer, the samples were analyzed using a BD Accuri C6 benchtop 
flow cytometer.  
A.1.1.3 Quantitative evaluation of cp33 binding on macrophages primed with rmIFNγ. 
RAW 264.7 macrophages were primed in the same way as described in A.1.1.2 or keep 
unprimed. After transferring to FACS tubes, the cells were incubated with 10 μM cp33-
biotin for 1 hr at 4 °C in PBS followed by washing with FACS buffer. The control 
samples were left untreated until the next step. After incubation, all the cells, except the 
control samples, were stained with streptavidin-FITC conjugates 5 μg/tube in PBS for 1 
hr at 4 °C. After washing, the cell samples were resuspended in 200 μL of FACS buffer 
and analyzed on BD Accuri C6 flow cytometer. 
A.1.1.4 Quantitative evaluation of cp33 binding on macrophages blocked with anti-
CD16/CD32 antibodies 
RAW 264.7 macrophages were primed in the same way as described in A.1.1.2 or keep 
unprimed. After transferring to FACS tubes, half of the tubes were treated with anti-
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CD16/CD32 antibodies 2 μL /tube in 50 μL of FACS buffer for 10 mins in 4 °C. Then, 
all the cells, except the control samples, were incubated with 10 μM cp33-biotin for 1hr 
at 4 °C in PBS followed by washing with FACS buffer. The cells were then stained with 
streptavidin-FITC conjugates 5 μg/tube in PBS for 1 hr at 4C. After washing, the cell 
samples were resuspended in 200 μL of FACS buffer and analyzed on BD Accuri C6 
flow cytometer.  
A.1.1.5 Confocal microscopic imaging of cp33-modified nanoparticles binding on 
macrophages  
Janus gold nanoparticles SA-AuNP-SH were modified with the cp33-biotin and Alexa 
Fluor 647-maleimide (AF647) using the method described in chapter 2. The modified 
particles were purified with dialysis to remove the excessive ligands and dye. RAW 
264.7 macrophages were seeded on poly-L-lysine coated cover slips at 200,000 cells per 
well in 1mL DMEM complete medium and treated with 25 ng/mL rmIFNγ in 24 well 
plates for overnight at 37 °C. After priming with rmIFNγ, the cells were washed with 
PBS and stained with 1×CellMask Orange solution 300 μL /well for 10 mins in 37C. 
Following another wash with PBS, the particles, i.e., SA-AuNP-SH-AF647 or cp33-
AuNP-SH-AF647, were added to the cells, and incubated at 4 °C for 1 hr. The cells were 
then fixed with cytofix solution for 30 mins at 4 °C in dark and stained with DAPI 
(1:1000 dilution) for nucleus at 10 mins in dark. The coverslips were mounted with 
ProLong Gold antifade mountant on glass slides and then sealed with nail polish. The 




A.1.2.1 The effect of rmIFNγ on Fc receptor expression on macrophages 
CD16 and CD32b are the two Fc receptors that have high binding affinity with mouse 
IgG1, the possible most relevant mouse IgG isotype to cp33. We evaluated whether 
priming with rmIFNγ could affect the expression of CD16 and CD32b on macrophages 
by flow cytometry and this information was used to guide the design of experiments for 
ADCC and ADCP with macrophages. The mean fluorescence intensity showed the 
average expression level of each type of receptors on the cells. Clearly seen from the 
results, overnight priming with rmIFNγ increased the amount of CD16 and CD32b on the 
macrophages by over three folds. Meanwhile, the expression of F4/80, which is the M1 
macrophage marker, and CD11b, which is the monocyte marker, were decreased due to 
rmIFNγ priming.  
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Figure A 1. RmIFNγ treatment affected the expression of CD16, CD32b, F4/80, and 
CD11b on RAW 264.7 macrophages. 
 
A.1.2.2 The binding of cp33 on macrophages unprimed or primed with rmIFNγ  
As shown in A.1.1, rmIFNγ priming changes the expression of CD16 and CD32b, which 
are likely to be the binding partner of cp33. We wanted to see if this in turn affects the 
binding level of cp33 on macrophages. By probing the biotinylated cp33 with fluorescent 
streptavidin, we saw that cp33 clearly bound strongly to macrophages. However, 
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rmIFNγ-boosted increase in CD16 and CD32b didn’t enhance the binding of cp33 on the 
cells.  
 
Figure A 2. RmIFNγ-primed and unprimed macrophages have similar cp33 binding 
profile.  RAW macrophages were primed with rmIFNγ 25ng/mL or left unprimed in 
medium for overnight and then treated with cp33-biotin and probed with streptavidin-
FITC. The unprimed (A) and primed macrophages (B) were analyzed on a BD Accuri C6 
flow cytometer. The samples treated with cp33 (red) were compared with samples 
untreated (blue) and unstained sample (yellow). The cp33 binding profiles on rmIFNγ-
primed samples  (red) and unprimed samples (blue) were compared side by side in C.  
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A.1.2.3 The binding of cp33 on macrophages treated with anti-CD16/CD32 antibodies 
To further study whether CD16 and CD32 are important for cp33’s binding on 
macrophages, we tested the binding of cp33 with or without the presence of anti-
CD16/32 antibodies. Interestingly, the blockade of CD16 and CD32 also didn’t affect the 
binding of the peptides.  
 
Figure A 3. Anti-CD16/CD32 treatment didn't affect the binding of cp33 on RAW 264.7 
macrophages.  Red: cp33-biotin (10 μM) binding on RAW macrophages primed with 
rmIFNγ (25ng/mL) for overnight and treated with anti-CD16/CD32 antibodies; Blue: 
cp33-biotin (10 μM) binding on RAW macrophages primed with rmIFNγ (25 ng/mL) for 
overnight and untreated; Orange: SA-FITC control without cp33-biotin on RAW 
macrophages primed with rmIFNγ (25 ng/mL) for overnight and untreated; Green: 






A.1.2.4 Cp33-modified Janus gold nanoparticles bound on RAW 264.7 macrophages 
 
Figure A 4. Cp33-modified Janus AuNP bound on macrophages.  A. Janus AuNP-AF647 
control particle-treated macrophages; B. Janus cp33-modified AuNP-AF647 particles-
treated macrophages. Red: Janus nanoparticles; Blue: Nucleus; Green: Cell Membrane.  
As described in the method section, we imaged the particle-treated macrophages under 
confocal microscope. Because the size of the nanoparticles (30nm) was under the 
detection limit of the confocal microscope, only clustered nanoparticles can be seen on 
the image. Clearly, the unmodified Janus AuNP-AF647 didn’t bind on the cells, while the 
Cp33-AuNP-AF647 crosslinked the Fc receptors and circled around the cell membrane. 
The binding on the Fc receptors by Cp33 forced the nanoparticles to cluster together and 
gave detectable signals on the confocal images.  
A.1.3 Discussion 
CD16 is FcγRIII, the activating receptors highly expressed on macrophages and NK cells 
that mediate the antibody-dependent cellular responses, while CD32b is the only 
inhibitory receptors that also bind with IgG strongly but negatively regulates the antibody 
responses. CD32b was not expressed on NK cells. As shown in A.1.2.1, rmIFNγ 
treatment increased the expression of both CD16 and CD32b, as a result of which it is 
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hard to tell whether the macrophages would become more or less activated after priming. 
However, more and more evidence emerged that the effective antibody-mediated immune 
responses on monocytes have to do with both activating and inhibitory Fc 
receptors,
5,132,134
 so in the experiments where we tested the functions of MDSC-SNAbs 





 defines the classically activated M1 macrophages and rmIFNγ plus LPS 
(lipopolysaccharide) treatment was usually used to polarize the macrophages and 
dendritic cells towards the M1 phenotype.
205
 However, what we observed was 
contradictory to it. After rmIFNγ treatment, the expression level of F4/80 and CD11b was 
decreased. Taking into consideration that we didn’t treat the macrophages with LPS and 
the RAW 264.7 is a stable M1-like cell line, the observation is not completely 
unreasonable. Also, the down-regulation of expression of F4/80 and CD11b does not 
necessarily mean the reversion of M1 polarization. Therefore, the observation was 
regarded as an important side-effect to know of rmIFNγ-treatment on RAW 264.7 
macrophages.  
Anti-CD16/CD32 antibodies were used to block the binding of cp33 onto CD16 and 
CD32. However, the blockade didn’t decrease the amount of cp33 bound onto 
macrophages. Two possible reasons are that cp33 mainly bind to FcγRI and cp33 is a 
small molecule whose binding sites on CD16 and CD32 were not blocked by the anti-
CD16/CD32 antibodies. While we were not able to test the blockade of all four FcγRs 
due to the unavailability of the blocking reagents, we could further investigate if CD64 
(FcγRI) blockade significantly affect the binding of cp33 on macrophages. Lastly, the 
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confocal imaging clearly indicated that cp33 is important for the binding of Janus 
nanoparticles on the macrophages.  
A.2. Fc receptor expression on splenocytes 
FcγRs are essential for the antibody-dependent immune responses and the targeted 
depletion of cells by SNAbs. Splenocyte suspensions are used in Aim 2 to evaluate the 
functions of MDSC-SNAbs for specific killing of MDSCs. However, the majority of 
splenocytes have FcγR expression, including MDSCs themselves. Therefore, it is 
important to assess the level of expression of each type of FcγRs to shed light on the 
possible impact of SNAbs on these different types of cells in the system ex vivo as well as 
in vivo.  
A.2.1 Materials and methods 
A.2.1.1 Materials 
For cell type sorting, the anti-Gr1-biotin, anti-F4/80-biotin, anti-CD11c-biotin, anti-
CD49b-biotin, anti-B220-biotin, anti-CD3-biotin antibodies were purchased from 
Biolegend. The anti-biotin microbeads and LS column were purchased from Miltenyi 
Biotechnology. For staining in flow cytometry, the purified anti-mCD32, anti-mCD64-
APC, anti-mCD16.2-PE/Cy7, Armenian Hamster IgG-PE/Cy7, mouse IgG1,k-APC, rat 
IgG2a,k-PE were purchased from Biolegend. The anti-CD16-PE antibodies were 
purchased from R&D Systems. The anti-FcRn was purchased from Sigma Aldrich. The 
secondary antibodies anti-rat IgG Alexa fluor 555 (AF555) and anti-rabbit Alexa fluor 
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647 (AF647) were purchased from Thermofisher Scientific. The MACS buffer and FACS 
buffer were prepared as described in Chapter 4. 
A.2.1.2 Isolation of different cell types with magnetic activated cell sorting (MACS).  
The spleens of 4T1-tumor bearing mice were harvested on day 16 post tumor inoculation 
and then processed into single cell suspension using the same method as described in 
chapter 4. The resulting cell suspension was divided into six equal parts in six tubes. 
Cells were spun down and resuspended in MACS buffer, followed by incubation with 
biotinylated antibodies at 20 μg/mL for each cell type, i.e., MDSCs (anti-Gr1-biotin), 
macrophages (anti-F4/80-biotin), DCs (anti-CD11c-biotin), NK cells (anti-CD49b-APC), 
B cells (anti-B220-biotin), T cells (anti-CD3-biotin) for 10 mins at 4 °C. The cells were 
then washed with 5 mL of MACS buffer, resuspended into 800 μL and then incubated 
with anti-biotin beads 200 μL /tube for 10mins at 4 °C. Cell sorting was performed for 
each cell type according to the manufacturer’s protocol with LS columns. The 
concentration of collected cell suspensions was counted with hemocytometer and trypan 
blue. 
A.2.1.3 Flow cytometry analysis of Fc receptor expression on immune cells in spleen 
The cell samples were divided into two panels for the staining with different anti-Fc 
receptor antibodies. The first panel of the cell samples was stained with anti-mCD64-
APC, anti-mCD16.2-PE/Cy7, and anti-CD16-PE and fluorescent antibodies for each cell 
marker (Gr1, F4/80, CD11c, CD49b, B220, CD3). Isotype controls were prepared with 
the corresponding isotype antibody. The second panel of the cell samples were stained 
with anti-mCD32 followed by staining with anti-rat IgG-AF555 and anti-mFcRn 
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followed by staining with anti-rabbit IgG-AF647. For the second panel, no-primary-
antibody control and no-secondary-antibody control samples were prepared as well to 
help with data analysis. After removing excessive antibodies, the cells were fixed with 
cytofix buffer and analyzed on a BD LSRFortessa flow cytometer.  
A.2.2 Results  
A.2.2.1 CD64, CD16, and CD16.2 expression on the splenocytes.  
In accordance with literature reports, macrophages and DCs express the most CD64 
(FcγRI) on the cell membrane, while other cells almost have no expression of CD64 
(Figure A5). 
In terms of CD16, a higher percentage of NK cells expresses this Fc receptor, however, 
macrophages, MDSCs, as well as DCs all have a considerable population of cells 
expressing CD16 (Figure A6).  
Interestingly, a part of DCs has a highest abundance of CD16.2 receptors, followed by 
macrophages and MDSCs, which have a moderate expression of CD16.2. Surprisingly, 
we also detected CD16.2 expression on NK cells and a little bit on T cells and B cells, 
which is not reported in previous published literatures
206




Figure A 5. Expression of CD64 on major cell types in splenocytes.
 




Figure A 7. Expression of CD16.2 on major cell types in splenocytes. 
 
A.2.2.2 CD32, FcRn expression on the splenocytes.  
CD32 and FcRn expression are so minimal that we could hardly detect any on most of the 
cells types (MDSCs, macrophages, DCs, NK cells and B cells). However, we did see a 
significant percentage (10% or so) of CD3
+
 T cells showing signals in PE channel, 
indicating expression of CD32, but we could not exclude staining error because the 
control samples also have high fluorescence. Therefore, we concluded that the expression 
of CD32 and FcRn are not strong on splenocytes.  
A.2.3 Discussion 
A summary of Fc receptor expression on the major cell types in splenocytes were given 
below in Table 5: 
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Table 5. Expression of Fc receptors on the major cell types of splenocytes 










++ - +++ + ++ - - - 
CD32 
(FcRII) 
N N Y N Y Y Y Y 
CD16 
(FcRIII) 
++ ++ +++ ++ ++++ + Y Y 
CD16.2 
(FcRIV) 
++ - ++ + ++++ - - - 
FcRn N N Y Y Y Y Y Y 
 
Two important things to note in the above table are: one, for CD64, CD16, CD16.2, the 
number of “+” indicates the level of expression, and “-”means no expression; second, for 
CD32 and FcRn, because the signal detected on cells were very little, we could not 
quantitatively compare the expression level. Here, Y means expression observed, N 
means no expression.  
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In mouse, there are four major types of FcγRs, i.e.,CD64 (FcγRI), CD32 (FcγRIIa, 
FcγRIIb),, CD16 (FcγRIII),, CD16.2 (FcγRIV), and one neonatal Fc receptors, FcRn. 
Among them, FcγRIIb is the only inhibitory receptors that contain an intracellular 
immunoreceptor tyrosine-based inhibition motif (ITIM) to suppress the antibody-
mediated immune responses. All other types of Fc receptors are important mediators for 
ADCC and ADCP with antibodies. Mouse IgG1 binds more strongly to FcγRIIb and 
FcγRIII, while human IgG1 bind to all four types of Fc gamma receptors modestly.
56,155
 
The FcRns are main regulators of the serum half-lives of IgG and bind with all types of 
isotypes.
13
 Our results are in accordance with the literature reports on the Fc receptor 
expression pattern of macrophages and dendritic cells. Both dendritic cells and 
macrophages have high expression of FcγRI, FcγRIII, FcγRIV and some expression of 
FcγRIIb and FcRn, showing the potential of these two cell types being effector cells for 
ADCC and ADCP. NK cells only has strong expression of FcγRIII and can mediate 
robust ADCC with IgG1, IgG2a and IgG2b. B cells were detected to have little 
expression of FcγRI, FcγRIII and FcγRIV, and it is still under debate whether B cells can 
also conduct antibody-dependent innate immune responses. What was conflicting in our 
results with previous studies is that we saw light expression of CD16 and CD32. As the 
staining results on surface markers showed that the purity of cells isolated with the 
biotinylated antibodies were not 100%, we cannot exclude the possibility of false signal 
from other cell types in the T cell samples. Last but more importantly, MDSCs were 
observed to have expression of FcγRI, FcγRIII and FcγRIVs. This testified the binding of 
cp33 and cp33-modified nanoparticles on MDSCs. It is also one of the factors that 
complicated the results of killing assays and mechanism in vivo studies. Despite the 
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possibility of MDSCs quenching the cp33 on SNAbs due to the expression of the Fc 
receptors, we can conclude from the above discussed experiment that macrophages, NK 
cells and possibly DCs are the major effector cells of ADCC/ADCP induced by SNAbs.   
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APPENDIX B. MECHANISM OF ACTION STUDIES 
An antibody-opsonized cell crosslinks the FcγRs and triggers ADCC or ADCP to remove 
the cell targets by phagocytes or other effector cells, such as NK cells. Different FcγR 
will signal slightly differently, and different cells will mediate the ADCC/ADCP in 
different ways. However, there are common signaling events occurring in the process. 
The process elicited by the clustering of FcγRs includes the release of cytokines, 
production of reactive oxygen or nitrogen specifies, secretion of enzymes, proliferation, 
phagocytosis and antigen presentation.
134
 The majority of these events are mediated by 
the ITAM phosphorylation with the support of calcium fluxes and ATP. As the Fc-
mimicking peptides, cp33, are multivalently presented on the surface of the nanoparticles, 
we hypothesized that the SNAbs by themselves can crosslink FcγRs and induce the 
signaling cascades. In Appendix B, we documented the signaling studies we did with 
SNAbs and macrophages as a model type of effector cells and discussed how the results 
proved the hypothesis is incorrect.  
B.1 Materials and methods 
B.1.1 Materials 
2’,7’-Dichlorodihydrofluoroscein Diacetate (DCFH-DA) , phorbol 12-myristate 13-
acetate (PMA), hydrogen peroxide (H2O2), ionomycin,and vanadium (III) chloride (VCl3) 
were purchased from Sigma Aldrich. Rat anti-mouse CD16/32 and AF647 anti-mouse 
CD64 antibodies were purchased from Biolegend. AF555- and AF633-conjugated Goat 
anti-rat IgG (H+L) secondary antibodies, Indo-1, AM calcium binding dye, Griess 
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reagent kit, Celltrace CFSE, propidium iodie (PI), RNAse I, Dihydrorhodamine 123 and 
microBCA kit were purchased from Thermofisher Scientific. Recombinant human IFN-
gamma protein (rhIFNγ) and the mouse TNFα ELISA kit were purchased from R&D 
Systems. The recombinant mouse IFN-gamma protein (rmIFNγ) and recombinant murine 
M-CSF were purchased from PeproTech.Inc. The anti-Her2 human IgG1 was purchased 
from InvivoGen. Rabbit anti-SYK 352 or 525/526 antibody, anti-actin antibodies and 
Tris-buffered-saline solution were purchased from CellSignaling Technology.Inc. The 
RIPA lysis buffer was purchased from Boston Bioproducts. Inc. The LaemmLi sample-
loading buffer was purchased from Amresco. Inc. The Platt Lab in Georgia Institute of 
Technology was acknowledged for providing SDS-PAGE gels and donkey anti-rabbit 
secondary monoclonal antibodies, IRD-800CW conjugated, from LI-COR Biosciences. 
The phosphotase inhibitor, PhosStop, was purchased from Sigma-Aldrich. The protease 
inhibitor mini tablets and PVDF membrane were purchased from Thermofisher Scientific. 
The pre-stained Chamleon DUO protein standard and Odesey TBS buffer were purchased 
from LI-COR Biosciences. U937 human monocyte-like cell line was purchased from 
ATCC and cultured in RPMI 1640 medium supplemented with 10% FBS and 1% PS. 
RAW 264.7 macrophages were cultured in DMEM medium supplemented with 10% FBS 
and 1% PS. Bone marrow derived macrophage (BMDM) culture medium is high glucose 
DMEM supplemented with 10% heat-inactivated FBS and 1×beta-mercaptoethanol, 
1mM sodium pyruvate, 1×non-essential amino acid and 10 nM HEPES.  
B.1.2 Western blotting of Syk phosphorylation 
RAW macrophages and U937 cells were passaged and washed with cold 1% BSA in PBS 




/mL for RAW 
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macrophages and U937 cells respectively. The resuspended cells, 50 μL of RAW 
macrophages and 100 μL of U937 cells, were added to eppendorf microcentrifuge tubes 
and treated with 50 μL of 10 mM H2O2 or SNAbs (3×10
11
/mL) or left untreated for 5 
mins, 10 mins or 30 mins at 37 °C. The cells were then washed with 1% BSA in PBS 
solution and lysed with 50 μL RIPA buffer on ice, shaking at 150 rpm for 30 mins. The 
lysed cells were centrifuged at 16000 g for 20 mins at 4 °C. The supernatant containing 
proteins were transferred to a new tube. Part of it was used for measurement of protein 
concentration with a microBCA kit. The protein samples were stored at -20 °C until use. 
A 10% SDS gel was prepared according to the Platt Lab recipe with Protogel, TEMED, 
1-Butanol and DI H2O. The sample buffer was prepared with RIPA buffer, PhosStop and 
protease inhibitors and the protein samples. SDS-PAGE was run with 30 μL of the 
collected protein samples or the pre-stained Chamleon DUO protein standards. 
Afterwards, the protein in the gel was transferred to the PVDF membrane using semi-dry 
method. The protein left on the gel was stained with Ponceau S staining solution. The 
membrane was washed with TBS-0.05% Tween solution and blocked with Odessey TBS 
blocking buffer for 1 hr at room temperature. The membrane was then stained with 
1:1000 dilution of primary antibodies, i.e.,anti-SYK-352 (Zap 70) or anti-SYK-525/526 
and anti-β actin antibodies at 4 °C for overnight. After washing, the membranes were 
stained with donkey anti-rabbit IRD-800CW secondary antibodies at a 1:5000 dilution in 
TBS-0.1% Tween buffer for 1 hr at room temperature. After washing, the membranes 




B.1.3 Calcium refluxes 
RAW 264.7 macrophages were primed with rmIFNγ 25 ng/mL for overnight. 
Alternatively, U937 cells were primed with rhIFNγ 1000 U/mL for 72 hrs. For antibody-
mediated Fc receptor crosslinking, macrophage cells were coated with anti-CD16/CD32 
antibodies for 30 mins at 37 °C followed by washing with calcium-free PBS. The primed 
cells, including the anti-CD16/CD32-treated cells were resupsended into 1 million/mL in 
complete medium with 5 μM Indo-1, AM and incubated at 37 °C for 1 hr. Cells were 
then washed and resuspended with PBS buffer. Afterwards, cells were seeded in FACS 
tubes or black-bottom 96-well plates and treated with peptide-modified nanoparticles (1-5 
×10
10
/sample), ionomycin (10 μg/mL), or secondary antibodies (15 μg/mL). The samples 
were analyzed on a BD LSRFortessa flow cytometer or a Biotek Cytation 5 plate reader 
immediately after adding treatment for the kinetic changes in the intracellular or overall 
calcium concentration. 
B.1.4 Production of reactive oxygen species 
RAW 264.7 cells or U937 cells were passed and resupended in PBS at 1×10
6
/mL for 
RAW macrophages and at 5×10
6
/mL for U937 cells. Cells were seeded into FACS tubes, 
150 μL per tube, and incubated with 150 μL of 40 μM DCFH-DA in PBS solution for 30 
mins at 37C in dark. Following washing with 1 mL of PBS, RAW macrophages were 
either treated with anti-CD16/CD32 antibodies or peptide-modified nanoparticles for a 
desired period of time (30 mins, 1 hr, 2hrs). Similarly, the U937 cells were treated with 
anti-human CD64-AF647 or peptide-modified nanoparticles. As positive controls, the 
RAW macrophages or U937 cells were treated with H2O2 100 mM for at least 1hr in 37C. 
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The anti-CD16/CD32 antibodies-treated RAW cells or the anti-CD64-treated U937 cells 
were washed and subsequently treated with AF633-conjugated goat anti-rat IgG (H+L) 
secondary antibodies for RAW cells and AF647-conjugated goat anti-mouse IgG (H+L) 
secondary antibodies for U937 cells at 37 °C for 1hr. The cells were further washed and 
analyzed with three methods: 1. flow cytometry analysis on a BD LSRFortessa cytometer; 
2. fluorescence measurement on a Biotek Synergy HT plate reader;3.imaging of the 
samples on a Biotek LionHeart FX automated microscope. Dihydrorhodamine 123 (DHR) 
was also used in some experiments according to the protocol of the manufacturer to 
detect the oxidative burst of the macrophages or monocytes.  
B.1.5 Production of reactive nitrogen species 
RAW 264.7 macrophages were primed with rmIFNγ 25ng/mL for overnight and then 
seeded into a clear bottom 96 well plate at 0.5×10
5
 per 150 uL in each well. The 
macrophages were treated with 1×10
10
 peptide-modified nanoparticles or unmodified SA-






VCl3 solution was prepared by dissolving 51.1 
mg of VCl3 in DI water and then mixed with 20 mL of 1M HCl solution. The Griess 
reagent solution was prepared by adding 770 μL of component A and component B in a 
tube and mixed with 10 mL of the prepared VCl3 solution. The supernatant from the 
treated macrophages was added to a fresh 96 well clear-bottom plate, 150 μL/well, 
followed by adding 150 μL of the prepared Griess reagent solution. A standard curve was 
prepared on the same plate with a series of dilutions of the 1M nitrite solution provided in 
the Griess reagent kit. The plate was incubated at RT for 30 mins in dark and read at 
548nm for the quantification of nitrate in the supernatant.  
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B.1.6 Culture of bone marrow derived macrophages 
Bone marrow derived macrophages were differentiated from the bone marrow cells 
isolated from femurs and tibias of naïve Balb/c or C57BL/6 mice of 6-16 weeks old. 
Briefly, the bone marrow cells were isolated from the bones using the method described 
in chapter 5 and then seeded in a petri dish, 3 to 4.5 million cells per 20 mL of BMDM 
medium with 20 ng/mL M-CSF. Ten milliliter of old medium was aspirated and replaced 
with 10 mL of fresh BMDM medium containing 40 ng/mL of M-CSF on day 3 and day 6 
after seeding. The cells were ready to use on Day 7.  
B.1.7 Proliferation of bone marrow derived macrophages 
According to a paper published by Yong Luo, et. al.,
207
 bone marrow derived 
macrophages (BMDM) were starved for M-CSF for two days from day 5 after seeding. 
On day 7, the BMDMs were harvested and then stained with Celltrace CFSE 10 μM in 
PBS at 37 °C for 30 mins. CFSE staining was quenched by incubating the cell suspension 
with DMEM medium for 5 mins at room temperature and then the cells were washed 
with medium by centrifugation at 500 g for 5 mins twice. Cells were resuspended in 
DMEM at 0.5×10
6
/mL and seeded in a coated 12 well plates, 1mL/well. Twelve-well 
plates were pre-coated with human IgG1 or BSA at 10, 20, 40 μg/mL for overnight at 4 
°C and washed with PBS. At desired time-point (2,5,8 hr), cells were harvested and fixed 
with BD cytofix buffer. Fixed cells were subsequently stained with 1 μL /ml PI with 10U 
of RNAse for 20 mins at room temperature. The cells were analyzed on a BD 
LSRFortessa flow cytometer within 2 hours after staining.  
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B. 2 Results 
B.2.1 Syk Phosphorylation  
Previous studies reports strong phosphorylation of Syk at Tyrosine 525/526 position and 
Zap70 (Syk-Tyrosine 352) triggered by the crosslinking of FcγRs by immune-complexes, 
and the event was time-dependent and hard to capture.
155,158,159,200
 We chose the specific 
time points, 5, 10 and 30 mins tested by the above-mentioned  studies to detect the 
phosphorylation of Syk induced by the SNAbs. However, we only observed strong 
upregulation of phosphorylated Syk-Tyrosine 362 by the positive treatment, H2O2, but no 
difference between the SNAb-treated samples and negative controls at all time points. 
B.2.2 Calcium fluxes 
The calcium refluxes in monocytes triggered by FcγR crosslinker is usually reported as 
the maximum relative fluorescence units detected during the measurement. The events 
happen within minutes after FcγR crosslinking. As it was hard to control the start of 
signal acquisition by manually addition of treatment (ionomycin, nanoparticles or buffer), 
for the trials with both RAW macrophages and U937 cells, we only got fluctuating 
signals, which was hard to distinguish from noise. Longer kinetic measurement 
introduced bleaching of the Indo-1, AM calcium-binding dye. The Biotek Cytation 5 
plate reader and the LionHeart automated imaging microscope allows automated addition 
of treatments. However, we could not prepare enough nanoparticle formulations to rinse, 
wash and fill the injection tubing and the automated injection system only allows two 
types of treatment at a time, which did not satisfy the needs of the experiments. 
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B.2.3 Production of reactive oxygen species 
DCFH-DA is freely permeant to cell membranes and will be oxidized to green-
fluorescent calcein after reacting with reactive oxygen species (ROS) in the cell, so the 
fluorescence intensity of the cell after labeling with DCFH-DA is a measurement of the 
intracellular ROS concentration. We didn’t observe significant changes in ROS 
production upon treatment with nonJanus AuNP-cp33 particles or G3-SNAbs compared 
to DCFH-DA stained untreated cells (Figure B1). Also, the induction of ROS production 
by crosslinking of Fc receptors using anti-FcγR primary antibodies (anti-mouse 
CD16/CD32 for RAW macrophages, anti-human CD64 for U937 cells) and secondary 
antibodies (anti-rat IgG and anti-mouse IgG antibodies) was also not significant 
compared to single primary- or secondary-antibody-treated samples. We also tried 
dihydrohodamine 123 (DHR) for the oxidative burst in the macrophages after treatment 
with SNAbs and didn’t observe any detectable changes.  
 
Figure B 1. ROS production by U937 monocytes and RAW 264.7 macrophages after 
treatment. U937 cells and RAW 264.7 macrophages were stained with DCFH-DA and 
seeded in 96 well plates. The production of ROS was measured by quantification of the 
fluorescence in FITC channel of each sample on the plate reader after 1 hr treatment with 
the indicated formulations shown on the legend. A shows the ROS production of U937 
monocytes and B shows that of the RAW 264.7 macrophages.  
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B.2.4 Production of reactive nitrogen species.  
In the assay, we used VCl3 to reduce all the nitrate into nitrite for the quantification of 
reactive nitrogen species (RNS) production with a Griess Reagent kit. The calculation of 
the RNS concentration was enabled with a standard curve prepared by diluting the 
known-concentration nitrite solution. During the optimization of the SNAb fabrication 
method, we tested the reliability of RNS production as one of quality control methods for 
SNAb fabrication. Obviously, the treatment of SA-AuNP-SA alone induced increase in 
the production of RNS by macrophages, but G3-SNAbs didn’t augment the response 
consistently (Figure B2). The PBS buffer also contributed to the noisiness of the results. 
As the RNS production results varied a lot from time to time and from batch to batch, we 
determined that it is unreliable for testing the functionality of SNAbs.  
 
Figure B 2. The variable results of RNS production assay.The experimental results were 
from three separate experiments with different batches of nanoparticles. The graphs show 
the nitrite concentration (μM) in the supernatant of macrophages cultured with the 
treatment shown in the legends. Results were all produced with nanoparticles 
formulations prepared with SA-AuNP-SA from Nanopartz Inc. 
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B.2.5 Proliferation of bone-marrow derived macrophages.  
Yong Luo et al. reported the proliferation of macrophages after the activation of ERK 
pathway by Fc receptor-crosslinking.
207
 They observed an increase of the percentage of 
division and decreased percentage of G1-phase cells in bone marrow-derived 
macrophages (BMDM) after 5 hr treatment with plate-bound IgG1. We followed the 
protocol described in their paper, but didn’t observe any changes in the DNA content in 
the cells as suggested by the consistent PI staining profile among various treatment 
groups. A very minimal decrease in the CFSE fluorescence of BMDMs was noticed upon 
treatment with high-density IgG1-coated plate. Because we failed to reproduce the results 
reported in the paper, we didn’t continue the assay with SNAbs.  
B.3 Discussion 
Here, we documented the attempts to capture the signaling mediated by FcγR-crosslinker 
to elucidate the mechanism of actions of SNAbs. The signaling cascade is time-
dependent and sensitive to the assay conditions, such as the presentation method of Fc, 
concentration of Fc and buffer components.
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 We failed to produce meaningful results 
and thus could not conclude whether SNAbs were able to crosslink FcγRs efficiently to 
induce antibody-mediated responses by themselves. However, as we discussed previously, 
the receptor-clustering stimulation of immune cells are highly dependent on the size of 
the particles presenting the stimuli and a nanoparticle of 50 nm in diameter could be too 
small and of too high curvature that it could not crosslink a sufficient high number of 
receptors to induce the FcγR-mediated response.
160,190
 Therefore, the lack of changes in 
the signaling after treatment by SNAbs could be attributed to the lack of target cells, 
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which are responsible for amplifying the interaction between the cp33-presenting SNAbs 
and FcγRs on the effector cells. As the addition of MDSCs drastically increases the 
complexity of the assays, we turned to the effector-target co-culture assay and the 
splenocyte suspension assay for the evaluation of antibody-dependent responses induced 
by SNAbs. Clearly, our hypothesis that the multivalent presentation of Fc-mimicking 
ligands on the nanoparticle could induce FcγR-mediated signaling cascade was proved 
wrong. Indeed, as we reflect back on the application of SNAbs, the inability to trigger 
FcγR response avoids the non-specific activation of the immune system and is an 
advantage of SNAbs in terms of safety in clinical treatment.  
To further explore the mechanism of action of SNAbs in vivo, in vitro assays of 
granzyme B and perforin production by NK cells and complement activation in the 
presence of both effector cells and target cells would be helpful. In addition, an “artificial 
target cell” made of cell-sized microbeads coated with antigens would also be useful to 
investigate the ADCC/ADCP process (e.g., phagocytosis, cytokine production) of SNAbs 
with macrophages or NK cells as effector cells in vitro.    
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APPEXDIX C. SIZES AND ZETA POTENTIALS OF THE 
NANOPARTICLES 
Here lists the sizes and zeta potential of modified Janus and non-Janus nanoparticles. The 
sizes listed are representative of all experiments using SA-AuNP-SA from 
Nanohybrid.Inc.  



















Ave. Size (nm) 178.9 95.04 92.14 90.80 115.00 73.79 
ST.DEV (nm) 103.7 41.5 39.93 34.73 52.6 22.15 
 




SA-AuNP-SA G3-AuNP-Fc G3-AuNP-cp33 AuNP-cp33 
Ave. Size (nm) 84.08 83.69 79.96 73.79 




Table 8. Zeta potential of peptide-modified Janus nanoparticles 
Zeta Potentials Ave. Zeta Potential (mV) ST.DEV (mV) 
Unmodified SA-AuNP-SA -3.50 2.17 
Janus G3-AuNP-cp33 (SNAbs) -3.54 0.47 
Janus scAHNP-AuNP-cp33 -2.31 0.64 




APPENDIX D. ANTIBODIES USED IN FLOW CYTOMETRY AND 
MACS SORTING 
Table 9. Antibodies used in flow cytometry and MACS sorting experiments. 
Flow Cytometry 
Name Clone Company Function 
ANTI-FCRN (FCGRT) Polyclonal 
Sigma-
Aldrich Neonatal FcRn 
Anti-mouse CD32 (Fcγr2) S17012B Biolegend 
Fc gamma receptor 
II 
Alexa Fluor 647 Rat Anti-Mouse 
S100A9 MRP-14 
BD 
Bioscience S100A9 protein 
APC Annexin V Annexin A5 Biolegend Apoptotic cells 
APC Anti-Foxp3 FJK-16s eBioscience Treg 
APC anti-mouse CD49b (pan-NK 
cells) DX5 Biolegend NK cells 
APC Anti-CD64 X54-5/7.1 Biolegend Fc gamma receptor I 
APC/Cy7 Anti-mouse CD4 RM4-5 Biolegend T cell 
APC/Cy7 Anti-CD49b (pan-NK 
cells) DX5 Biolegend NK cells 
APC/Cy7 anti-mouse CD25 3C7 Biolegend Treg 
APC/Cy7 anti-mouse Ly-6C HK1.4 Biolegend MDSC 




CD45R/B220 RA3-6B2 Biolegend B cell 
FITC anti-mouse F4/80 BM8 Biolegend Macrophages 
PE anti-mouse CD4 RM4-5 Biolegend T cell 




Table 9 Continued 
 
 
 PE anti-mouse CD32b AT130-2 eBioscience 
Fc gamma receptor 
Iib 
PE anti-mouse CD16 275003 
R&D 
Systems 
Fc gamma receptor 
III 
PE anti-mouse CD279 (PD-1) 29F.1A12 Biolegend T cell exhaustion 
PE Anti-Ki-67 SolA15 eBioscience Proliferation 
PE anti-mouse Perforin S16009A Biolegend Cytolytic function 
PerCP/Cy5.5Anti-CD223 (LAG-3) C9B7W Biolegend T cell exhaustion 
PerCP/cy5.5 anti-human/mouse 
Granzyme B QA16A02  Biolegend Cytolytic function 
PerCP/Cy5.5 anti-mouse CD107a 
(LAMP-1) 1D4B Biolegend Degranulation 
PerCP/Cy5.5 anti-mouse Ki-67 16A8 Biolegend Proliferation 
PerCP/Cy5.5 anti-mouse Ly-6G 1A8 Biolegend MDSC 
PE/Cy7 anti-mouse CD3ε 145-2C11 Biolegend T cell 
PE/Cy7 anti-mouse/human CD11b M1/79 Biolegend Myeloid cells 
PE/Cy7 anti-mouse CD16.2 
(FcγRIV) 9E9 Biolegend 
Fc gamma receptor 
IV 
Purified anti-mouse CD16/32 93 Biolegend 
Blockade of Fc 
receptors 
MACS Sorting 
Biotin anti-mouse CD3ε 145-2C11 Biolegend T cell 
Biotin anti-mouse CD11c N418 Biolegend DC 
Biotin Anti-CD49b DX5 Biolegend NK 
Biotin Anti-mouse F4/80 BM8 Biolegend Macrophages 
Biotin anti-mouse Ly-6G/Ly-6C (Gr1) RB6-8C5 Biolegend MDSCs 
For antibodies used in depletion assays as treatments or in vivo experiments, please refer 
to the material and method sections in the corresponding chapters.  
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